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 I 
ABSTRACT 
 
Background  
Ventilator associated pneumonia occurs commonly in critically ill patients. Despite 
recommended antibiotic therapy, outcomes remain poor. Inadequate antibiotic 
concentrations at the site of action, the interstitial space fluid, could be one of the 
reasons. Whilst the risk of causing systemic side effects limits the ability to use 
increasing doses of parenteral therapy, the subtherapeutic concentrations commonly 
associated with current regimens could lead to emergence of drug resistant 
organisms. This, and the drying up of the antibiotic pipeline, have led to a renewed 
interest in the investigation of alternative drug delivery to maximise drug effects. 
 
Nebulized therapy is one such therapy and has been used successfully for many 
respiratory diseases. Nebulized antibiotic therapy for lung infections whilst not novel, 
has  been used increasingly worldwide with the aim of improving patient outcomes, 
particularly in the context of drug resistant pathogens. However, understanding and 
applying key pharmacokinetic principles is important for effective antibiotic therapy. A 
number of factors affect nebulized drug delivery in mechanically ventilated patients 
and for nebulized antibiotics, there is a paucity of robust data. Moreover, the current 
methods to study the pharmacokinetics of aerosolized antibiotics have critical 
limitations. Pseudomonas aeruginosa is a common cause of, both hospital and 
ventilator-associated pneumonia. Tobramycin, an aminoglycoside, is an effective 
antibiotic to treat infections caused by this pathogen. High-dose parenteral tobramycin 
therapy is not able to be used to treat lung infections caused by P. aeruginosa due to 
the likelihood severe side effects. Nebulized tobramycin might be a valid application 
for critically ill patients with ventilator-associated pneumonia given the supportive data 
from cystic fibrosis patients and patients with bronchiectasis, although the dose and 
frequency, type of formulation (nebulized, dry powder), position of the nebulizer in the 
circuit for optimal therapy in this population is unclear.  
 
Therefore, the primary aim of this Thesis was to describe current knowledge of factors 
affecting nebulized tobramycin delivery with mechanical ventilation. Using a suite of in 
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vitro and in vivo studies, the Thesis proceeded to provide valuable data describing the 
lung pharmacokinetics of nebulized tobramycin with mechanical ventilation.  
 
Firstly, a structured review of literature on the fundamentals of nebulized drug therapy 
in critical care was performed. This review concluded that whilst there is an important 
role for nebulized antibiotic therapy in the treatment of ventilator associated 
pneumonia there exist important gaps in the science and application of this therapy. 
Important findings such as the efficacy of vibrating mesh nebulizer and optimal 
ventilator settings for effective nebulized antibiotic delivery were derived from the 
review. Further studies elucidating the pharmacokinetics of nebulized antibiotic 
therapy may aid in developing an evidence based accurate dosing guidelines.  
 
To provide experimental data that address the various gaps identified in the structured 
review to, an incremental research program to study the essential aspects of nebulized 
tobramycin delivery with mechanical ventilation was established.  
 
In order to define optimal microdialysis parameters for use in the in vivo studies, an in 
vitro recovery study was performed. The results of this study showed that for 
tobramycin the best recovery rates were for perfusate flow rate of 1 µL/min. Recovery 
studies of moderate to highly protein bound drugs using plasma can replicate in vivo 
conditions. Moreover, for large molecules and/or highly protein bound drugs need 
additional consideration for recovery studies prior to in vivo studies.  
 
The study of aerosol characteristics of two preservative-free tobramycin solutions in a 
simulated adult mechanical ventilation model showed that in comparison to the 40 
mg/mL solution, nebulizing tobramycin 100 mg/mL solution delivered a higher dose. 
Moreover, the type or the size of the tracheal tubes did not affect the effective delivered 
dose. The data from this study was used in the design of the in vivo studies. 
 
To study the regional lung distribution of nebulized tobramycin, a healthy mechanically 
ventilated ovine model was used. Using a gamma camera and direct tissue 
measurements, the lung and extra-pulmonary distribution including blood 
concentrations were compared between intravenous and nebulized radiolabelled 
tobramycin. It was seen that whilst, there was good distal lung penetration of nebulized 
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radiolabelled tobramycin, the whole and regional lung deposition was significantly 
lower for nebulized radiolabelled tobramycin. The study findings also confirmed that 
extra-pulmonary and blood concentrations of radiolabelled tobramycin were 
significantly lower with nebulized tobramycin. Thus, having demonstrated the 
distribution of tobramycin through the lungs, the correlation of these results with actual 
drug concentrations using the microdialysis technique was needed.  
 
In a healthy mechanically ventilated ovine model, using microdialysis catheters 
inserted in the lungs and internal jugular vein, a pharmacokinetic study comparing 
nebulized and intravenous tobramycin was conducted. The results of the study 
showed that compared to intravenous, using nebulized tobramycin achieved 
significantly higher concentrations in the lung interstitial space fluid and epithelial lining 
fluid. The plasma concentrations were also lower with nebulized tobramycin compared 
to intravenous tobramycin. Thus, the treatment and hence outcomes of ventilator 
associated pneumonia is likely to be improved by using nebulized tobramycin without 
causing systemic side effects.  
 
Thus, this Thesis provides vital lung pharmacokinetic data to inform optimal nebulized 
antibiotic delivery with mechanical ventilation. Further research is needed in lung 
infection models to inform clinical trials in this area.   
 
 
  
 IV 
Declaration by author 
 
This Thesis is composed of my original work, and contains no material previously 
published or written by another person except where due reference has been made in 
the text. I have clearly stated the contribution by others to jointly-authored works that 
I have included in my Thesis. 
 
I have clearly stated the contribution of others to my Thesis as a whole, including 
statistical assistance, survey design, data analysis, significant technical procedures, 
professional editorial advice, and any other original research work used or reported in 
my Thesis. The content of my Thesis is the result of work I have carried out since the 
commencement of my research higher degree candidature and does not include a 
substantial part of work that has been submitted to qualify for the award of any other 
degree or diploma in any university or other tertiary institution. I have clearly stated 
which parts of my thesis, if any, have been submitted to qualify for another award. 
 
I acknowledge that an electronic copy of my Thesis must be lodged with the University 
Library and, subject to the policy and procedures of The University of Queensland, the 
Thesis be made available for research and study in accordance with the Copyright Act 
1968 unless a period of embargo has been approved by the Dean of the Graduate 
School.  
 
I acknowledge that copyright of all material contained in my Thesis resides with the 
copyright holder(s) of that material. Where appropriate I have obtained copyright 
permission from the copyright holder to reproduce material in this Thesis. 
 
Jayesh Dhanani  
(July 2018) 
 
 
  
 V 
Publications during candidature 
 
Published article 
Jayesh Dhanani, John F. Fraser, Hak-Kim Chan, Jordi Rello, Jeremy Cohen, 
Jason A. Roberts. Fundamentals of aerosol therapy in critical care. Critical Care 2016; 
20 (1) :269.  
 
Publications included in the Thesis 
 
Published article- incorporated as Chapter 2. 
Jayesh Dhanani, John F. Fraser, Hak-Kim Chan, Jordi Rello, Jeremy Cohen, 
Jason A. Roberts. Fundamentals of aerosol therapy in critical care. Critical Care 2016; 
20 (1) :269.  
Contributor Statement of contribution 
Jayesh Dhanani (Candidate) Conception and design (80%) 
Literature review (80%) 
Drafting and production (80%) 
John F. Fraser Conception and design (10%) 
Drafting and production (10%) 
Critical Review (25%) 
Hak-Kim Chan Critical Review (25%) 
Jordi Rello Critical Review (25%) 
Jeremy Cohen Critical Review (25%) 
Jason A. Roberts Conception and design (10%) 
Literature review (20%) 
Drafting and production (10%) 
 
 
 
 
 
 
 
 
 
 
 
 VI 
Published article incorporated as Chapter 5 
 
Jayesh Dhanani, Patricia Tang, Steven C. Wallis, Suzanne L. Parker, Preeti Pandey, 
John F. Fraser, Jeremy Cohen, Adrian Barnett, Jason R. Roberts, Hak-Kim Chan. 
Characterisation of 40 mg/ml and 100 mg/ml tobramycin formulations for aerosol 
therapy with adult mechanical ventilation. Pulmonary Pharmacology & Therapeutics 
50 (2018) 93- 99. 
 
Contributor Statement of contribution 
Jayesh Dhanani (Candidate) Conception and design (80%) 
Literature review (80%) 
Experiments and sample collection 
(90%) 
Drafting and production (80%) 
Patricia Tang Experiments and sample collection 
(10%) 
Critical review (20%) 
Steven C. Wallis Sample analyses (50%) 
Critical review (10%) 
Suzanne L. Parker Sample analyses (40%) 
Critical review (10%) 
Preeti Pandey Sample analyses (10%) 
Critical review (10%) 
John F. Fraser Critical Review (15%) 
Jeremy Cohen Critical Review (15%) 
Adrian Barnett Critical Review (15%) 
Jason A. Roberts Critical Review (15%)  
Conception and design (10%) 
Drafting and production (10%) 
Hak-Kim Chan Conception and design (10%) 
Literature review (20%) 
Drafting and production (10%) 
 
 
  
 VII 
Presentations: 
 
1. “Using lung microdialysis to describe the pharmacokinetics of inhaled 
antibiotics in mechanically ventilated sheep”. The Prince Charles Hospital 
Research Forum, Brisbane, 6th November 2015 
2. “My PhD: Using inhaled antibiotics to treat lung infections caused by 
superbugs”. CRE REDUCE Conference, Brisbane, 29th July 2016.  
 
 
  
 VIII 
Contributions by others to the Thesis  
 
I would like to acknowledge the significant contribution made to this Thesis by 
Professor Jason Roberts (University of Queensland). Professor Roberts played a 
significant role in formalising the concepts and facilitating the conduct of the studies 
within this Thesis. Professor Roberts provided assistance and expertise in the 
analyses and drafting of most of the chapters. 
 
I would also like to acknowledge the significant contribution of Professor John F. 
Fraser (University of Queensland). Professor Fraser played a significant role in 
deploying his resources for the conduct of the animal experiments included in the 
Thesis.  
 
Associate Professor Jeremy Cohen contributed to the Thesis by assisting with the 
drafting and editing the chapters.  
 
Statement of parts of the Thesis submitted to qualify for the award of another 
degree 
 
None 
 
Research Involving Human or Animal Subjects 
 
All the ovine studies have got ethics approval from the Queensland University of 
Technology Animal Ethics Committee (Approval no. 1100000052) and University of 
Queensland Animal Ethics Committee (Approval no. SOM/268/16/RBWH).  
 
  
 IX 
Acknowledgements 
 
I would like to acknowledge the grant support provided by the Prince Charles Hospital 
Foundation and the Royal Brisbane and Women’s Hospital Foundation.  
 
The work for this Thesis has been completed under the supervision of Professor Jason 
Roberts, Burns Trauma and Critical Care Research Centre, Intensive Care Unit, Royal 
Brisbane and Women’s Hospital and CRE REDUCE, University of Queensland. Co-
supervision from Professor John F. Fraser, Critical Care Research Group, University 
of Queensland and from Associate Professor Jeremy Cohen, Burns Trauma and 
Critical Care Research Centre, Intensive Care Unit, Royal Brisbane and Women’s 
Hospital has also facilitated this undertaking.  
 
My foremost gratitude is directed to Professor Roberts for the development of the 
Thesis topic and his continued and ongoing support, advice and guidance during this 
Thesis. Professor Roberts’ enthusiasm and productive research approach as well as 
the personal support he has provided, enabled me to author numerous publications 
and to collaborate with international research groups.  
 
I am very grateful for the support and expertise of Professor John F. Fraser who 
directed his resources and specialized skills in animal experiments toward a 
successful completion of vital studies in this Thesis.  
 
I would like to thank Associate Professor Jeremy Cohen who provided vital support 
and his expertise in the field of research toward the various aspects of the studies. 
 
I would like to thank Professor Hak-Kim Chan and Dr. Patricia Tang from the University 
of Sydney for their contributions toward the conduct of the laboratory studies  
 
To Dr. Steven Wallis and Dr. Suzanne L. Parker, my heartfelt thanks for helping with 
the analyses of a variety of samples in a timely and efficient manner. 
 
 X 
No amount of thanks will be enough for Professor Adrian Barnett from the Queensland 
University of Technology who provided his valuable time and expertise in the statistical 
analyses of the often-complicated datasets. 
 
I would like to thank Professor Michelle Chew, from Lund University, Sweden, for 
providing valuable support and expertise for the microdialysis studies.  
 
To Dr. Benjamin Ahern, Mr. Steven Goodman and Dr. Manoj Bhatt, I would like to 
thank for their help and extra-ordinary support for a very challenging study. 
 
My good friend Dr. Jivesh Chaudhary deserves my thanks for being available for me 
to undertake all the animal studies. 
 
Ms. Sara Diab deserves a special mention as she has been the driving force without 
which the vital studies wouldn’t be possible to undertake. 
 
With great pleasure I would like to thank my mother Hansa, father Anil and brother 
Mukund, who provided vital moral and emotional support for me to undertake this 
journey of a lifetime.  
 
Finally, I would forever be grateful for the immense support provided to me by lovely 
wife, Sonal and my beautiful angels, Arjun and Jiya. Their presence and 
encouragement laid the foundations and provided the scaffolding for the successful 
completion of this life-changing enterprise. 
 
 
 
 
 
 
  
सुखद:ुखे समे कृत्वा लाभालाभौ जयाजयौ | 
ततो युद्धाय युज्यस्व नैव ंपापमवाप्सस्यसस || 
38|| 
 
 XI 
Financial support 
 
1. Royal Brisbane and Women’s Hospital (RBWH) Foundation Research Grant 
 
Project: Does inhaled tobramycin distribute effectively into the lungs? A comparative 
study using radiolabeled tobramycin. 
 
Investigators: Dr. Jayesh Dhanani, Prof John Fraser, Prof Jason Roberts, A/Prof 
Jeremy Cohen. 
 
Funded amount- $40,000 
 
 
2. The Prince Charles Hospital Foundation Research Grant- MS2011-40 
 
Project: Study of the pharmacokinetics of inhaled antibiotics in lung tissue using the 
microdialysis technique. 
 
Investigators: Dr. Jayesh Dhanani, Prof John Fraser, Prof Michelle Chew, Prof Jason 
Roberts, Prof David Paterson 
 
Funding- $60,234.79 
 
 
3. Royal Brisbane and Women’s Hospital (RBWH) Foundation Research Grant 
 
Project: Does inhaled antibiotics deliver optimal concentrations to the lung to improve 
treatment of pneumonia? An animal in vivo study using the microdialysis technique. 
 
Investigators: Dr. Jayesh Dhanani, Prof John Fraser, Prof Michelle Chew, Prof Jason 
Roberts 
 
Funding- $20,000 
 
 
 
  
 XII 
Keywords 
 
Antibiotic, nebulize, microdialysis, pharmacokinetics, mechanical ventilation, ventilator 
associated pneumonia, biodistribution, relative recovery, aerosol characteristics 
 
Australian and New Zealand Standard Research Classifications (ANZSRC) 
 
ANZSRC code: 110310, Intensive Care, 50% 
ANZSRC code: 110203, Respiratory Diseases, 25% 
ANZSRC code: 110502, Clinical Pharmacology and Therapeutics, 25% 
 
Fields of Research (FoR) Classification 
 
FoR code: 1102, Cardiorespiratory Medicine and Haematology, 50% 
FoR code: 1103, Clinical Sciences, 25% 
FoR code: 1115, Pharmacology and Pharmaceutical Sciences, 25% 
 
 
  
 XIII 
Table of Contents 
 
ABSTRACT ............................................................................................ I 
Publications during candidature ........................................................ V 
Publications included in the Thesis ................................................... V 
Presentations: .................................................................................... VII 
Contributions by others to the Thesis ............................................ VIII 
Statement of parts of the Thesis submitted to qualify for the award 
of another degree ............................................................................. VIII 
Research Involving Human or Animal Subjects ............................. VIII 
Acknowledgements ............................................................................ IX 
Financial support ................................................................................ XI 
Keywords ........................................................................................... XII 
Australian and New Zealand Standard Research Classifications 
(ANZSRC) ........................................................................................... XII 
Fields of Research (FoR) Classification ........................................... XII 
List of Figures ................................................................................. XVIII 
List of Tables ...................................................................................... XX 
List of Abbreviations ....................................................................... XXII 
Chapter 1 Overview ............................................................................. 1 
1.1 Overview ..................................................................................................... 1 
 Ventilator associated pneumonia .......................................................... 1 
 Nebulized antibiotics for the treatment of VAP ...................................... 1 
 Pharmacokinetics of nebulized antibiotics with mechanical ventilation . 2 
1.2 Aims ............................................................................................................ 4 
 XIV 
Chapter 2 The principles of aerosol therapy in critical care ............. 5 
2.1 Synopsis ..................................................................................................... 5 
2.2 Published manuscript entitled “Fundamentals of aerosol therapy in 
critical care” .......................................................................................................... 6 
 Abstract ................................................................................................. 8 
 Introduction ........................................................................................... 9 
 Factors affecting aerosolized drug delivery in the critically ill patient .. 12 
 Conclusions ........................................................................................ 39 
2.3 Conclusions of the chapter 2 “The principles of aerosol therapy in 
critical care” ........................................................................................................ 41 
Chapter 3 Research pathway for the study of the delivery and 
disposition of nebulized antibiotics ..................................................42 
3.1 Synopsis ................................................................................................... 42 
3.2 Accepted manuscript entitled “A research pathway for the study of the 
delivery and disposition of nebulized antibiotics: an incremental approach 
from in vitro to large animal models” ............................................................... 43 
 Abstract ............................................................................................... 46 
 Background ......................................................................................... 47 
 Methods .............................................................................................. 48 
 Results ................................................................................................ 65 
 Discussion .......................................................................................... 69 
 Conclusion .......................................................................................... 72 
3.3 Conclusion of the chapter 3 “Research pathway for the study of the 
delivery and disposition of nebulized antibiotics” .......................................... 73 
Chapter 4 Effect of combination antibiotic therapy on microdialysis 
recovery rates .....................................................................................74 
4.1 Synopsis ................................................................................................... 74 
 XV 
4.2 Accepted manuscript entitled “Recovery rates of combination 
antibiotic therapy using in vitro microdialysis simulating in vivo conditions”
 75 
 Abstract ............................................................................................... 77 
 Introduction ......................................................................................... 78 
 Materials and methods........................................................................ 79 
 Results ................................................................................................ 84 
 Discussion .......................................................................................... 88 
 Conclusion .......................................................................................... 90 
4.3 Conclusion of the chapter 4 “Effect of combination antibiotic therapy 
on microdialysis recovery rates” ...................................................................... 91 
Chapter 5 Effect of different tobramycin formulations on aerosol 
characteristics with mechanical ventilation. ....................................92 
5.1 Synopsis ................................................................................................... 92 
5.2 Published manuscript entitled “Characterisation of 40 mg/mL and 100 
mg/mL tobramycin formulations for aerosol therapy with adult mechanical 
ventilation” .......................................................................................................... 93 
 Abstract ............................................................................................... 95 
 Introduction ......................................................................................... 96 
 Materials and Methods........................................................................ 97 
 Results .............................................................................................. 103 
 Discussion ........................................................................................ 109 
 Conclusion ........................................................................................ 112 
5.3 Conclusions of the chapter 5 “Effect of different tobramycin 
formulations on aerosol characteristics with mechanical ventilation.” ...... 114 
Chapter 6 Pulmonary drug distribution of nebulized and 
intravenous tobramycin ................................................................... 115 
 XVI 
6.1 Synopsis ................................................................................................. 115 
6.2 Submitted manuscript entitled “Nebulized versus intravenous: a 
comparative lung distribution study in a mechanically ventilated ovine 
model using radiolabelled tobramycin.” ........................................................ 116 
 Abstract ............................................................................................. 118 
 Introduction ....................................................................................... 119 
 Methods ............................................................................................ 120 
 Results .............................................................................................. 125 
 Discussion ........................................................................................ 132 
 Conclusion ........................................................................................ 136 
6.3 Conclusions of the chapter 6 “Pulmonary drug distribution of 
nebulized and intravenous tobramycin” ........................................................ 137 
Chapter 7 Lung concentrations of nebulized and intravenous 
tobramycin ........................................................................................ 138 
7.1 Synopsis ................................................................................................. 138 
7.2 Submitted manuscript entitled “Lung pharmacokinetics of tobramycin 
by intravenous and nebulized dosing.” .......................................................... 139 
 Abstract ............................................................................................. 141 
 Introduction ....................................................................................... 142 
 Methods ............................................................................................ 143 
 Results .............................................................................................. 147 
 Discussion ........................................................................................ 155 
 Conclusion ........................................................................................ 158 
7.3 Conclusions of the chapter 7 “Lung concentrations of nebulized and 
intravenous tobramycin” ................................................................................. 159 
Chapter 8 General discussion, conclusions and future directions
 ........................................................................................................... 160 
 XVII 
8.1 Summary of findings ............................................................................. 160 
8.2 Suggested future research .................................................................... 162 
References ........................................................................................ 164 
Appendices: ...................................................................................... 194 
Appendix 1- Ethics approval certificates ........................................ 194 
 
 XVIII 
List of Figures 
 
Figure 2.1: Mechanisms of aerosol particle deposition............................................ 12 
Figure 2.2: Factors favourable for aerosol drug delivery in the critically ill patients. 14 
Figure 2.3 (A) Relationship of lung aeration (%) to pulmonary concentration of 
amikacin (µg/g) for different routes of administration. (B) Relationship of route of 
drug administration to pulmonary concentration of amikacin (g/g) for different 
severities of pneumonia. .......................................................................................... 17 
Figure 2.4: Comparison of lung concentration (measured by HPLC) of amikacin 
between aerosolized and intravenous administration. .............................................. 36 
Figure 2.5: Comparison of lung concentration (measured by HPLC) and bacterial 
burden of colistin between aerosolized and intravenous administration. .................. 37 
Figure 3.1: Principle of laser diffraction technique for particle sizing ....................... 53 
Figure 3.2 A: Experimental set up for particle sizing experiments. B: Experimental 
set up for inhaled mass experiments ........................................................................ 55 
Figure 3.3 A: Principles of Lung Microdialysis with nebulized antibiotics. B:Principles 
of Lung Microdialysis with intravenous antibiotics. ................................................... 61 
Figure 3.4: Comparative dorsal scintigraphy images of lung deposition of i.v and 
nebulized radiolabelled tobramycin. ......................................................................... 67 
Figure 3.5: Comparative lung concentrations of tobramycin between nebulized and 
intravenous route of administration. ......................................................................... 68 
Figure 4.1: Structure of vancomycin (A) and tobramycin (B). .................................. 80 
Figure 5.1: Schematic diagram illustrating the circuit set up for the inhaled mass 
study ......................................................................................................................... 99 
Figure 5.2: Schematic diagram illustrating the circuit set up for the particle size 
distribution study. ................................................................................................... 100 
Figure 6.1:Schematic diagram explaining the scintigraphic assessment of lung 
deposition. .............................................................................................................. 124 
 XIX 
Figure 6.2: Static dorsal scintigraphic images of lung deposition of 99mTc-
tobramycin in ventilated sheep. Sheep were anesthetized, mechanically ventilated 
and administered 99mTc-tobramycin 400 mg with a vibrating mesh nebulizer. ..... 129 
Figure 7.1: Study set up showing the operating theatre set up, the sheep position, 
and instrumentation. ............................................................................................... 143 
Figure 7.2: Log scaled plot showing regional concentration-time profile for lung ISF 
and plasma with nebulized and i.v. tobramycin. ..................................................... 152 
 
 XX 
List of Tables 
 
Table 2.1: Comparison of different types of nebulizers. ........................................... 22 
Table 2.2: Common applications of aerosol therapy in intensive care (*). ............... 33 
Table 2.3: Optimization of ventilator parameters required for aerosolization of 
antibiotics ................................................................................................................. 38 
Table 3.1: Overview of the research pathway with the study components aimed at 
characterising the pharmacokinetics of nebulized tobramycin. ................................ 49 
Table 3.2: Comparative characteristics between tobramycin 40 mg/mL and 100 
mg/mL solutions ....................................................................................................... 65 
Table 3.3: Quantitative extra- pulmonary tissue radioactivity concentrations. ......... 67 
Table 3.4: Comparative epithelial lining fluid concentrations for nebulized and 
tobramycin sheep at two time points; 1 hour and 6- hours post antibiotic 
administration. .......................................................................................................... 69 
Table 4.1 A: Mean ( SD) vancomycin concentrations in microdialysate (µg/mL). .. 84 
Table 4.2 A: Mean ( SD) vancomycin relative recovery (%). B: Mean ( SD) 
tobramycin relative recovery (%) .............................................................................. 85 
Table 4.3: Multiple regression analysis for relative recovery rates (mean % and 95% 
confidence interval) of vancomycin for different concentrations and perfusate flow 
rates. ........................................................................................................................ 86 
Table 4.4: Multiple regression analysis for relative recovery rates (mean % and 95% 
confidence interval) of tobramycin for different concentrations and perfusate flow 
rates. ........................................................................................................................ 87 
Table 5.1: Comparative physicochemical and aerosol characteristics of tobramycin 
solutions- 100mg/ml and 40mg/ml (mean ± S.D.) using endotracheal tubes and 
tracheostomy tubes of sizes 7, 8 and 9 mm I.D. .................................................... 103 
Table 5.2: Aerosol characteristic for tobramycin 100mg/ml endotracheal tube (Top 
panel) and tracheostomy tube (Bottom panel) of 3 different sizes (mm- internal 
diameter) mean ± S.D. ........................................................................................... 105 
 XXI 
Table 5.3: Aerosol characteristic for tobramycin 40mg/ml endotracheal tube (Top 
panel) and tracheostomy tube (Bottom panel) of 3 different sizes (mm- internal 
diameter) mean ± S.D. ........................................................................................... 107 
Table 6.1: Quantitative lung distribution of tobramycin activity based on scintigraphic 
analysis. ................................................................................................................. 128 
Table 6.2: Lung P/C ratio (penetration index) in mechanically ventilated sheep with 
nebulized 99mTc- tobramycin. .................................................................................. 129 
Table 6.3: Quantitative tissue distribution of 99mTc-tobramycin activity................ 131 
Table 6.4: Blood 99mTc-tobramycin activity levels for nebulized and i.v. 99mTc- 
tobramycin in mechanically ventilated sheep (mean, SD). ..................................... 132 
Table 7.1: Comparative lung pharmacokinetic parameters between intravenous and 
nebulized tobramycin (median, IQR). ..................................................................... 147 
Table 7.2: Pharmacokinetic parameters of tobramycin in the right and left, upper and 
lower lobes as well as plasma (Intravenous group). ............................................... 149 
Table 7.3: Pharmacokinetic parameters of tobramycin in the right and left, upper and 
lower lobes as well as plasma (Nebulized group). ................................................. 150 
Table 7.4: Comparative tobramycin concentration levels in ELF and ratio of ELF to 
plasma concentration for intravenous and nebulized tobramycin. .......................... 154 
 
 XXII 
List of Abbreviations 
 
L/min: microliters/minute 
°C: Degree Celsius 
99mTc-tobramycin: technetium 99m labelled tobramycin 
ABG: arterial blood gas 
ABP: arterial blood pressure 
AD: administered dose 
ARDS: Acute Respiratory Distress Syndrome 
AUC0-∞: area under the concentration- time curve from 0 h to infinity  
AUC0-last: area under the concentration-time curve from 0 h to the last 
measurement at the completion of the study  
AUCplasma: AUC in plasma using unbound concentrations. 
AUMC0-∞: area under the moment curve from 0 h to infinity  
AUMC0-last: area under the moment curve from 0 h to the last measurement at the 
completion of the study  
BAL: bronchoalveolar lavage 
C/P: central to peripheral ratio 
Cdialysate: Drug concentration in the microdialysate 
Cmax: maximum concentration 
Cmin: minimum concentration  
COPD: chronic obstructive pulmonary disease 
cP: centipoise 
Csolution: Drug concentration in perfusate solution 
CT: computed tomography;  
Ctissue: Drug concentration in the tissue interstitial space fluid 
CVP: central venous pressure 
Da: Daltons 
DPI: dry powder inhaler 
dv10: volume diameter under which 10% of the particles reside  
dv95: volume diameter under which 95% of the particles reside 
ECG: electrocardiography 
ED: emitted dose 
ELF: epithelial lining fluid 
 XXIII 
ET: endotracheal tube 
ETCO2: end-tidal carbon dioxide. 
EUCAST: European Committee on Antimicrobial Susceptibility Testing 
fAUCisf tissue: unbound AUC in interstitial space fluid of lung 
FDA: Food and Drugs Administration 
FiO2- fraction of inspired oxygen 
FPF: fine particle fraction 
GSD: geometric standard deviation 
HH: heated humidifier 
HME: heat and moisture exchanger 
i.v.: intravenous 
ISF: interstitial space fluid 
kDa: kilo Daltons 
Kel: elimination rate constant  
LC-MS/MS: liquid chromatography tandem mass spectrometry 
MBq: mega-becquerel 
MD: Microdialysis 
mg: milligrams 
MIC: minimum inhibitory concentration 
mL: millilitres 
mm: millimetres 
MRSA: Methicillin-resistant Staphylococcus aureus 
MRT: mean residence time  
MV- mechanical ventilation 
MW: molecular weight 
NIV: non-invasive ventilator 
P/C ratio: peripheral: central ratio 
PaO2 – partial pressure of oxygen 
PD: pharmacodynamics 
PEEP: positive end expiratory pressure 
PET: positron emission tomography 
PK: pharmacokinetics 
pMDI: pressurized metered dose inhaler 
PVC: polyvinyl chloride 
 XXIV 
ROI: region of interest 
RR: Relative Recovery 
SD: Standard deviation 
SIMV: synchronised intermittent mandatory ventilation 
SPECT: single-photon emission computed tomography;  
Tmax: time that Cmax was observed 
TT: tracheostomy tube 
VAP: ventilator associated pneumonia 
VHC: valved holding chamber 
VMD: volume median diameter 
VMN: vibrating mesh nebulizer 
µg/mL: micrograms/millilitre 
 
 
 
 
 
 
 
 
 
 
 1 
Chapter 1 Overview 
 
1.1 Overview 
 
 Ventilator associated pneumonia 
 
Ventilator associated pneumonia (VAP) is defined as pneumonia that occurs 48-72 
hours, or greater, following endotracheal intubation, characterized by the presence of 
a new or progressive infiltrate, signs of systemic infection (fever, altered white blood 
cell count), changes in sputum characteristics, and detection of a causative 
pathogen[1]. VAP contributes to almost half of all cases of hospital acquired 
nosocomial pneumonia[1, 2]. Worldwide, there is significant mortality and morbidity 
associated with VAP[3-6]. Moreover, there is also a concern of an increasing 
emergence of multi-resistant organisms as a cause of VAP[7]. Hence, VAP continues 
to be a challenge from both a prevention and treatment perspective in critical care.  
 
Conventional therapy of VAP consists of systemic administration of antibiotics via 
intravenous route. However, despite therapy, the outcomes remain poor leading to 
mortality rates ranging 20 to 70%[8]. One reason for therapeutic failure could be due 
to inadequate antibiotic concentration at the site of infection for pneumonia, the lung 
interstitial space fluid (ISF)[9]. A paucity of newer antibiotics and limitations to dose 
escalation due to the risk of systemic drug toxicity remain ongoing concerns[10]. There 
is now a growing need for investigation into effective drug delivery to attain optimal 
lung ISF concentrations of antibiotics and improve pneumonia outcomes.  
 
 Nebulized antibiotics for the treatment of VAP 
 
One way of achieving high antibiotic concentrations in the lung ISF may be to 
administer via the nebulized route. Nebulized antibiotic therapy has the inherent 
advantage of potentially achieving higher lung ISF concentrations whilst limiting 
systemic toxicity due to minimal systemic drug absorption[11, 12]. Drug administration 
of antibiotics via the nebulized route involves using a delivery system that consists of 
an appropriate formulation and a delivery device. Further to this, there are patient-
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related factors that need consideration, namely airway geometry, patency and sputum 
characteristics amongst others[13]. 
 
Nebulized antibiotics have been extensively and studied in cystic fibrosis patients[14]. 
Its use has now extended to prevention and treatment of VAP, ventilator associated 
tracheobronchitis, bronchiectasis[15]. Few antibiotic formulations for the nebulized 
route are studied and approved[13]. Intravenous formulations of other antibiotics e.g. 
preservative free tobramycin, beta-lactams, are often used off label for nebulized 
therapy which is highly problematic as these formulations may not enable sufficient 
drug delivery[16].  
 
Despite increasing worldwide use of nebulized antibiotics, recent randomized 
controlled trials failed to demonstrate clinical outcome benefits of adjunctive nebulized 
therapy compared to systemic therapy alone for VAP[17, 18]. Insufficient drug delivery 
could be one of the reasons for the failure of therapy. Besides the factors mentioned, 
nebulized antibiotic delivery with mechanical ventilation is influenced by a number of 
factors such as ventilator settings including tidal volume, flow pattern, flow rate, 
inspiratory to expiratory ratio, circuit related factors, humidification, position of 
nebulizer in the circuit, continuous versus synchronised nebulization systems[13]. 
Numerous in vitro and in vivo studies have attempted to study the effects of these 
different factors with a view to generate data to guide optimal settings. Consequently, 
expert groups have made recommendations for the appropriate use of nebulized 
antibiotics with mechanical ventilation[19]. However, dosing schedules for nebulized 
antibiotics remains an ongoing concern. The current dosing guidelines are based on 
the studies in the CF population, data from experimental pneumonia models or from 
underpowered trials[20, 21]. Data from studies are required to guide the generation of 
appropriate dosing schedules for the nebulized antibiotic therapy in VAP.   
 
 Pharmacokinetics of nebulized antibiotics with mechanical ventilation 
 
For antibiotic therapy, understanding pharmacokinetics (PK) should be considered 
essential for designing effective dosing. For nebulized antibiotics, the PK parameters 
of significance includes particle size characteristics, aerosol output parameters, 
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regional drug distribution, and lung ISF concentration-time profile. Lung antibiotic PK 
is the relation between dose and the concentration-time profile of the antibiotic in the 
lungs and, to date, is poorly understood. Currently, the PK data for nebulized 
antibiotics is acquired from studies in ambulant cystic fibrosis patients[22], PK data 
from experimental pneumonia models. PK studies on nebulized antibiotics with 
mechanical ventilation are done using sputum, BAL and serum samples. However, 
there are inherent limitations of the sampling methods used for describing the lung PK 
of nebulized antibiotics[23]. Microdialysis is a semi-invasive technique that has been 
used for the accurate sampling of lung ISF for the measurement of antibiotics[23].  
 
Hence, our current knowledge suggests that inadequate nebulized antibiotic dosing is 
likely to be common when treating patients with VAP. This may lead to therapeutic 
failure and emergence of drug resistant organisms due to exposure to sub-therapeutic 
antibiotic concentrations. For better dosing guidance for nebulized therapy, research 
describing the PK of nebulized antibiotics is required.  
 
This Thesis investigates tobramycin as the study antibiotic as it is microbiologically 
highly effective against gram negative organisms such as Pseudomonas spp which 
are the major pathogens associated with VAP[24].   
 
Chapter two of the Thesis is a structured review providing the background to this field 
of research. The chapter explores and discusses in detail the fundamentals of the 
application of aerosol therapy in critically ill patients.  
 
Chapter three describes the methodological details for the research to be undertaken 
throughout the Thesis. The chapter will provide the overall plan of research with further 
specific detail included for each of the chapters containing the studies contained within 
this Thesis.  
 
Chapter four, five, six and seven are prospective studies, each addressing an 
important aspect of the PK of nebulized tobramycin. Chapter four describes the effect 
of combination antibiotics on the microdialysis relative recovery rates using in an in 
vitro study performed in simulated in vivo conditions. Chapter five explores the aerosol 
characteristics of two different tobramycin formulations in a simulated mechanical 
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ventilation set up. Chapter six is a comparative description of the distribution of 
intravenous and nebulized radiolabelled tobramycin. Chapter seven details the 
comparison of lung concentrations of intravenous and nebulized tobramycin.  
 
Chapter eight provides a general discussion on the findings of this Thesis and provides 
suggestions for future research in this field.  
 
1.2 Aims 
 
The aim of this Thesis was to characterise the disposition of nebulized tobramycin 
during mechanical ventilation. The specific aims of this Thesis were to: 
 
1. Review of published literature to describe the fundamentals of aerosol therapy 
in the critically ill patients.  
2. Describe the methodological aspects of the research pathway program for the 
study of PK of nebulized antibiotics. 
3. Describe and compare the physicochemical and nebulized mass 
characteristics of two formulations of nebulized tobramycin  
4. Describe and compare the pulmonary distribution features of technetium 99m-
labelled tobramycin when administered via intravenous route with the 
nebulized route of delivery. 
5. Describe and compare the lung ISF concentrations and systemic PK of 
tobramycin between intravenous and nebulized route of delivery.      
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Chapter 2 The principles of aerosol therapy in critical care 
 
2.1 Synopsis 
 
The aim of this chapter is to review the published literature in order to describe the 
various factors that require attention for optimization of aerosol drug delivery in order 
to achieve better drug concentrations at the target sites and potentially improve clinical 
outcomes.  
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2.2 Published manuscript entitled “Fundamentals of aerosol therapy in 
critical care”  
 
The manuscript entitled, “Fundamentals of aerosol therapy in critical care” has been 
accepted for publication by Critical Care (2016; 20:269). 
 
The co-authors contributed to the manuscript as follows: All literature reviews were 
performed by the PhD candidate, Jayesh Dhanani, under the supervision of Prof Jason 
Roberts. Data extraction from cited articles was done by the PhD candidate, Jayesh 
Dhanani under the guidance of Prof John Fraser, Prof Hak-Kim Chan and Prof Jordi 
Rello. The final editing was done by the PhD candidate, Jayesh Dhanani, with 
supervision from Associate Prof Jeremy Cohen and Prof Jason Roberts. The PhD 
candidate, Jayesh Dhanani, took the leading role in the manuscript preparation and 
writing.  
 
The manuscript is presented as published; except figures and tables have been 
inserted into the text at slightly different positions. Also, the numbering of the pages, 
figures and tables has been adjusted to fit the overall style of the Thesis. The 
references are found alongside the other references of the Thesis, in the section 
‘References’.  
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 Abstract 
 
Drug dosing in critically ill patients is challenging due to the altered drug 
pharmacokinetics/pharmacodynamics associated with systemic therapies. For many 
drug therapies, there is potential to use the respiratory system as an alternative route 
for drug delivery. Aerosol drug delivery can provide many advantages over 
conventional therapy. Given that respiratory diseases are the commonest causes of 
critical illness, use of aerosol therapy to provide high local drug concentrations with 
minimal systemic side effects makes this route an attractive option. To date, limited 
evidence has restricted its wider application.  The efficacy of aerosol drug therapy 
depends on factors relating drug (particle size, molecular weight), device factors, 
patient related factors (airway anatomy, inhalation patterns) and mechanical 
ventilation related factor (humidification, airway). This review identifies the relevant 
factors that require attention for optimization of aerosol drug delivery that can achieve 
better drug concentrations at the target sites and potentially improve clinical outcomes.  
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 Introduction 
 
The main goal of aerosolization is to achieve high drug concentrations in lung tissue. 
Aerosol therapy has been used as part of the treatment for a variety of respiratory 
diseases[25]. Indeed, there is also significant interest in the utilization of the respiratory 
system as a portal for systemic therapy[26] of conditions that are not purely respiratory 
in nature. Factors such as a large surface area, thin air- blood barrier, vascular 
epithelium coupled with low first pass metabolism and enzymatic activity could achieve 
high bioavailability for aerosolized drug therapy[27]. Thus, the possibility of achieving 
very high local drug concentrations at the therapeutic site for respiratory pathology, 
rapid onset of action and lower systemic side effects[28] has led to a renewed interest 
in the field of aerosolized drug therapy in intensive care.  
 
Datura administration in India, tobacco in ancient South America and smoking pipes 
from North American Indians are some of the early uses of airways as a route for 
systemic drug delivery[29, 30]. Vaporized opium was used as a treatment for cough. 
Anticholinergic properties of inhaled herbal preparations were used in asthma and 
inhaled epinephrine was first used around 1910 [31]. Aerosolized therapy is used for 
many therapies now including bronchodilators and corticosteroids with a particular 
interest in antibiotic administration re-emerging recently. Although there are 
references to the use of inhaled penicillin as early as 1946 [29], the first randomized 
controlled trial of inhaled antibiotics was first reported in cystic fibrosis patients in 1981. 
In critical care, it was only in the 1970s that endotracheal antibiotic administration was 
first reported [32], when Klastersky et al reported that endotracheal polymyxins were 
effective for prevention of ventilator-associated pneumonia in tracheostomised 
patients [33-35]. Following these and other studies it was noted that there were 
adverse effects such as bronchospasm and poor tolerance[33] as well as concerns 
regarding emergence of drug resistance associated with prolonged (>3 weeks) 
endotracheal administration and pharyngeal aerosolization [36]. This led to reduction 
in the use of inhaled antibiotics. Even so, some investigators continued to prescribe 
intratracheal antibiotics in the critically ill, often successfully, especially in drug 
resistant pneumonias[37, 38]. Antibiotic instillation practices were used in some early 
studies, but this practice was largely abandoned in the 1980s. Subsequent use of 
bench models enabled an improved understanding of the aerosolization factors such 
 10 
as optimal ventilator parameters, device position in the circuit and effects of humidity 
to enable optimal therapy[39-41]. This work was then supplemented with antibiotic 
studies in experimental pneumonia that demonstrated higher lung tissue 
concentrations of antibiotics[42]. The later development of ‘new generation’ devices 
such as the ultrasonic and the vibrating mesh nebulizers encouraged further study and 
application of aerosol therapy in critical care because of the ability of these devices to 
consistently generate desired aerosol particle sizes which are considered optimal for 
deep lung penetration[41, 43, 44].  
 
Previously, the formulations of drugs used for aerosolization was the reconstituted 
form of compounds developed for parenteral administration. These were poorly 
tolerated by patients due to hyperosmolarity and added preservatives (i.e., phenols), 
which induced bronchial irritation and bronchospasm, leading to abandonment of this 
route of therapy. These formulation issues were particularly problematic for antibiotics 
until the 1990s, when aerosolized tobramycin was evaluated in patients with cystic 
fibrosis (CF) chronically infected with increasingly resistant Pseudomonas aeruginosa 
[45, 46]. A number of high quality studies using preservative free and iso- osmolar 
formulations of tobramycin showed improvements in lung function, decreased 
exacerbation rate, and reductions in sputum bacterial load[45-47]. These results have 
encouraged further developments in the application aerosolized antibiotics in non-CF 
patient populations such as critical care. In the critically ill patient, certain anatomico- 
physiological changes can significantly affect the pharmacokinetic- 
pharmacodynamics (PK-PD) characteristics, thus causing dosing difficulties. [48]. 
Mechanically ventilated patients pose a challenge for the effective delivery of 
aerosolized drugs[49]. These various factors need to be considered and optimised to 
achieve desired therapeutic outcomes with aerosolized drug therapy[49].  
 
The research interest in aerosol drug therapy in the critically ill patients is not yet 
reflected in the bench-to-bedside transfer of knowledge. One report mentions up to 
95% intensivists are routinely prescribing aerosol medications[50]. This report also 
highlighted the lack of application of scientific principles during therapy and indicating 
the need for education and research in the bench-to-bedside transfer of 
knowledge[50]. In another study, it was seen that every fourth critically ill patient and 
fifth ventilated patient received aerosol therapy[51]. A recent International survey 
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performed in Europe, Asia, Australasia and North America showed that although 45% 
of the intensive care units practice antibiotic nebulization, very few actually follow the 
recommendations[52]. Given the commonness of use of aerosolization in critical care, 
yet the uncertainty over the optimal approach for administration, this paper aims to 
discuss the essential concepts related to aerosolized drug therapy in critical care.  
 
 The Aerosol System 
 
An aerosol is defined as a suspension of liquid or solid in a gaseous medium[53]. For 
successful aerosolization, consideration of the aerosol system is required. The aerosol 
system includes the drug, the aerosol device, the disease (i.e. the target site) and 
patient’s respiratory system with the ventilator being an additional factor in 
mechanically ventilated patients. The aim of the aerosol system is to produce aerosols 
with characteristics suitable for drug delivery to the lungs. Drug deposition, absorption, 
metabolism and elimination are essential determinants of the pharmacokinetic profile 
resulting from the aerosol system.  
Key expressions used to evaluate the aerosol system performance include[54]-  
• Emitted dose (ED) – the amount of drug exiting the delivery device 
• Fine particle fraction (FPF) – the mass of particles below a cut-off diameter[55].  
The overall efficiency of the aerosol system is a composite of the ED, dose delivered 
to the lung (FPF as a surrogate markers) and lung bioavailability. The ED and FPF 
are normally determined in vitro and are governed by particulate properties and device 
design. The bioavailability of the drug is influenced by patient factors such as airway 
and lung anatomy, drug permeability across membranes, metabolism of the drug and 
phagocytic clearance in the lung[56] as well as FPF.  
 
 Aerosol deposition 
 
The efficacy of the aerosolized drug depends on the dose deposited at the target site 
of action as well as its distribution in the lungs[57]. Deposition in the airways can occur 
by inertial impaction, gravitational sedimentation or diffusion (Brownian motion) (see 
Figure 2.1 on page 12). Due to the turbulence and high air velocity associated with 
aerosolization, inertial impaction method is predominant in the first 10 branchings of 
the airway[58]. This proximal region is the target for aerosol therapy for diseases such 
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as COPD, asthma and ventilator associated tracheobronchitis. In the distal 5 to 6 
airway generations however, sedimentation predominates due to lower air 
velocity[58]. At the alveolar level, minimal air velocity means no effect of impaction will 
occur and a combination of sedimentation and diffusion will influence drug 
deposition[58]. Most aerosolized particles for therapeutic purposes are in the range of 
2- 5 m and for lung deposition diffusion is the predominant mechanisms. Optimal 
technique for aerosolization is important to achieve distal airway and alveolar 
deposition.  
 
Figure 2.1: Mechanisms of aerosol particle deposition 
 
 Factors affecting aerosolized drug delivery in the critically ill patient 
 
Drug concentrations in lung tissue are affected by the aerosolized dose administered, 
patient factors, device factors and the formulation of the drug. Mechanical ventilation 
(MV) introduces additional elements such as the circuit and the ventilator and its 
associated factors. For the purposes of describing the factors affecting the aerosol 
therapy, the critically ill patients could be classified into two groups, ventilated and 
non-ventilated patients[59-62]. Figure 2.2  on page 14 lists the factors conducive for 
effective aerosol drug delivery in the critically ill mechanically ventilated and non-
mechanically ventilated patient groups. 
Brownian motion 
(diffusion)
sedimentation
Impaction
The Airway
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Figure 2.2: Factors favourable for aerosol drug delivery in the critically ill patients. 
(Figure derived from references – [43, 44, 49, 53, 55, 62-69] 
(NIV- noninvasive ventilation, HME- heat and moisture exchanger, pMDI- pressurized metered dose inhaler, AAD- adaptive aerosol 
device, VHC- valved holding chamber, VMN- vibrating mesh nebulizer, DPI- dry powder inhaler) 
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Factors conducive for effective aerosol drug 
delivery in the critically ill patient 
Mechanically ventilated  Non-mechanically ventilated  
Ventilator parameters 
• Slow flow (40 lpm better than 80 lpm) 
• Long inspiratory time (duty cycle 0.5 better than 0.25) 
• NIV with nebulizer 
• PEEP 
 
Circuit and related factors 
• Larger airway (Endotracheal tube or tracheostomy) 
• For tracheostomy, use T- piece interface 
• Humidification- remove HME and heated humidifier 
 
Patient 
• Clear and patent airway i.e. minimal secretions 
 
Drug 
• Particle size 2-5 m 
• Off label use- monitor for adverse events 
 
Aerosol Device 
• VMN for aqueous solutions (AAD when possible) 
• If pMDI then with spacer (breath synchronized) 
• Position -Adult- VMN/ultrasonic/pMDI- 15cm from Y-piece 
in inspiratory limb. Paediatric- closer to ventilator 
 
     
 
 
 
 
Patient 
• Slow and deep breathing pattern  
 
Drug 
• Particle size 2-5m 
• Off label use- monitor for adverse effects 
• Expiratory filter to be used to prevent environmental 
contamination 
 
Device 
• VMN for aqueous solutions 
• If pMDI then use spacer (breath synchronized)  
• DPI (breath activated) if adequate respiratory reserves 
• Heliox may improve drug delivery 
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 General Factors affecting aerosolized drug delivery. 
 
2.2.3.1.1 Airway anatomy and physiology 
 
Airflow and tidal volume influence the effect of airway anatomy on the aerosol 
deposition. Patients suffering from airways obstruction such as asthma or COPD have 
impaired mucociliary clearances and mucus retention [70]. For drugs with poor trans-
mucus permeability e.g. aerosolized aminoglycosides, this could mean reduced  drug 
delivery and hence impaired efficacy although yet to be confirmed in clinical 
studies[71].  
Chronic inflammation may result in airway remodelling which changes the dynamics 
of airflow[57, 59], and impaired mucociliary clearance thus reducing the pulmonary 
drug deposition [57, 72]. These changes lead to a proximal shift in the airway 
deposition pattern of the aerosols[73].  
 
Significance – Abnormal airways and impaired mucociliary clearance serve as a 
barrier to effective aerosolized drug therapy when the target site is the lung 
parenchyma. 
 
2.2.3.1.2 Regional lung aeration 
 
The airflow is not homogenous throughout the lungs even in health. The result in an 
upright patient is that the apical portions of the lungs receive lung deposition of the 
order of a 2:1 higher ratio compared to the basal regions[74]. This difference is 
significantly reduced in the supine position[75]. Moreover, most lung diseases are 
regional which adds to the heterogeneity to regional airflow, an important determinant 
of aerosol deposition[63]. For example, it has been shown that there is lower 
deposition in areas of poor air flow i.e. atelectatic lungs[76].  
 
In the area of antibiotics, there is a large body of work been done with experimental 
pneumonia models which have demonstrated that lung tissue concentrations of 
nebulized amikacin, using an ultrasonic nebulizer, was significantly higher than the 
concentrations resulting from administration via the intravenous route[77, 78]. Indeed, 
even though deposition of nebulized drug decreased with more severe pneumonia, it 
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still resulted in higher lung tissue concentrations than that achieved from intravenous 
administration. Figure 2.3 illustrates this phenomenon. The same group also 
demonstrated that nebulized amikacin resulted in greater bactericidal activity leading 
to greater sterility rates compared to the intravenous route[79].  When compared to 
continuous intravenous infusion of ceftazidime, frequent nebulization achieved higher 
lung tissue concentrations with better bactericidal effects in an experimental model of 
Pseudomonas pneumonia[80].  
 
Significance- This phenomenon may explain some of the variability in therapeutic 
outcomes amongst different lung diseases.  
 
Figure 2.3 (A) Relationship of lung aeration (%) to pulmonary concentration of 
amikacin (µg/g) for different routes of administration. (B) Relationship of route of 
drug administration to pulmonary concentration of amikacin (g/g) for different 
severities of pneumonia.  
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Pulmonary concentrations derived from homogenized lung tissue specimens 
measured by an immunoenzymatic method. 
(Figure derived from Elman et al[77]). 
 
2.2.3.1.3 Inhalation Patterns 
 
In a critically ill, spontaneously breathing patient, air flow is likely to be turbulent 
leading to impaction in the proximal airway. For drugs dependent on lung deposition 
for their effect, this results in a decreased pharmacological effect. In contrast, laminar 
flow patterns are considered to enable optimal lung deposition[64]. In the critically ill 
patient, certain mechanical ventilation settings e.g. square wave airflow pattern, 
enable generation of laminar airflow to improve drug deposition in the lungs.  
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On the other hand, lower flows may reduce the emitted dose (ED) when dry powder 
inhalers (DPIs) are used[81]. Using pressurized metered dose inhalers (pMDIs) with 
valved holding chambers (VHCs) or spacers) could mitigate this effect. 
 
Significance – Whilst a laminar flow pattern would be beneficial for aerosolized drug 
delivery, mechanistic data need to be confirmed using clinical trial.  
 
2.2.3.1.4 Surfactant 
 
Diseases such as pneumonia and other inflammatory lung diseases result in 
deficiencies of lung surfactant both in content and/or effect[82, 83]. Drugs with high 
solubility will likely have a uniform dispersion compared to insoluble drugs. Inferentially 
the soluble drugs are likely to have longer and more effective lung residence times 
thus improving drug potency[84]. Surfactant deficiency, is associated with atelectasis, 
which in turn impairs drug deposition[73]. Studies on surfactant replacement therapy 
in acute lung injury and ARDS however have failed to demonstrate benefit and may 
even be deemed harmful [85, 86]. Aerosolized surfactant therapy has been studied as 
a mucokinetic agent in specific conditions[87]. Its application for this purpose in the 
critically ill patients needs further studies. 
 
Significance – Uncertain benefits requiring further studies to demonstrate effect. 
 
2.2.3.1.5 Mucus barrier and atelectasis 
 
A major fraction of the aerosolized drug is entrapped in the mucus in the conducting 
airways. Factors such as particle size, solubility, lipophilicity and charge govern the 
ability of the drug to penetrate this mucus barrier. For example steroids and 
antimicrobial agents are seen to have a reduced trans-mucus transport[70, 71].  
Atelectasis is a common occurrence in the majority of critically ill patients. This may 
have adverse effects on drug deposition and may result in heterogeneous distribution 
in the lung[88]. 
 
Significance – Barrier to effective aerosolized drug therapy. 
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2.2.3.1.6 Device effects 
 
A detailed discussion on the effect of device-related factors has been reviewed 
elsewhere[44, 89]. Appropriate particle sizes are important to enable adequate 
concentrations at the target site. Particle size also determines the mechanism of 
deposition in the respiratory system[55]. Particles that distribute deep in the smaller 
airways (<5 m) are reported to have up to 70% deposition efficiency [57, 90].  Smaller 
particles (1-3 m) are considered to have the optimal droplet size for efficient 
deposition in the alveolar airspaces, for systemic delivery[91]. In this regard, the 
efficiency of the aerosol device can be defined to be the ability to generate the aerosol 
in the desired particle size range.  
 
pMDI with spacers or valved holding chambers (VHC), have demonstrated superior 
deposition efficacy over nebulizers in various studies[92-94]. Although, for mechanical 
ventilators, the VHCs cannot be used due to the inability to trigger/activate the device. 
DPIs have no propellant, are inherently breath-synchronized/ activated and produce 
little variation in particle size. These features may make DPIs the preferred delivery 
device. However, in critically ill patients, poor respiratory reserve and diminished 
patient efforts are barriers to achieving the desired respiratory pattern for effective use 
of DPIs.  DPIs also vary widely in their efficacy[95] and their use in mechanically 
ventilated patients is not typically possible with a standard set up[96]. Thus, presently, 
DPIs are used in stable and unventilated patient groups. Both pMDI and DPI are 
limited by the formulations available to be delivered by these devices.  
 
Nebulizers are different devices that are used to transform liquid formulations and 
suspensions into an aerosol form. These devices can be used to deliver larger 
volumes of a drug as an aerosol either intermittently or continuously, for prophylaxis 
or treatment purposes. Depending on their mechanism of operation, there are three 
types of nebulizers: jet, ultrasonic and vibrating mesh nebulizers. Jet nebulizers are 
the cheapest and simplest, albeit being inefficient in drug delivery[97]. Other 
drawbacks are noise, poor dosing control, and the requirement for changes in the 
ventilator settings such as airflow and tidal volume. Although improvements have been 
made in the form of reservoirs and new baffles that ensure more optimal particle sizes. 
Breath enhanced versions of the jet nebulizers could increase FPF, improved drug 
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delivery and reduced drug loss. There are limited studies evaluating the efficiency of 
these newer jet nebulizers and data is certainly lacking in critical care 
settings[98].Newer ventilators have in-built nebulization systems which improve the 
efficiency by synchronizing nebulization with the respiratory cycle. Ultrasonic 
nebulizers are infrequently used and also have limitations[43, 99]. They are expensive, 
large in size, increase concentration of the drug during nebulization and can cause 
thermal inactivation of the nebulized drug. Mesh nebulizers are the result of 
improvement in nebulizer technologies.  Although, more efficient and with significant 
advantages, there is a dearth of human studies using mesh nebulizers. Despite major 
improvements in the technology there is a need to reduce the cost of these devices.  
Table 2.1 on page 22 compares and contrasts the principles, advantages and 
disadvantages of different nebulizers. 
 
Significance – Where possible pMDI with spacer should be used. DPI use is likely to 
be limited in critical care. For nebulizers, the device should be selected according to 
the formulation used and the desired site of deposition and effect. 
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Table 2.1: Comparison of different types of nebulizers. 
 
Nebulizer type Mechanism of Action Types Advantages Disadvantages 
Jet[97] Pressurized gas forms a jet 
passing through a tube 
creating a low pressure zone 
(Venturi effect) that draws 
liquid formulation into the jet 
stream (Bernoulli effect). 
Droplet size > 5 um 
 
• with a corrugated 
tube,  
• with a collection 
bag,  
• breath-enhanced 
jet nebulizers, and  
• breath-actuated jet 
nebulizers. 
• Cheap 
• Easy to use  
• Effective in 
delivering drugs 
that cannot be 
delivered with 
pMDIs and DPIs  
• Breath enhanced 
and breath 
actuated options. 
• Inefficient  
• Difficult to clean  
• Need compressed 
gas and additional 
tubing  
 
Ultrasonic[99, 
100] 
Piezoelectric crystal converts 
an electrical signal into high 
frequency vibrations in the 
liquid, forming an aerosol 
using cavitation and capillary 
mechanisms. 
Drug output  vibration 
• small volume (e.g. 
for medications). 
• large volume (e.g. 
For hypertonic 
saline used for 
sputum induction)  
 
• Easy to use  
• More efficient than 
jet nebulizers  
• Shorter 
nebulization time 
(better for large 
volumes) 
• Large residual 
volume 
• Unable to nebulize 
viscous solutions  
• Degradation of 
heat-sensitive 
materials- so 
inappropriate for 
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amplitude 
Particle size  vibration 
frequency 
Droplet size variable, may be 
less than 5um 
 
 proteins. 
• Aerosol 
temperature 10-14 
C higher than that 
in jet nebulizer. 
• Large device size  
 
Vibrating 
mesh[43, 99] 
Aerosol is produced by 
forcing the liquid using the 
micropumping action through 
the vibrating mesh containing 
funnel-shaped holes.  
Droplet size < 5 um. 
 
 
• active e.g. Aeroneb 
® (Aerogen, 
Galway, Ireland)  
• passive e.g. 
Microair NE-U22 ® 
(Omron, 
Bannockburn, IL). 
 
• Silent operation, 
portable  
• Short treatment 
time 
• Minimal residual 
volume 
• Self-contained 
power source 
• Optimize particle 
size for specific 
drugs  
• More output 
• More expensive  
• Cleaning can be 
difficult  
• Drug dose needs 
to be adjusted in 
transition from jet 
nebulizers.  
• Inability to use to 
aerosolize viscous 
liquids  
• Inability to 
aerosolize drugs 
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efficiency than 
other nebulizers 
• 2-3 times higher 
drug deposition 
compared to jet 
nebulizers.   
• Aerosol 
temperature 
usually 
unchanged 
• Unchanged 
osmolality 
• Easy to use  
 
that crystallize on 
drying  
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2.2.3.1.7 Drug Effect  
 
The rate and extent of absorption of the aerosolized substances is dependent on 
molecular weight, pH, electrical charge, solubility and stability.  
Macromolecules with <40 kDa are observed to be better absorbed (in minutes) in the 
blood stream following inhalation in the airways, e.g. insulin (molecular weight (MW) 
5.7 kDa)[101]. However macromolecules with >40 kDa are absorbed slowly over 
hours, e.g. albumin (MW 68 kDa)[102]. Molecules with MW above 30 kDa may need 
an absorption enhancer for absorption in the alveoli[103].  
 
Significance – Depending on desired site of action, appropriate drug formulations 
should be used alongside delivery devices that would generate a suitable particle size.  
 
2.2.3.1.8 The Heliox Effect 
 
A combination of helium and oxygen (Heliox) reduces gas density and increases 
aerosol deposition, particularly in the peripheral lung [104]. With pMDI, Heliox has 
been reported to increase aerosolized drug delivery during MV[105]. However, with jet 
nebulizers it also increases the nebulization time, requires higher gas flows to 
compensate for the low density gas[106]. In an experimental study, there was no 
increase in lung deposition of nebulized ceftazidime in bronchopneumonic compared 
to healthy lungs [107].  
 
Significance – Further investigations and large-scale trials are needed to evaluate the 
effect of heliox in critical illness. 
 
2.2.3.1.9 Sputum Antagonism 
 
Due to a variety of proposed mechanisms patient sputum is thought to cause 
aminoglycoside inactivation resulting in ‘sputum antagonism’[108]. 
 
Significance – Uncertain and requires further in vivo investigation. Current data from 
cystic fibrosis patients support use of inhaled aminoglycosides[109, 110]. 
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 Specific Factors affecting aerosolized drug delivery in mechanically 
ventilated patients. 
 
Aerosol therapy is routinely used in mechanically ventilated patients, both invasive 
and non-invasive, and is inherently challenging due to the interplay of a variety of 
factors [49]. However, not all nebulization techniques are comparable. Patient 
position, formulation, temperature, endotracheal tube size, presence of airway 
obstruction or ventilatory asynchrony, flow pattern, respiratory rate, dose applied and 
frequency, or position of the nebulizer in the circuit are important factors that influence 
delivery to the lung. The higher the turbulence, the lower the drug deposition in the 
distal airways. Optimal settings of nebulization are not tolerated by many patients 
(such as those with severe hypoxemia, associated with ARDS or pneumonia) and 
require the need of adding deep sedation and relaxation, which prolongs the duration 
of MV. Disposition in unilateral pneumonia might be imbalanced. 
 
2.2.3.2.1 Type of the aerosol generator in the circuit 
 
Currently, nebulizers and pMDI, with and without spacers, are two types of devices 
available for use in the mechanically ventilated patients. Depending on the site of 
action, devices producing appropriate particle size should be used. [66].  
 
Nebulizers take a considerably longer time to deliver a standard dose as compared to 
other devices. There is also a variation in efficiency between nebulizer types and 
between nebulizers in different batches[44]. This effect is accentuated when coupled 
with the effects of different ventilator modes and lung mechanics[67]. Inadequate 
cleaning and disinfection of the nebulizer increases the risk of nosocomial 
pneumonia[111]. Compared to jet nebulizers, VMNs could increase the drug delivery 
by 2- 4 fold[43], although as discussed previously, the nebulizer choice is dependent 
on the formulation and the desired delivery site. 
 
pMDIs are easy to administer, require less staff time, provide reliable dosing and have 
minimal risk of bacterial contamination when compared with nebulizers. When used 
with a collapsible spacer in the circuit, the circuit does not need to be disconnected[49]. 
pMDIs are also more cost effective than nebulizers[112]. Although only 
bronchodilators and anti-inflammatory agents are available for this device, it is seen 
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that using pMDIs significantly reduces overall costs of care and could be equally 
effective in the treatment of inflammatory airways disease such as asthma and 
COPD[44, 113, 114],[112, 115, 116]. In vitro studies have shown improved aerosol 
delivery with large spacers than with small for pMDI and VMN.[117]. Published 
recommendations for the correct methods of their use are available[49].  Others have 
shown modest improvement in the aerosol delivery[118]. 
 
Significance – pMDI are possibly more effective than nebulizers. VMNs appear 
superior to other nebulizer types although the choice should be dependent on the drug 
formulation properties and the desired deposition site. At this time, there is insufficient 
evidence to support the use of either delivery method over the other[68]. The use of 
spacers with pMDI needs further clinical trial to test its efficacy. 
 
2.2.3.2.2 Position of the aerosol generator 
 
In vitro studies[119] using adult ventilators have shown that using vibrating mesh and 
ultrasonic nebulizers as well as the pMDI, a position 15 cm from the Y-piece in the 
inspiratory limb of the circuit yields highest drug delivery. In constant flow pattern of 
ventilation, the VMN connected to the endotracheal tube could be as effective[69]. 
However, jet nebulizers seem to perform better when positioned closer to the ventilator 
possibly due to the effect of the continuous gas flow ‘charging’ the circuit, which 
functions as an aerosol reservoir[119]. For non- invasive ventilation (NIV), using the 
VMNs position after the exhalation port is more efficient for drug delivery compared to 
that before the exhalation port[120]. 
 
Significance – The best position of the aerosol generator may be 15 cm from the Y-
piece in the inspiratory limb. In vivo studies are required to make definitive 
conclusions. 
 
2.2.3.2.3 Effect of tracheostomy and airway size 
 
Though the endotracheal tubes and tracheostomy tubes present certain similarities, 
the tracheostomy tube is shorter and more curved than an endotracheal tube.  In 
patients which are not mechanically ventilated,  it has been demonstrated that a T 
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piece interface between the tracheostomy tube and the nebulizer is more effective 
than a tracheostomy mask[121, 122]. Preferably, the inner cannula should be removed 
before nebulization particularly for the smaller sized tubes[123] as smaller diameter 
airways lead to an increase in the resistance to airflow resulting in increased drug 
deposition in the artificial airways and tracheobronchial region [124]. [125]. 
 
Significance – For aerosolized drug delivery, larger size artificial airways are better. 
 
2.2.3.2.4 Heat and Humidity of the circuit 
 
In mechanically ventilated patients, a temperature of 34-41C (average 37C) and 
relative humidity of 95- 100% is required to prevent heat loss[126]. Humidification also 
prevents drying of secretions, mucus plugging and consequently atelectasis. There 
are two major methods of humidification – active and passive. Active methods include 
a heated humidifier (HH) and passive methods include heat and moisture exchanger 
(HME). 
 
Humidification is thought to have a significant effect on aerosol drug delivery. Due to 
the hygroscopic effects of humidification, there may be a 2-3-fold growth in particle 
size as they pass through airways. This increase in size may reduce peripheral lung 
drug deposition and hence pharmacological efficacy[127]. Compared to humidified 
conditions, drug delivery can be doubled in non-humidified conditions[119]. It is 
recommended that HH should be ceased for the duration of therapy. Of interest, in an 
in vitro non-mechanically ventilated model, using the excipient enhanced growth 
(EEG) of submicrometer particles, one group has demonstrated increased aerosol 
deposition in airways and lungs[128, 129]. Further investigations in this method are 
required to harness its effect in MV. 
 
The HME is a physical barrier and should not be placed between the delivery device 
and the patient. The particulate air filter in the expiratory limb, used to protect the 
ventilator and the flow meter could get saturated resulting in airflow obstruction. It is 
recommended that the filter be changed after every nebulization treatment[42, 50, 52]. 
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Significance – Using HME or a particulate air filter with nebulization could result in air 
flow obstruction. Awareness and routine changing of air filters after each nebulization 
should be performed. 
  
2.2.3.2.5 Breath characteristics 
 
Ventilator breath characteristics have an important effect on the efficacy of aerosol 
delivery. Slower inspiratory flows, long inspiratory times[130] and tidal volumes > 
500mL (using pMDI)[131] correlate well with improved aerosol delivery.. Higher bias 
flow is seen to reduce the delivery efficacy of nebulizers[43]. Decelerating flow pattern 
is considered inferior to constant flow pattern for drug delivery[69]. The effect of 
ventilation mode is negligible for pMDIs[40]. The delivery efficiency in patients on NIV 
is seen to be comparatively less[132]. However, it must be remembered that specific 
techniques of ventilation may in themselves produce a greater benefit than the relative 
detriment of drug delivery – e.g. in NIV and asthma. Hence, in acute asthma NIV plus 
nebulization is more effective than nebulization alone[133]. 
 
A prescribed ventilatory pattern may not be practical in the critically ill patient. The 
most effective combination of tidal volume, flow and other ventilator parameters for 
aerosol delivery can be calibrated to the drug and delivery device using in vitro 
models.[134].  
 
Significance – Tidal volumes > 500mL may enhance aerosolized drug delivery. NIV 
results in effective therapy despite reduced drug delivery in conditions like asthma. 
Ventilator settings optimal for nebulization could however lead to patient-ventilator 
dyssynchrony in severely hypoxemic patients (e.g. due to severe pneumonia) thus 
requiring deep sedation, which may increase the duration of MV. 
 
2.2.3.2.6 Effect of PEEP 
 
Positive end expiratory pressure (PEEP) is a commonly used ventilator setting as part 
of the lung protective ventilatory strategy in severe lung diseases[135]. It has 
significant effects on regional ventilation and perfusion[136] and hence could influence 
the pharmacokinetics of an aerosolized drug. In an animal model using radiotracers, 
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PEEP was found to enhance aerosol clearance. This could be due to the stretching of 
the alveolar epithelium and enhancing the distribution of aerosol into the blood 
stream[137].  
 
Significance – PEEP is potentially beneficial although further data are needed to 
quantify the effect on aerosolized drug delivery. 
 
2.2.3.2.7 Effect of Drugs. 
 
The choice of one antimicrobial against another should consider efficacy data, costs, 
local antimicrobial resistance patterns and drug availability. Aminoglycosides require  
tissue concentrations >10-fold higher than the MIC to be maximally effective. Because 
airway inflammation could increase systemic absorption and the molecular weight is 
low, serum aminoglycoside concentrations should be monitored to avoid systemic 
toxicity. Beta-lactams are rapidly cleared from airways, requiring frequent 
administration. Colistin is administered in its anionic (methanesulfonated) form- 
colistimethate. Despite high doses  [up to 1 million units of colistimethate every 8 hours 
(80 mg of colistimethate, equivalent to 33 mg of colistin base)], as administered in 
colonized patients with bronchiectasis, lung epithelial lining fluid concentrations are 
not above 4 mg/L after 8 hours (upper threshold of EUCAST MIC breakpoint for 
Pseudomonas) or even above 2 mg/L after 8 hours in many patients (EUCAST MIC 
breakpoint for Klebsiella sp. and A. baumannii). Therefore, high doses (5 million units 
8 hourly) should be considered in pneumonia.  
 
2.2.3.2.8 Effect of Dosing 
 
Despite delivery of drugs via the inhaled route, significant extrapulmonary drug losses 
may mean that the actual amount of drug delivered may be less than 60% of the 
emitted dose into the trachea and even less will reach the alveolar space [138]. This 
factor should be taken into account when calculating dosing regimens. A number of 
animal studies have been useful to better understand the mechanistic principles of 
aerosol therapy.  Guillon et al[139] showed effective teicoplanin nebulization during 
MV with good PK properties compared to intravenous route.  Others successfully 
nebulized ceftazidime to achieve high local concentrations[107, 140]. 
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Further studies are required to quantify the exact dosing amount and schedule using 
PK studies. Doses should be different in patients with colonization, tracheobronchitis 
or pneumonia. Increasing doses (e.g. 5 million units of colistin) require longer periods 
of nebulization (~1 hour) which is not well tolerated by patients suffering from ARDS. 
 
Significance – Inhaled drug dose is likely to be significantly higher than expected due 
to concerns about drug losses.  Further PK-PD studies are required to guide inhaled 
drug dosing. 
 
2.2.3.2.9 Effect of Timing of nebulization  
 
Most of the drug losses occur in exhalation phase of ventilation. To minimize this, the 
actuation of the inhaler or nebulizer could  be matched with inspiration[41]. However, 
the use of the spacer-pMDI combination negates the effect of lack of breath 
synchronization[131].  
 
The effect of breath synchronization on aerosol deposition is unproven. Using 
radiolabeled aerosols, Dubus et al[141] showed that in neonatal ventilation with breath 
synchronization, there is no significant increase in aerosol deposition in neonatal 
ventilation. Thus, further investigations are needed to evaluate the effects of breath 
synchronization on aerosol deposition. In any event, devices which introduce 
synchronization of drug delivery facilitate tolerance. 
 
Significance – Breath actuation of the drug delivery devices has the potential to 
improve drug delivery. However, trial based data are required to establish its efficacy 
in aerosolized drug deposition. 
 
 Effect of High flow nasal cannula 
 
High flow nasal oxygen therapy is becoming a widely prevalent therapy in intensive 
care[142]. A number of factors influence the nebulization therapy in patients using high 
flow which was studied in an in vitro model recently [143]- 
1. Position of the nebulizer- a position distant from the humidifier (closer to the 
patient) improved delivery of the drug upstream. 
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2. Nebulizer type- VMNs demonstrated improved delivery as compared to jet 
nebulizer although the nebulizer choice is dependent on the formulation and 
desired site of action. 
3. Airflow- It is seen that the delivery of respirable mass is lower with higher airflow 
and improves at a lower airflow. 
4. Patient efforts- Converse to the effect of airflow with high flow oxygen system, 
it is seen that with situations mimicking respiratory distress i.e. increased 
patient inspiratory airflow, the delivery was in fact better. Open mouth on the 
other hand had no significant difference to closed with respect to drug delivery. 
 
Significance- Limited data suggest better drug delivery using VMNs at a lower airflow 
even in patients with respiratory distress. Further in vivo studies need to be performed 
using high flow oxygen therapy devices.  
 
Contemporary applications of aerosol therapy in critical care: focus on antibiotics. 
(Table 2.2 summarizes the common applications of aerosol therapy in critical care) 
 
 
 
 
 33 
Table 2.2: Common applications of aerosol therapy in intensive care (*). 
       D r u g   
                c l a s s 
 
 
F e a t u r e 
Bronchodilators Anti- 
inflammatory 
Antimicrobial agents Vasoactive 
agents 
Heliox 
Indications Bronchospasm 
e.g. acute asthma, 
COPD exacerbation 
Airway 
inflammation e.g. 
acute asthma or 
COPD 
exacerbation, 
acute interstitial 
lung disease 
MDR 
Tracheobronchitis 
MDR Pneumonia 
Aspergillus Prevention 
(lung transplant) 
Right ventricular 
failure 
Pulmonary 
hypertension 
 
Asthma 
Site of action Airways Airways or alveoli Airways or alveoli Alveoli Airways 
Preferred device pMDI with spacer pMDI with spacer VMN VMN  
Drugs Beta agonists e.g. 
salbutamol, 
salmeterol 
Anticholinergics e.g. 
ipratropium, 
tiotropium 
Budesonide 
Fluticasone 
Antibiotics- e.g. 
tobramycin, colistin, 
amikacin, ceftazidime, 
amphotericin B. 
Epoprostenol 
Iloprost 
Helium 
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Formulations available Yes Yes Some Yes  
 
COPD- chronic obstructive pulmonary disease, MDRO- Multidrug Resistant Organism, RDS- respiratory distress syndrome of the 
newborn, ARDS- adult respiratory distress syndrome, pMDI- pressurized metered dose inhaler, VMN- vibrating mesh nebulizer. 
(*) Anesthetic gases were out of the objectives of this analyses. 
Table derived from references- [43, 48, 61, 115, 144-163]. 
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Aerosolized bronchodilators and corticosteroids have been effectively utilised in 
critical care. Aerosolized antibiotics are quickly gaining more data to support their 
position in the critical care armamentarium. With improvements in drug formulation 
and delivery devices more is now known about the optimal conditions required for 
effective aerosolized therapy as summarised in figure 1.2. 
 
Despite these developments there are concerns that best evidence for administration 
is not being applied, particularly for aerosolized antibiotic therapy[164, 165]. Clinical 
and experimental study data for aminoglycosides and colistin are perhaps most 
numerous for antibiotics in the critical care[52]. Aminoglycosides are concentration-
dependent antibiotics whereby bactericidal effect is best described by the Cmax/MIC 
ratio. Studies have shown that intravenous aminoglycosides penetrate poorly in the 
epithelial lining fluid[78, 166]. In an Escherichia coli inoculation pneumonia model, 
aerosolized amikacin was seen to achieve significant lung concentrations[78]. Figure 
2.4 is an illustration of this phenomenon. On the other hand, with repeated 
administration, it was seen that there were no accumulation effect hence no toxicity 
concerns with aerosolized amikacin[76]. In experimental studies, it was seen that 
serum concentration of amikacin was higher when aerosolized amikacin was used in 
pneumonia model[78] compared to that of healthy lungs[76]. Moreover, a combination 
of intravenous and aerosolized aminoglycosides has not shown to increase cure rates 
compared to that of aerosolized antibiotic alone. Thus, for the treatment of ventilator-
associated pneumonia, aerosol therapy alone may be adequate without the need for 
intravenous therapy, decreasing risk of systemic toxicity[167].  
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Figure 2.4: Comparison of lung concentration (measured by HPLC) of amikacin 
between aerosolized and intravenous administration. 
Measurement done 1 hour after second administration performed 48 hours after 
bacterial inoculation. Diagram derived from the data from Goldstein et al[79].  
 
 
 
Colistin, also a concentration dependent antibiotic is another antibiotic widely used in 
the aerosolized form. Colistin aerosolization is not approved by the FDA and not 
licensed for human use in China. Like aminoglycosides, colistin has poor lung 
penetration when given intravenously. Experimental studies have shown that rapid 
and high bactericidal effect can be achieved with aerosolized colistin[138]. Figure 2.5 
illustrates this phenomenon. As demonstrated by Lu et al[138], with low serum 
concentrations resulting from aerosolized colistin in an inoculation pneumonia model 
the risk of toxicity is minimal. In a prospective observational study, Lu et al[167] 
demonstrated similar clinical cure for patients with VAP where susceptible P. 
aeruginosa or A. baumannii were treated with only intravenous colistin and MDR 
strains were treated with nebulized colistin. Combined intravenous aminoglycoside 
and aerosolized colistin have not shown to be superior to that of aerosolized colistin 
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alone although implemented worldwide. The benefit of the use of aerosolized colistin 
instead of systemic is to avoid nephrotoxicity and this was further confirmed in one 
randomized clinical trial [168]. 
 
Figure 2.5: Comparison of lung concentration (measured by HPLC) and bacterial 
burden of colistin between aerosolized and intravenous administration. 
Samples taken 1 hour after the third aerosol in the aerosol group and fourth infusion 
in the intravenous group and 49 hours after the bacterial inoculation. Diagram derived 
from data from Lu et al[138]. 
 
 
 
 Limitations of aerosol therapy in intensive care 
 
Observational cohort studies report less adverse events than randomized clinical 
trials. Indeed, there is potential to cause systemic (e.g., nephrotoxicity by 
aminoglycosides) or local toxicity in the form of airway irritation, cough and often 
bronchospasm [169], worsening hypoxemia (and secondary arrhythmias), as well as 
pulmonary injury when using aerosol therapies[170]. Ventilator malfunction and 
obstruction of expiratory filters has been reported and contraindicate the use of drugs 
with lipid components or lactose sugar in the formulation (such as zanamivir or lipid-
based amphotericin formulations) and careful monitoring of potential increase of 
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airways pressure and oxygen saturation is required to anticipate severe adverse 
events[171]. Modification of ventilator parameters for appropriate jet nebulizer use 
(Table 2.3) is not tolerated by some patients, increasing work of breath and ventilator 
dyssynchrony (requiring additional sedation). Poor tolerance may preclude their use 
in patients with PaO2/FiO2 under 200 mmHg or high PEEP requirements. 
 
Table 2.3: Optimization of ventilator parameters required for aerosolization of 
antibiotics 
(modified from Lu et al[167]) 
• Nebulizer placement- in the inspiratory limb 10 cm proximal to Y piece 
• Diluted in 10mL saline 
• Remove HME filter 
• Ventilation mode- Volume controlled 
• Airflow pattern- constant inspiratory flow 
• Ventilator settings- RR 12/min, 50% I: E ratio, VT 8mL/Kg 
• End-inspiratory pause, 20% duty cycle 
• Delivered over 60 minutes 
• Expired aerosolized particles collected in a filter 
 
 
HME- heat and moisture exchanger 
RR- respiratory rate 
I: E- inspiratory: expiratory ratio 
VT- tidal volume 
 
Initial concerns regarding drug resistance as a result of intra-tracheal or nebulized use 
of antibiotics (polymyxin B) have been investigated and they do not appear to be 
supported with aerosolized antibiotics using newer devices not more likely than 
intravenous therapy to confer bacterial resistance [12]. This was probably linked to 
previous generation nebulizers and the technique of administration (instillation, 
pharyngeal aerosolization, etc.). However, this finding must be interpreted reservedly 
because no long term follow-up has been performed. 
 
Tolerance of aerosolization is different when drugs are nebulized for different 
durations of time. As a consequence, it might limit the use in patients with ARDS or 
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severe hypoxemia, such as pneumonia (in contrast to ventilator associated 
tracheobronchitis) who often have poor tolerance. When high doses of colistin are 
nebulized, the infusion volume may represent an hour of nebulization and many 
patients require to add sedatives or relaxation (with potential increased risk of 
myopathy or hypotension). This requirement would be associated with prolonged MV 
period and extra length of stay[171]. Therefore, further clinical trials should use pre-
defined outcome parameters (rather than surrogates), control by hypoxemia, and 
careful recording of adverse events.  
 
Environmental contaminations resulting from aerosolization of drugs in an open circuit 
system pose a small but significant risk to the caregivers. Using expiratory filters with 
valves in the aerosol delivery devices could minimize this. This occupational risk 
exposure should be assessed and interventions to mitigate the risks should be 
implemented[172]. When using aerosolized antibiotics, it is recommended to change 
the filter after every therapy. 
 
Optimizing the aforementioned factors could lead to effective drug delivery. However, 
it is important to realize that aerosolization of medications do not automatically lead to 
beneficial drug effect and may in fact be harmful as shown in some studies[173, 174].  
 
 Conclusions 
 
Aerosol therapy provides effective drug delivery in the critically ill. Careful 
consideration of the various elements that affect pharmacological effect of aerosolized 
therapies is essential to derive optimal therapeutic benefit. Effective drug delivery 
alone does not ensure successful aerosol drug therapy. It is crucial that the drug in its 
aerosolized form should have efficacy in the specific disease condition to derive 
clinical benefit. 
 
Good quality data and clinical experience support use of bronchodilators such as 
salbutamol, anti- infectives such as tobramycin, aztreonam, colistin and anti-
inflammatory agents such as budesonide. Although with application of principles, it is 
possible to provide aerosol drug delivery, the effectiveness of the therapy in disease 
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conditions is yet to be proven. This is because there is a scarcity of high quality trial-
based data in this area to quantify how effective these agents are in the critically ill.  
 
Given the challenges of effective treatment of the critically ill, it is necessary to optimize 
as many factors as possible for effective drug delivery. Hence, it is important that 
guidelines for aerosol therapy are developed. It is envisaged that as the technologies 
become mature through rigorous evaluation, a diverse range of aerosol therapies with 
unique advantages (i.e. controlled release/sustained release or direct targeting) and 
or for specific indications may be possible.  
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2.3 Conclusions of the chapter 2 “The principles of aerosol therapy in 
critical care”  
 
This chapter has described and discussed the different factors affecting aerosol 
therapy in critical care. Whilst there are wide applications of aerosol therapy, there 
appears to be a more defined role for nebulized antibiotics for the treatment of VAP. 
However, despite advances in this field there are important gaps in the science and 
application of aerosolised antibiotic therapy for this indication. Hence, dosing 
schedules for nebulized antibiotics remain largely arbitrary. Using the current evidence 
for optimal ventilator parameters for nebulized antibiotics, further studies elucidating 
the PK-PD aspects of aerosol therapy may enable design of more evidence-based 
accurate dosing approaches. 
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Chapter 3 Research pathway for the study of the delivery 
and disposition of nebulized antibiotics  
 
 
3.1 Synopsis 
 
This chapter describes the research pathway to be taken for the completion of the 
studies required to describe the pharmacokinetics of nebulized antibiotics with 
mechanical ventilation. Detailed methodology of all the studies to be undertaken are 
included and discussed with tobramycin being used as the study antibiotic.  
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3.2 Accepted manuscript entitled “A research pathway for the study of 
the delivery and disposition of nebulized antibiotics: an incremental 
approach from in vitro to large animal models” 
 
The manuscript entitled, “A research pathway for the study of the delivery and 
disposition of nebulized antibiotics: an incremental approach from in vitro to large 
animal models” has been accepted for publication in Intensive Care Medicine- 
Experimental (2018; 6:17).  
 
The co-authors contributed to the manuscript as follows: The study design, writing, 
and editing was performed by the PhD candidate, Jayesh Dhanani, under the 
supervision of Prof Jason Roberts. The microdialysis studies were performed by the 
PhD candidate, Jayesh Dhanani, under the supervision of Dr. Jivesh Chaudhary, Ms. 
Sara Diab, Prof Michelle Chew, Prof John Fraser, Prof Lipman and Prof Jason 
Roberts. Dr.Steven Wallis and Dr. Suzanne Parker analysed the samples. The particle 
size and nebulized mass study was performed by the PhD candidate, Jayesh Dhanani, 
under the supervision of Dr. Patricia Tang and Prof Hak-Kim Chan. The pulmonary 
distribution of radiolabelled tobramycin study was performed by the PhD candidate, 
Jayesh Dhanani, under the supervision of Dr. Benjamin Ahern, Dr. Adeel Khan, Dr. 
Manoj Bhatt, Mr. Steven Goodman, Ms. Sara Diab and Prof Jason Roberts. Prof 
Adrian Barnett guided the PhD candidate, Jayesh Dhanani, in regards to the statistical 
analyses for the data. Associate Prof Jeremy Cohen aided with the editing and 
finalising the manuscript for journal submission. 
 
The manuscript is presented as published; except figures and tables have been 
inserted into the text at slightly different positions. Also, the numbering of the pages, 
figures and tables has been adjusted to fit the overall style of the Thesis. The 
references are found alongside the other references of the Thesis, in the section 
‘References’. 
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 Abstract 
 
Nebulized antibiotics are frequently used for the prevention or treatment of ventilator-
associated pneumonia. Many factors may influence pulmonary drug concentrations 
with inaccurate dosing schedules potentially leading to therapeutic failure and/or the 
emergence of antibiotic resistance. We describe a research pathway for studying the 
pharmacokinetics of a nebulized antibiotic during mechanical ventilation using in vitro 
methods and ovine models, using tobramycin as the study antibiotic. In vitro studies 
using a laser diffractometer and a bacterial-viral filter were used to measure the effect 
of the type and size of tracheal tubes, and antibiotic concentration on the particle size 
distribution of the tobramycin 400 mg (4 ml; 100 mg/ml) and 160 mg (4 ml; 40 mg/ml) 
aerosol and nebulized mass delivered. To compare the regional drug distribution in 
the lung of two routes (intravenous and nebulized) of drug administration of tobramycin 
400 mg, technetium 99m-labelled tobramycin 400 mg with planar nuclear medicine 
imaging was used in a mechanically ventilated ovine model. To measure tobramycin 
concentrations by intravenous and nebulized tobramycin 400 mg (4 ml; 100 mg/ml) 
administration in the lung interstitial space (ISF) fluid and blood of mechanically 
ventilated sheep the microdialysis technique was used over an 8-hour duration. 
Tobramycin 100 mg/ml achieved a higher lung dose (121.3 mg) compared to 40 mg/ml 
(41.3 mg) solution. The imaging study with labelled tobramycin indicated that 
nebulized tobramycin distributed more extensively into each lung zone of the 
mechanically ventilated sheep than intravenous administration. A higher lung ISF peak 
concentration of tobramycin was observed with nebulized tobramycin (40.8 mg/l) 
compared to intravenous route (19.0 mg/l). The research methods appear promising 
to describe lung pharmacokinetics for formulations intended for nebulization during 
mechanical ventilation. These methods need further validation in an experimental 
pneumonia model to be able to contribute toward optimising dosing regimens to inform 
clinical trials and /or clinical use. 
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 Background 
 
Ventilator associated pneumonia (VAP) is common in intensive care patients and is 
associated with high morbidity and mortality rates [175]. To improve outcomes, 
nebulized antibiotic therapy has been recommended for prevention [176] and 
treatment of VAP [177]. However, there is controversy, with recent guidelines not 
recommending use of nebulized antibiotics, citing a lack of robust effectiveness data, 
possibly due to inadequate trial designs and/or ineffective drug delivery [178]. 
Antibiotic nebulization can potentially be a viable alternative to conventional therapy 
for lung infection, because if administered appropriately, it should enable high lung 
antibiotic concentrations without significant side effects [179]. However, there are a 
number of factors involved in achieving optimal delivery [13, 180], which need to be 
characterised to ensure desired concentrations are achieved. These include 
physicochemical properties of the antibiotics, tracheal tube size and type[13, 181, 
182], besides factors associated with mechanical ventilation such as ventilator 
settings, circuit-related factors, nebulizer factors and patient related factors such as 
airway geometry and patency[13]. Due to methodological limitations, the 
pharmacokinetics (PK) of nebulized antibiotics during mechanical ventilation is not 
well understood.  
 
For effective nebulization therapy with mechanical ventilation, it is essential to optimise 
these factors. Vital information regarding drug deposition, metabolism, absorption, 
kinetic profile and tolerability should be considered when designing optimised dosing 
regimens[183]. The clinical environment provides limited opportunities to accurately 
study these numerous factors affecting nebulized drug delivery and lung concentration 
of antibiotics [183]. Hence, in vitro studies are essential to study these factors, in 
isolation and in combination [184]. Further to this, animal models can allow the 
manipulation of variables and study of their effects, which may not be feasible in 
human subjects [185]. Although small animals have been extensively used for these 
purposes [186, 187], when the study involves factors that may significantly affect drug 
delivery such as airway and lung anatomy as well as circulatory parameters, large 
animals are preferable as they more accurately represent the human scenario [188, 
189]. The pathophysiological changes that occur in respiratory diseases could 
influence the PK of nebulized antibiotics[13]. Sheep are considered an appropriate 
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large animal model to study pulmonary PK associated with different devices and/or 
formulations [183] in 
 healthy and in experimental pneumonia models[190, 191]. In this paper, we describe 
an approach to providing a detailed characterization of pulmonary PK of nebulized 
drug delivery using a combination of in vitro and ovine studies.  
 
The specific aims of this research are: 
1. To calibrate the nebulized delivery system during mechanical ventilation. 
2. To quantify and compare the regional pulmonary distribution when 
administered via intravenous and nebulized routes during mechanical 
ventilation in a healthy ovine model. 
3. To calibrate the microdialysis system and its application to quantify and 
compare lung interstitial fluid (ISF) concentrations of tobramycin when 
administered via intravenous and nebulized routes during mechanical 
ventilation in a healthy ovine model. 
 
 Methods 
 
The program of research comprises of complementary studies investigating different 
aspects of nebulized antibiotic therapy with a view to addressing key questions (Table 
3.1). Each individual sub-study is described in detail below. 
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Table 3.1: Overview of the research pathway with the study components aimed at characterising the pharmacokinetics of nebulized 
tobramycin. 
Research Pathway 
Study 1. In vitro particle sizing 
and inhaled mass study 
2. In vivo lung 
distribution study 
3. In vitro 
microdialysis 
recovery study 
4. In vivo lung 
microdialysis study 
Aims Describing and comparing 
the aerosol characteristics of 
two formulations of 
tobramycin  
Comparing lung 
distribution of i.v. vs. 
nebulized 
radiolabelled 
tobramycin 400 mg 
Comparing relative 
recovery of 
vancomycin and 
tobramycin with 
microdialysis  
Comparing ISF, ELF 
and blood 
concentrations of i.v. 
vs nebulized 
tobramycin 400 mg 
Design In vitro simulated adult 
mechanical ventilation using 
• Laser diffraction 
• Inhaled mass 
Mechanically 
ventilated healthy 
ovine model 
In vitro study using 
simulated in vivo 
conditions 
Mechanically 
ventilated healthy 
ovine model 
Materials and 
Methods 
• Size 9.0 mm I.D. ETT and 
Tracheostomy tube 
• 4 ml Tobramycin 100 
mg/mL (400 mg) and 40 
mg/mL (160 mg) 
• Technetium 99 m 
labelled 
tobramycin 400 
mg 
• I.V. administration 
(n=1) 
• Vancomycin 5 
µg/ml 
• Tobramycin 5 
µg/ml 
• Bilateral 
thoracotomy 
approach for 
insertion of 
microdialysis 
catheters 
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• Vibrating mesh nebulizer 
just proximal to the Y- 
piece 
• Triplicate experiments 
 
• Nebulization (n=1) 
• CT scan to derive 
lung outline 
• Gamma camera 
scanning- dorsal, 
ventral, bilateral 
• Tissue and blood 
sampling 
• In 50 ml FFP 
solution and 
constant stirrer 
• Perfusate flow 
rates 1, 1.5 and 2 
µl/min 
• Sample collection 
every 20 min for 
100 min (n=5) 
• Triplicate 
experiments 
• I.v.  tobramycin 
400 mg (n=1) 
• Nebulized 
tobramycin 400 
mg (n=1) 
• Bronchoalveolar 
lavage (1-hour and 
6 hours) 
• Intravascular 
microdialysis 
• Sample 
collection every 
20 min for 8 
hours (n=24) 
Analysis Particle size distribution 
parameters: 
• dv10 (µm) 
• dv50 (µm) 
• dv90 (µm) 
• FPF (%) 
Inhaled mass parameters: 
• P/C ratio 
• Dorsal: ventral 
ratio 
• Right: left lung 
ratio 
• Upper: middle: 
lower lung zone  
• Relative recovery 
values for each of 
the flow rates 
• ELF concentration 
and PK  
• ISF concentration 
and PK 
• Plasma 
concentration and 
PK 
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• Inhaled drug percentage 
(%) 
• Lung dose (mg) 
 
• Quantitative 
analysis in lung, 
liver, kidney, blood 
and urine 
specimens 
 
dv10: volume diameter under which 10% of the sample resides; dv50: volume median diameter; dv90: volume diameter under which 
90% of the sample resides; FPF: fine particle fraction (particle size 1 to 5 µm); inhaled drug percent: percent quantity of drug in the 
inhaled mass filter at the end of the tracheal tube post nebulization; lung dose: the product of FPF and inhaled drug mass (mg); ELF: 
epithelial lining fluid derived from urea levels; ISF: interstitial space fluid; PK: pharmacokinetics 
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 Calibrating the nebulized delivery system during mechanical ventilation. 
 
Two experimental techniques were employed for this purpose.  
 
3.2.3.1.1 Aerosol particle size distribution 
 
3.2.3.1.1.1 Equipment- 
 
We used an adult-use mechanical ventilator and circuits (Puritan Bennett 840 
ventilator, Covidien-Medtronic, Mansfield, Massachusetts) in conjunction with a 
disposable vibrating mesh nebulizer (VMN) (Aeroneb pro, Aerogen, Inc., Galway, 
Ireland) placed in the inspiratory limb of the circuit as per the recommendations [192]. 
Although there are a number of delivery devices available, VMN is recommended for 
nebulized antibiotic therapy in mechanically ventilated patients [192, 193]. We 
investigated the effects of different concentrations of tobramycin (Tobra-day, Phebra) 
100 mg/ml and 40 mg/ml (Tobramycin PF, Pfizer, Australia) on the nebulization 
characteristics. We also investigated the effects of different types of tracheal tubes 
(endotracheal tube vs tracheostomy tube; Portex, Smiths Medical International Ltd, 
UK) with tube size 9.0 mm internal diameter.  
 
3.2.3.1.1.2 Study method-  
 
As ventilator settings can affect aerosol drug delivery[13], the parameters set here 
were adjusted for their use in the ovine in vivo studies later. Ventilator parameters 
were fixed for all the in vitro experiments with a tidal volume of 500ml, respiratory rate 
14/min, square wave flow pattern, flow rate 40 lpm, positive end-expiratory pressure 
(PEEP) = 5 and FiO2 = 0.21.  
 
As recommended by expert consensus, humidification was turned off for the 
experiments [194]. The tips of the tracheal tubes were placed in the receptacle of the 
laser diffractometer (Spraytec, Malvern Instruments, UK) using a silicone adaptor. The 
principle of the laser diffraction technique is shown in Figure 3.1. The circuit was 
closed using an adult test lung (Dräger Medical, Lubeck, Germany) thus enabling 
continuous operation. The nebulizer was then filled with 4ml tobramycin 100 mg/ml 
(400 mg) and then repeated with 4 mL of 40 mg/ml concentration (160 mg). 
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Nebulization was considered to be complete when no mist was visible from the 
nebulizer. The nebulizer and bacterial filter was changed after every experiment as 
per the guidelines [192]. Figure 3.2 A demonstrates the study set up in the laboratory. 
 
3.2.3.1.1.3 Data collection and analysis-   
 
The following data was collected: baseline temperature, pH, and viscosity of the 
tobramycin solution and nebulization time. The viscosity of the tobramycin solution 
was determined at a constant temperature of 25 oC using a DHR-3 rheometer (TA 
Instruments, USA). Particle size distributions were expressed as dv10 (volume 
diameter under which 10% of the sample resides), dv50 (volume median diameter), 
and dv90 (volume diameter under which 90% of the sample resides). In addition to 
dv10, dv50, and dv90, the percentages of particles between sizes 1 μm and 5 μm (the 
sizes conventionally considered for lung deposition) obtained from the laser 
diffractometer was included in this work. 
 
 
 
Figure 3.1: Principle of laser diffraction technique for particle sizing 
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3.2.3.1.2 In vitro nebulized mass study 
 
3.2.3.1.2.1 Equipment- 
 
Adult use mechanical ventilator, VMN, endotracheal tubes and tracheostomy tubes 
and tobramycin was used as per the particle size distribution study described above. 
In addition, respiratory (bacterial and viral) filters (Filter Pads, Fisher and Paykel, 
Auckland, New Zealand) were used. 
 
3.2.3.1.2.2 Study method-  
 
Using a previously described methodology [66], we used the same set up as described 
previously and insert the tip of the tracheal tube into a respiratory (bacterial and viral) 
filter (Filter Pads, Fisher and Paykel, Auckland, New Zealand). The circuit was closed 
using an adult test lung (Dräger Medical, Lubeck, Germany) thus allowing continuous 
operation. The nebulizer was filled with 4 ml tobramycin 100 mg/ml (400 mg) instilled 
with the nebulization process to continue until there is no visible mist from the 
nebulizer. The ventilator was paused whilst the filter was removed from the circuit and 
stored at -80oC for drug assay using liquid chromatography with tandem mass 
spectrometry (LC/MS-MS). The process was repeated with 4 ml tobramycin 40 mg/ml 
(160 mg). The nebulizer was weighed before and after nebulization to describe 
residual drug quantity. The experiment was done with each of the tracheal tubes as 
previously mentioned. Each experiment was repeated in triplicate. The nebulizer and 
bacterial filter was changed after every experiment as per the guidelines [192]. Study 
set up was as shown in Figure 3.2 B. 
 
3.2.3.1.2.3 Sample and data analysis-  
 
Tobramycin was extracted from the filter using water in a sonication bath, stored at -
80°C and analysed later using LC-MS/MS as described later. The amount of drug was 
reported as milligrams (mg) of tobramycin. The percentage of nebulized drug on the 
filter was calculated and expressed with ranges. Combined data from the particle 
sizing and nebulized mass study was used to describe the lung dose i.e. amount of 
drug in the effective particle size range for distal lung deposition.  
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Figure 3.2 A: Experimental set up for particle sizing experiments. B: Experimental 
set up for inhaled mass experiments 
 
A.
 
B. 
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 Development of an ovine model for aerosol studies 
 
3.2.3.2.1 Design- 
 
We used a healthy ovine model to assess the regional drug deposition and lung ISF 
concentrations of intravenously and nebulized tobramycin.  
 
3.2.3.2.2 Ethics-  
 
All the ovine studies have been ethically approved by the Queensland University of 
Technology animal ethics committee approval (Approval no. 1100000052; lung ISF 
study) and University of Queensland animal ethics committee approval (Approval no. 
SOM/268/16/RBWH; regional distribution studies).  
 
3.2.3.2.3 Operating Room Set up 
 
The basic operating room set-up and the anaesthesia and instrumentation 
components of the study was the same for the regional drug distribution study and the 
tobramycin concentration in the lung ISF study.  
 
The operating room was equipped to manage and monitor for the animals’ health and 
well-being. A ‘head box’ or suspender was used to stabilize and immobilize the head 
while being sedated and mechanically ventilated in a prone position. Syringe drivers 
and infusion pumps were used for fluid infusions and anaesthesia maintenance. 
Precision microdialysis pumps (CMA 107, CMA microdialysis, Solna, Sweden) were 
used for microdialysis. A fibreoptic bronchoscope ((Pentax FB15TV, Philips, Tokyo, 
Japan) was used to obtain mini- bronchoalveolar lavage (BAL) samples. A qualified 
vet supervised the procedure at all times.  
 
3.2.3.2.4 Anaesthesia and Instrumentation 
 
3.2.3.2.4.1 Pre-study 
 
The veterinary specialist examined all merino sheep and baseline blood samples were 
collected with only healthy merino sheep weighing 40 to 50 kg selected for the study. 
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Sheep were fasted overnight and were led to the operating room in a protective sling 
with face, neck and chest area shaved.  
 
3.2.3.2.4.2 Venous access, anaesthesia induction, airway access and mechanical 
ventilation. 
 
Using aseptic technique, a central venous line was inserted through the right jugular 
vein under local anaesthesia. Anaesthesia was commenced using induction agents, 
midazolam 0.5mg /kg and alfaxalone 3mg/kg (Jurox Pty Ltd, Hunter Valley, Australia). 
Orotracheal intubation was performed using an endotracheal tube (Portex, Smiths 
Medical, London, UK). Tracheal intubation was confirmed using a colorimeter and 
mechanical ventilation commenced. Ventilator parameters used throughout the 
experiment fulfilled the Acute Respiratory Distress Syndrome Network criteria for lung 
protective ventilation [195].  Initial ventilator settings for all the sheep were respiratory 
rate 14 breaths per minute, tidal volume 500ml, peep 5 cm H2O, fraction of inspired 
oxygen (FiO2) 0.21. During nebulization, square wave flow pattern was applied and 
the humidifier was turned off. Respiratory rate and FiO2 was adjusted according to 
arterial blood gas (ABG) results to maintain normal parameters. Due to the long length 
of the sheep airway, it was necessary to perform a tracheostomy to represent the 
human airway. This was performed with aseptic technique using a size 9 tracheostomy 
tube (Portex, Smiths Medical, London, UK) and confirmed using bronchoscope and 
capnography. The airway was assessed using bronchoscopy for any anatomical 
variation or pathological abnormality. The animal was subsequently positioned in 
prone position. Anaesthesia was maintained using ketamine 3-5 mg/kg/h, midazolam 
0.25-0.5 mg/kg/h and alfaxalone 4-6 mg/kg/h infusion titrated to effect. Hydration was 
maintained using Hartmann’s solution at the rate of 2 ml/kg/h. The animal was kept 
warm using warming blankets. The operating room setup, anaesthesia and 
instrumentation was common to the two ovine studies- regional drug distribution and 
microdialysis.  
 
3.2.3.2.5 Monitoring 
 
The sheep had routine monitoring using ECG, arterial blood pressure (ABP), end- tidal 
carbon dioxide monitor (ETCO2), pulse oximetry and central venous pressure (CVP) 
monitoring. An invasive arterial line was inserted in the facial artery using a cut-down 
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method for the ABP monitoring and ABG sampling. Vital physiological data was 
recorded using Marquette Solar 8000 monitor (GE Healthcare, Little Chalfont, UK). A 
urinary catheter and orogastric tube was also inserted. Regular ABGs (2 hourly) were 
obtained to confirm adequacy of ventilation and other parameters such as electrolytes, 
glucose, and lactate levels. 
 
 Comparing regional pulmonary distribution of intravenous and nebulized 
tobramycin during mechanical ventilation 
 
3.2.3.3.1 Computed Tomography (CT) scan 
 
Following adequate instrumentation, a CT scan of the chest was performed to confirm 
normal lung anatomy and the images were used to obtain a region of interest (ROI) 
during image analysis. The ROI provides the lung outline for superimposition onto the 
gamma camera images for subsequent analysis.  
 
3.2.3.3.2 Drug administration-  
 
3.2.3.3.2.1 Nebulization  
 
Using a disposable (VMN) (Aeroneb pro, Aerogen, Inc., Galway, Ireland) in the 
inspiratory limb of the ventilator circuit, tobramycin 400mg (100mg/ml) labelled with 
technetium 99m was nebulized until no further mist is visible. Previous studies have 
shown that the aerosol characteristics of labelled tobramycin are similar to that of 
unlabelled tobramycin[196].  
 
3.2.3.3.2.2 Intravenous  
 
Technetium 99m labelled tobramycin 400mg was injected via a central venous line as 
a 30-minute infusion. The lumen was flushed with 100ml of 0.9% saline.  
 
3.2.3.3.3 Image acquisition 
 
A single head gamma camera (GE Starcam 600 XR/T Gamma Camera, GE 
Healthcare Global Diagnostic Imaging, Waukesha, WI, USA) was used to acquire 
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planar images. The CT scan and the gamma camera scan equipment were located 
within the same research facility.  Dynamic (10 second frames) and static scans were 
obtained. Images were acquired from both lateral, dorsal, and ventral aspects. Blood 
samples at predetermined intervals were obtained to coincide with the scans. 
Radiation count in the nebulizer and the syringe was performed before and after the 
nebulization and intravenous administration respectively, to define the dose and 
radioactivity administered.  
 
3.2.3.3.4 Euthanasia and tissue sampling  
 
At the completion of the study, sheep was euthanized using sodium pentobarbitone 
(295mg/ml, 0.5ml/kg). Death was confirmed by loss of cardiac electrical activity and 
ABP trace. After euthanasia, the organs were surgically retrieved. Direct tissue 
sampling from pre-defined regions of the lungs, liver, both kidneys and urine were 
performed. The remains of the animals were frozen and stored until disposed of via 
incineration. 
 
3.2.3.3.5 Data analysis 
 
The images were analysed and reported as radioactivity distribution into peripheral to 
central ratio (P/C ratio), also known as ‘penetration index’ for the nebulized tobramycin 
group. For this analysis, the central region represents the conducting airways and the 
peripheral represents the alveoli. Parameters used to compare the intravenous and 
nebulized route of administration include dorsal to ventral ratio, right to left lung ratio, 
upper/middle/lower lung zone distribution. The quantitative analysis included 
describing the radioactivity in per gram of pulmonary and extra-pulmonary tissue. 
Blood radioactivity was compared between the two groups as a surrogate measure of 
drug level in the systemic circulation. 
 
 Calibration of the microdialysis system using in vitro microdialysis recovery 
study 
 
3.2.3.4.1 Equipment-  
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The study used fresh frozen plasma and a magnetic stirrer CMA 63 microdialysis 
catheters (molecular weight cut-off of 20 kDa; an outer diameter of 0.6 mm and a 
membrane length of 30 mm; CMA Microdialysis AB, Stockholm, Sweden), CMA 107 
precision microinfusion pump (CMA Microdialysis AB, Stockholm, Sweden) and Cole-
Parmer two-syringe infusion pump 230 VAC CE (John Morris Group, Chatswood, 
Australia). 
 
3.2.3.4.2 Study method-  
 
Microdialysis probes was perfused with Ringer’s solution at 3 different flow rates 1, 
1.5 and 2 µl/min using the precision pump. The membranes of the microdialysis probes 
were immersed in 50 ml solution of 5 µg/mL of tobramycin and 5 µg/mL vancomycin 
concentrations. The samples were collected at 20 min intervals for 100 min with 
experiments repeated in triplicate.  
 
3.2.3.4.3 Sample analysis-  
 
Samples were stored at -80oC and assayed using LC-MS/MS methods described 
previously.  
Recovery rates were expressed as relative recovery (RR)- 
RR (%) = (1- Cdialysate/Csolution) x 100 
Where Cdialysate= concentration of antibiotic in the microdialysate and Csolution= 
concentration of antibiotic in the test solution. 
Figure 3.3 A and B. describes the principles of microdialysis when used for the study 
of inhaled antibiotics and intravenous antibiotics respectively. The principles have 
been described in detail previously[23].  
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Figure 3.3 A: Principles of Lung Microdialysis with nebulized antibiotics. B:Principles 
of Lung Microdialysis with intravenous antibiotics. 
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 Comparing lung ISF concentrations of intravenous and nebulized tobramycin  
 
3.2.3.5.1 Microdialysis catheter priming and set up 
 
Various factors influence in vivo recovery of analytes hence in addition to in vitro 
studies, it is essential to perform in vivo recovery[23]. Methods for in vivo recovery 
calculations have been described in literature[197]. Internal indicator technique was 
used in this study. The perfusate for microdialysis was prepared using 0.1 ml (4mg) of 
gentamicin 80mg/2ml vial. This was injected into a one-litre bag of Hartmann’s solution 
to make up a concentration of 4 ug/ml which was then be used as the perfusate for 
the catheters. Gentamicin was used as an internal standard to enable in vivo recovery 
calculations and was chosen due to similarities with tobramycin (molecular weight of 
gentamicin= 467 vs tobramycin= 477 g/mol). Using CMA 107 battery pumps, the 
microdialysis catheters were primed with the perfusate solution at a rate of 5 µl/min 
for 10 mins. The catheters were then inserted and the perfusate rate was reduced 1 
µl/min for the remainder of the experiment. Once inserted, the catheters were perfused 
for a period of one hour to achieve steady state equilibrium.  
 
3.2.3.5.2 Insertion of microdialysis catheters 
 
After anaesthesia induction and instrumentation, bilateral thoracotomies were 
performed in the 5th intercostal space exposing the interlobar fissures. A CMA 63 
microdialysis catheter (CMA Microdialysis AB, Stockholm, Sweden) with a molecular 
weight cut-off of 20 kDa, an outer diameter of 0.6mm and a membrane length of 30 
mm, was used. Four microdialysis catheters were inserted, in the right upper, lower 
and the left upper and lower lobes using an introducer needle under direct vision. 
Bioglue (Coseal surgical sealant, Cohesion technologies, US) was applied at the lung 
puncture site to minimize catheter movement post insertion. An intercostal catheter 
was inserted in each of the pleural spaces and low-pressure suction applied and the 
thoracotomy incisions will be closed. An intravascular microdialysis catheter, CMA 64 
(CMA Microdialysis AB, Stockholm, Sweden) with a molecular weight cut- off 20 kDa, 
and a membrane length of 20 mm, was inserted in the left jugular vein through a 
percutaneously inserted 18G cannula (B. Braun Australia Pty Ltd, Bella Vista, 
Australia).  
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3.2.3.5.3 Drug administration 
 
3.2.3.5.3.1 Nebulization  
 
Using a disposable (VMN) (Aeroneb pro, Aerogen, Inc., Galway, Ireland) in the 
inspiratory limb of the ventilator circuit, tobramycin 400 mg (Tobra-day, Phebra 500 
mg/5 ml) was nebulized. The nebulization was continued until the visible mist from the 
nebulizer stopped. A baseline pre-nebulization microdialysis sample was collected 
(T0).  
 
3.2.3.5.3.2 Intravenous antibiotic administration  
 
Tobramycin 400 mg (Tobra-day, Phebra 500 mg/5 ml) was administered intravenously 
through the central venous line as a 30-minute infusion. A baseline pre- intravenous 
administration, microdialysis sample was collected (T0).  
Following the drug administration (nebulized and intravenous), samples were 
collected at every 20 minutes in a microvial (CMA, Microdialysis AB) for eight hours. 
The samples were stored at -80°C for further analysis. 
 
3.2.3.5.4 Bronchoalveolar lavage (BAL)  
 
A mini- BAL was performed at T= 60 min, 4 hours and 7 hours using two 20 ml aliquots 
of normal saline as previously described [198, 199]. This procedure was performed 
using a fibreoptic bronchoscope with the tip wedged in the right lower lobe and left 
lower lobe bronchi. The actual epithelial lining fluid (ELF) concentrations of tobramycin 
were obtained from the measured BAL fluid concentrations after correction for dilution 
according to the equation: 
 
CELF= CBAL (UreaPLASMA/ UreaBAL) 
 
where CBAL corresponds to the tobramycin concentrations measured in the BAL fluid, 
and UreaBAL and UreaPLASMA correspond to the concentrations of urea determined in 
BAL fluid and plasma respectively. Blood samples were taken for measuring urea to 
assess adequacy of BAL.  
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3.2.3.5.5 Euthanasia, catheter inspection and organ retrieval 
 
At the completion of the study, the sheep were humanely euthanized using sodium 
pentobarbitone (295 mg/ml, dose 0.5 ml/kg). Using chest retractors, the microdialysis 
catheters were exposed and inspected to confirm that the catheters remained inside 
the lungs throughout the procedure. The catheters were inspected for obvious 
evidence of damage. Lungs were retrieved and sections of bilateral upper and lower 
lobes were visually inspected and harvested for further drug concentration analysis. 
The remains of the animals were frozen and stored until disposal via incineration. 
 
3.2.3.5.6 LC-MS/MS method for sample analysis 
 
The tobramycin concentrations in microdialysis samples reported were measured by 
an LC-MS/MS method using a simple dilution preparation and HILIC chromatography 
on a Shimadzu Nexera2 system coupled to a Shimadzu 8030+ triple quadrupole mass 
spectrometer (Kyoto, Japan). The assay method has validation for linearity (quadratic 
line from 0.1 to 20 µg/mL with precision and accuracy of all calibration standards within 
8%), LLOQ (precision and accuracy within 6% at 0.1 µg/mL), matrix effects 
(normalised matrix factor precision within 9% at 0.2 and 16 µg/mL), and precision and 
accuracy (precision and accuracy within 10% at 0.3, 2 and 16 µg/mL) using the FDA 
criteria for bioanalysis[200]. Recovery data was used to calculate the corrected 
tobramycin concentrations in the microdialysate.  
 
 Statistical Considerations 
 
The results were expressed as mean, median, minimum, maximum and standard 
deviation. For the in vitro particle size and inhaled mass study, multiple linear 
regression was used to estimate the effect of the variables on the outcomes. For the 
in vitro microdialysis recovery studies, a linear regression model using recovery as the 
dependent variable and flow rate as the independent variable was applied. Similarly, 
the blood radioactivity levels in the ovine study were compared using Bayesian 
regression analysis using a random intercept for each sheep and Bayesian p- values 
were obtained. These analyses were conducted using R version 3.4.2 and WinBUGS 
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version 1.4.3 for the Bayesian regression analysis. The individual studies were not 
powered to detect statistical significance and instead we used confidence intervals 
where appropriate and discuss the size of the differences in terms of their clinical as 
well as statistical significance. Plots of summary statistics were used to compare 
groups and results over time. 
 
 Results 
 
The simulated adult mechanical ventilation model to evaluate the particle size 
distribution and quantify the efficacy of the aerosol system showed that fine particle 
fraction (1 to 5 µm) was significantly higher for 100 mg/mL solution compared to 40 
mg/mL solution (99.4 ± 0.3% vs 82.3 ± 6%; p<0.001) . The lung dose delivered was 
significantly higher for 100 mg/ml solution compared to 40 mg/ml solution (132.7 ± 
12.6 mg vs 39.2 ± 1.1 mg; p<0.001). Nebulization duration was significantly higher for 
the 100 mg/mL solution compared to 40 mg/mL solution for endotracheal tube (18.56 
± 2.36 vs 7.88 ± 1.08 minutes; p<0.001) and tracheostomy tube (14.63 ± 1.14 vs 12 ± 
1.4 minutes; p<0.001). Tracheal tube type had minimal effect which was not 
statistically significant, on the aerosol delivery parameters. Other parameters like dv10, 
dv95 were not statistically different. Table 3.2 summarises the differences between the 
two formulations. The experiments were performed at a temperature of 25 C.  
 
 
Table 3.2: Comparative characteristics between tobramycin 40 mg/mL and 100 
mg/mL solutions 
Parameters Tobramycin 40 mg/mL  Tobramycin 100 mg/mL 
pH.88 6.88 6.99 
Viscosity (centipoise) 1.58 2.12 
Duration of Nebulization (minutes) 
Endotracheal tube 7.88±1.08 18.56±2.36* 
Tracheostomy tube 12±1.4 14.63±1.14* 
 66 
Dv10 (µm) 1.0±0.05 1.4±0.04 
VMD (µm) 1.8±0.2 2.1±0.08 
Dv95 (µm) 5.7±0.2 3.6±0.8 
FPF (%) 82.3±6  99.44±0.3* 
Lung dose (mg) 39.2±1.1 132.7±12.6* 
 
dv10: volume diameter under which 10% of the sample resides; VMD: volume median 
diameter under which 50% of the particles resides; dv95: volume diameter under which 
95% of the sample resides; FPF: fine particle fraction (1-5µm); *p<0.05 
 
The ovine model for the comparative regional lung distribution study between 
aerosolized and intravenous tobramycin was successfully established. Female sheep 
(ewes, n=4) were used for the study. There were no adverse events documented 
during the ovine studies. For the nebulized sheep, the P/C ratio (penetration index) 
was 0.9 for the right lung and 0.87 for the left lung. The blood radioactivity was 
significantly higher for the sheep with intravenous tobramycin compared to that for the 
nebulized tobramycin (209.2 ± 97.6 Mbq/mL vs 33.3 ± 5.4 Mbq/mL; p<0.001). The 
right to left ratio was 0.9 for intravenous and 0.89 for the nebulized sheep. Figure 3.4 
shows the comparative gamma camera scan images between i.v. and nebulized 
technetium labelled tobramycin.  
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Figure 3.4: Comparative dorsal scintigraphy images of lung deposition of i.v and 
nebulized radiolabelled tobramycin. 
 
 
Table 3.3 shows that the liver, kidney and urine levels were lower for nebulized 
compared to intravenous sheep.  
Figure 3.4: Comparative dorsal scintigraphy images of lung deposition of i.v and 
nebulized radiolabelled tobramycin. 
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Table 3.3: Quantitative extra- pulmonary tissue radioactivity concentrations. 
Organ  Nebulized tobramycin  Intravenous tobramycin  
Liver (Bq/g/Mbq) 76.5 2541.7 
Left kidney (Bq/g/Mbq) 585.8 1048.4 
Right kidney (Bq/g/Mbq) 704.2 2126.7 
Urine (Bq/g/Mbq) 1479.1 7866.3 
 
Bq/g/Mbq- Becquerel per gram per megabecquerel of administered dose. 
 
Microdialysis recovery in the simulated in vivo conditions showed that relative recovery 
for vancomycin was 32.6 ± 0.09 %, 27.5 ± 0.09 % and 20.7 ± 0.04 % respectively for 
perfusate flow rates of 1, 1.5 and 2 µl/min respectively. Thus, for vancomycin, the 
highest relative recovery was for a perfusate flow rate of 1 µL/min (95% C.I. 24.8 to 
35.7%). For tobramycin the recoveries were 69 ± 3.74 %, 69.5 ± 3.47 % and 65 ± 3.8 
% respectively. The differences were not seen to be statistically significant. 
 
The lung ISF concentrations in the mechanically ventilated ovine model showed that 
area under the concentration- time curve (mean) and peak (or maximum) 
concentration in the concentration- time curve (mean) for nebulized tobramycin was 
313 mg-h/L and 535.8 mg/L and 90.82 mg-h/L and 22.2 mg/L for intravenous 
tobramycin. Figure 3.5 shows lung ISF concentrations with nebulized tobramycin 
compared to intravenous tobramycin.  
 
Figure 3.5: Comparative lung concentrations of tobramycin between nebulized and 
intravenous route of administration. 
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For the nebulized tobramycin sheep, ELF concentration was 1938.99 mg/l at 1 hour 
and for intravenous tobramycin sheep, the level was 0.19 mg/l. (Table 3.4) 
 
Table 3.4: Comparative epithelial lining fluid concentrations for nebulized and 
tobramycin sheep at two time points; 1 hour and 6- hours post antibiotic administration. 
ELF time points Nebulized tobramycin Intravenous tobramycin 
1 hour (mg/l) 1938.99 0.19 
6 hours (mg/l) 72.89 0.38 
AUCELF (mg.h/l) 2179.84 5.366 
AUCplasma (mg.h/l) 56.88 53.60 
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AUClung/AUCplasma  
(mg.h/l) 
1.29 0.30 
 
ELF- epithelial lining fluid  
AUC- area under the concentration-time curve 
 
Technically the ovine model set up for the regional lung distribution and lung 
microdialysis study was uneventful. There were no adverse events affecting the 
interpretation of results. We have optimised anaesthesia, ventilation, surgical 
instrumentation, scintigraphy protocols, sample collection and analyses in this model.   
 
 Discussion 
 
This paper describes an incremental model of the study of the PK of nebulized 
antibiotics. As the lung is a heterogeneous organ, PK studies to accurately 
characterise drug concentrations in the various compartments are difficult. We have 
used a methodological approach for the assessment of the PK of nebulized antibiotics 
using in vitro and ovine models. For nebulized antibiotic administration, important PK 
parameters are pulmonary deposition efficiency, regional distribution, pulmonary 
absorption and residence time [180]. For therapeutic response, the dose deposited at 
the site of infection in lung is important [201] particularly the unbound concentration of 
the drug [180]. We studied these essential aspects of nebulized antibiotic therapy 
using tobramycin.  
 
For higher concentration tobramycin (100 mg/ml) the aerosol delivery system can 
deliver a higher lung dose. This is important for tobramycin and other aminoglycosides 
that rely on peak (or maximum) concentration as the PK measure for drug effect. 
Aerosol particle size and the aerosolized drug mass are important parameters for 
assessing the efficacy of an aerosol delivery system [13]. Methods for the study of the 
aerosol particle size distribution and nebulized mass have been summarized 
previously [55, 66]. We used the laser diffractometer which is a validated technique 
for the assessment of aerosol particle size distribution [202] and an established 
technique for the nebulized mass study [66]. Recent recommendations have been to 
place the VMN 10-15 cm from the Y-piece[19]. The VMN was placed just before the 
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Y-piece in the inspiratory limb to mimic local and international practices[203] as well 
as the manufacturer’s recommendations. 
 
Our results suggest that mechanically ventilated sheep could be effectively used for 
study of regional lung distribution studies especially for drugs administered for local 
effect on the lung diseases e.g. infections. The distribution parameters of nebulized 
tobramycin would support its use in lung infections especially with minimal systemic 
and extra pulmonary tissue levels as seen in our study. Methods of assessing 
pulmonary drug distribution have been summarized in detail previously [204]. Whilst 
single-photon emission computed tomography (SPECT) and positron emission 
tomography (PET) provide a 3D description of the regional drug distribution in the 
lungs, for most purposes, planar gamma scintigraphy is sufficient [205, 206] and 
feasible, therefore we used the gamma scintigraphy method for our study.  
 
The results of the present microdialysis calibration study suggests that large 
molecules like vancomycin have significantly reduced recovery and protein binding 
adversely affected the recovery. Perfusate flow rates also affected relative recovery 
rates for tobramycin and vancomycin. Thus, microdialysis based studies for large 
molecules as well as highly protein bound substances should be evaluated in vitro in 
a similar model. By calibrating the microdialysis system thus, depending on the study 
drug, it will enable the correct combination of microdialysis catheters and perfusate 
flow rates. The techniques used in other studies to assess pulmonary drug 
concentrations used could not inform adequately the longitudinal data desired over 
time. These studies have been previously summarized [23], but most studies 
employed antibiotic BAL concentrations as a surrogate [20, 207]. Some authors have 
used blood concentrations to perform population PK compartmental modelling [208]. 
For most bacterial infections, the antibiotic site of action is the ISF [209]. Lung 
microdialysis is an established technique to sample lung ISF for the purposes of 
measuring antibiotic concentrations [23]. The details of the microdialysis technique 
and relevant considerations have been described elsewhere [210-213]. Recovery 
studies are important for accurate calculation of the antibiotic concentration in the 
microdialysis sample[197].  
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For tobramycin, the high lung ISF concentration achieved with nebulized route meets 
the PK requirements for drug effect. Study of drugs with different PK parameters would 
elucidate if nebulized route is appropriate for therapy. Preclinical models for the study 
of pulmonary drug delivery have been well described [183]. Methods such as in vitro 
cell culture whilst providing a consistent method of assessing nebulized drugs, cannot 
predict the pulmonary bioavailability of the drug as it cannot assess the other barriers 
to absorption [183]. In vitro cell culture method remains a viable alternative to test for 
drug toxicity. Isolated perfused lung model provides an ex- vivo model for drug PK 
assessment but lack of tracheobronchial circulation could be a drawback in the 
assessment of systemic absorption[183]. In vivo models provide the most thorough 
quantitative and qualitative data to inform the PK of pulmonary drug delivery[214].  
 
As airway size and type were considered an important variable in drug deposition, the 
in vitro aerosol characteristics were investigated with the size 9.0 mm I.D. tracheal 
tubes as these were the tracheal tube sizes used for the in vivo studies in sheep. Thus, 
minimising the variables in the study data.  
 
Sheep are the ideal large animal model to study the PKs of nebulized antibiotics [185]. 
Their size and lung anatomical-physiological features are similar to humans [215]. By 
replicating the study, data could be acquired to describe the PK profile of a wide range 
of nebulized antibiotics. This adds valuable information for potential efficacy and 
toxicity of drugs and formulations. Our model can be applied to other potentially 
important questions and test other factors such as variations in ventilator parameters, 
the distribution characteristics of newer nebulized drug formulations, novel delivery 
devices, and different patient parameters such as posture that might affect pulmonary 
drug delivery. There is potential for study of other nebulized drugs where lung ISF 
concentrations are important e.g., other anti-infectives like antiviral and antifungal 
agents, chemotherapeutic agents, and immunomodulatory drugs. 
 
Future work will consist of pharmacodynamic studies in a variety of clinically important 
experimental pneumonia settings. This data could be used to improve the precision 
and accuracy of nebulized antibiotic dosing schedules in a variety of lung infections in 
the pre-clinical models. The complexity of the pathophysiological changes associated 
with pneumonia makes the development and management of the animal models of 
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experimental pneumonia challenging. Factors that need consideration include ethics, 
selection of appropriate animal species, number of subjects, inoculation routes, and 
sampling issues and the present animal model used account for some, but not all of 
these . Clinical trials using accurate information from these mechanistic and preclinical 
studies could yield better therapeutic outcomes.  
 
 Conclusion 
 
This program of research aims applies in vitro and ovine models for the study of 
nebulized antibiotic delivery and lung PK. This model can be used for further studies 
involving drugs where knowledge of pulmonary drug concentration is essential. 
Systematic investigation of other aspects of nebulized antibiotic therapy using this 
model will introduce further refinements in nebulized antibiotic therapy thus improving 
patient care and outcomes. 
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3.3 Conclusion of the chapter 3 “Research pathway for the study of the 
delivery and disposition of nebulized antibiotics” 
 
The indicative studies described in this chapter demonstrate the research pathway 
that can be used to describe the pharmacokinetics of nebulized drugs during 
mechanical ventilation. The successful completion of the studies and the results 
demonstrate the feasibility and utility of the studies for elucidating the 
pharmacokinetics of nebulized antibiotics. The conduct of the studies provided an 
opportunity to refine the methodology, techniques and protocols required to complete 
full studies for the Thesis. Using the roadmap that this chapter provided, individual 
studies will form separate subsequent chapters in the Thesis.  
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Chapter 4 Effect of combination antibiotic therapy on 
microdialysis recovery rates 
 
4.1 Synopsis 
 
The aim of this chapter is to determine whether combination antibiotic therapy (at least 
two antibiotics administered concomitantly) affects microdialysis relative recovery 
rates in an in vitro setting but simulating in vivo conditions by using fresh frozen plasma 
for the study. The effects of perfusate flow rates and antibiotic concentrations on the 
microdialysis recovery rates were studied to determine the effective microdialysis 
settings for maximal recovery.  
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4.2 Accepted manuscript entitled “Recovery rates of combination 
antibiotic therapy using in vitro microdialysis simulating in vivo 
conditions”  
 
The manuscript entitled, “Recovery rates of combination antibiotic therapy using in 
vitro microdialysis simulating in vivo conditions” has been accepted for publication in 
the Journal of Pharmaceutical Analysis (2018; 8:407). 
 
The co-authors contributed to the manuscript as follows: All study design, experiments 
and data collection were performed by the PhD candidate, Jayesh Dhanani, under the 
supervision of Prof Jason Roberts and Prof Michelle Chew. Dr. Steven Wallis and Dr. 
Suzanne Parker analysed the samples. Prof Adrian Barnett guided the PhD candidate, 
Jayesh Dhanani, in regards to the statistical analyses for the data. The final editing 
was done by the PhD candidate, Jayesh Dhanani, with supervision from Associate 
Prof Jeremy Cohen, Prof Jeffrey Lipman, Prof John Fraser and Prof Jason Roberts. 
The PhD candidate, Jayesh Dhanani, took the leading role in the manuscript 
preparation and writing.  
 
The manuscript is presented as published; except figures and tables have been 
inserted into the text at slightly different positions. Also, the numbering of the pages, 
figures and tables has been adjusted to fit the overall style of the Thesis. The 
references are found alongside the other references of the Thesis, in the section 
‘References’.  
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 Abstract 
 
Microdialysis is a technique used to measure the unbound antibiotic concentration in 
the interstitial spaces, the target site of action. In vitro recovery studies are essential 
to calibrate the microdialysis system for in vivo studies. The effect of a combination of 
antibiotics on recovery into microdialysate requires investigation.   
 
In vitro microdialysis recovery studies were conducted on a combination of 
vancomycin and tobramycin, in a simulated in vivo model. Comparison was made 
between recoveries for three different concentrations and three different perfusate flow 
rates.  
 
The overall relative recovery for vancomycin was lower than that of tobramycin. For 
tobramycin, a concentration of 20 µg/mL and flow rate of 1.0 µL/min had the best 
recovery. A concentration of 5.0 µg/mL and flow rate of 1.0 µL/min yielded maximal 
recovery for vancomycin. 
 
Large molecular size and higher protein binding resulted in lower relative recoveries 
for vancomycin. Perfusate flow rates and drug concentrations affected the relative 
recovery when a combination of vancomycin and tobramycin was tested. Low 
perfusate flow rates were associated with higher recovery rates. For combination 
antibiotic measurement which includes agents that are highly protein bound, in vitro 
studies performed prior to in vivo studies may ensure the reliable measurement of 
unbound concentrations. 
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 Introduction 
 
Combination antibiotic therapy is commonly used in clinical practice due to an increase 
in multidrug resistant bacterial infections[216, 217]. Consequently, antibiotic 
pharmacokinetic data is essential to develop accurate dosing regimens which can 
achieve effective antibiotic concentrations at the site of infection which is mostly the 
interstitial fluid of tissue [1, 218]. This principle is fundamental for not only optimal 
microbiological and clinical outcome, but also to minimise the risk of microbial 
resistance [219-223]. Moreover, it is the free (unbound) drug concentrations at the site 
of infection that are relevant with dosing challenges prominent because tissue 
interstitial space fluid penetration can differ substantially for some drugs [224]. 
 
Microdialysis is a minimally invasive sampling technique used to measure unbound 
drug concentrations in the interstitial space fluid of different tissues [225, 226], both in 
animals or humans [227]. The pharmacokinetic data from in vivo microdialysis studies 
can be a used to design antibiotic dosing guidelines [228]. The details of the 
microdialysis technique have been described elsewhere [210-213]. Briefly, the probe 
has a semipermeable membrane tip, which is perfused with a physiological solution 
(perfusate) at a slow flow rate. According to the concentration gradient, molecules with 
a size less than that of the membrane pore size will diffuse from the tissue interstitial 
space fluid (Ctissue) into the perfusate and collect as the microdialysate (Cdialysate). 
 
For most substances, the full equilibrium cannot be achieved i.e. Ctissue>Cdialysate. The 
term ‘recovery’ is used to describe the relationship between Ctissue and Cdialysate. The 
ratio of Cdialysate to Ctissue is termed ‘relative recovery’. This factor is then used to 
calculate the actual drug concentration in the tissue interstitial space fluid. Knowing 
the drug concentration in the solution, in vitro recovery studies could be used to 
investigate the effect of parameters such as perfusate flow rate, membrane 
characteristics, membrane length and drug characteristics on recovery [229]. 
Furthermore, data from these studies could inform subsequent in vivo studies. 
 
With combination antibiotic therapy a number of issues can affect drug recovery with 
in vivo studies [210]. In vitro microdialysis recovery studies using combination drugs 
can provide preliminary data on drug recovery and likely in vivo calibration [210]. 
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Despite this there are very few microdialysis studies investigating relative recovery of 
antibiotics, let alone a combination of antibiotics, despite how commonly they are used 
clinically [230]. Furthermore, for combination antibiotics therapy, previous in vitro 
microdialysis recovery studies have not fully accounted for in vivo conditions [230].  
 
Microdialysis catheters may have individual variation in membrane permeability. 
Diffusion through the microdialysis membrane follows Fick’s law. Hence, factors such 
as partition coefficient, particle size and surface area of the substance will affect the 
drug permeability through the membrane [231]. This necessitates individual probe 
calibration [232].  
 
The feasibility of using microdialysis for different drugs depends on the physico-
chemical characteristics of the substance, e.g. lipophilic and high molecular weight 
compounds are less likely to diffuse through the microdialysis catheter membrane and 
may be less feasible for microdialysis[233]. High molecular weight is associated with 
lower diffusion coefficients through the microdialysis membrane thus resulting in 
decreased recovery[233]. 
 
Vancomycin has protein binding of approximately 55% [234] and a molecular weight 
of ~1.5 Da. The molecular weight of tobramycin is 467 Da and with low serum protein 
binding (<30%) [235]. Both drugs are also hydrophilic and suited for microdialysis 
studies. 
 
Therefore, the aim of this study was to assess the relative recovery of concomitant 
vancomycin and tobramycin in an in vitro model simulating in vivo conditions. The 
study assessed the effect of different perfusate flow rates and the concentrations of 
the antibiotic solutions on the relative recoveries. 
 
 Materials and methods 
 
 Chemicals and standards 
 
Vancomycin hydrochloride was obtained from Aspen Pharmacare (St Leonards, 
Australia), tobramycin sulphate was obtained from Pfizer (Perth, Australia) and 
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compound sodium lactate IV solution was obtained from Baxter (Old Toongabbie, 
Australia). The chemical structures for these compounds are shown in Figure 4.1.  
 
 
  
Figure 4.1: Structure of vancomycin (A) and tobramycin 
(B). 
 
 (A) 
  
 
 (B) 
 
 
 
 
Acetonitrile was HPLC-gradient grade (Merck, Darmstadt, Germany), while 
dichloromethane (Merck, Darmstadt, Germany), formic acid (Ajax, Taren Point, 
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Australia), heptafluorobutyric acid (HFBA, Fluka, Castle Hill, Australia) and 
trichloroacetic acid (Sigma-Aldrich, Castle Hill, Australia) were analytical grade. 
Ultrapure water was obtained using a Permutit system (resistivity at 25°C at least 18 
ΩM). Drug-free human plasma was obtained from the Royal Brisbane and Women’s 
Hospital blood bank (Brisbane, Australia). 
 
 Microdialysis in vitro model 
 
Commercially available microdialysis probes CMA 63 (CMA Microdialysis AB, 
Stockholm, Sweden) with a molecular weight cut-off of 20 kDa; an outer diameter of 
0.6 mm and a membrane length of 30 mm were used. Probes were perfused with 
lactated Ringer’s solution at flow rates of 1 and 2 µL/min by using a precision 
microinfusion pump CMA 107 (CMA Microdialysis AB, Stockholm, Sweden). To 
enable perfusion at 1.5 µL/min, a Cole-Parmer two-syringe infusion pump 230 VAC 
CE (John Morris Group, Chatswood, Australia), was used. 
 
 Stock and standard solution preparation 
 
A stock solution was freshly prepared by dissolving tobramycin in compound sodium 
lactate IV solution at 2 mg/mL and stored at –80 °C. A stock solution was freshly 
prepared by dissolving vancomycin in compound sodium lactate IV solution at 2 
mg/mL and stored at –80 °C. These stock solutions were serially diluted with 
compound sodium lactate IV solution to produce a standard solution containing 200 
µg/mL of both vancomycin and tobramycin, and a standard solution containing 20 
µg/mL of both vancomycin and tobramycin. 
 
  Plasma sample solutions 
 
The study plasma solutions were prepared using the stock solutions containing both 
vancomycin and tobramycin and drug-free plasma, to yield plasma sample solutions 
containing vancomycin and tobramycin at 0.5, 5.0 and 20 µg/mL. 
 
 Recovery Experiments.  
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Microdialysis probes were fully immersed in four separate 100 mL beakers. The 
beakers contained either 0.5, 5 or 20 µg/mL of vancomycin and tobramycin plasma 
sample solution, or drug-free plasma. A magnetic stirrer was used to simulate in vivo 
conditions as previously described [236]. Temperature and pH of each of the study 
solutions were recorded to ensure consistency of these variables. 
 
The microdialysis probe was connected to the precision pump and perfused at 
5 µL/min with compound sodium lactate IV solution for 10 minutes to flush the air out 
of the system. Following this, the probe was perfused at 1 µL/min for 1 hour to enable 
equilibration. At the end of the equilibration period the following perfusate flow rates 
were used for 100 minutes each, with sampling occurring at 20-minute intervals (n=5 
sampling points): 1.0, 1.5 and 2 µL/min. Samples were then stored at –80 °C for 
analysis.  
 
4.2.3.5.1 Relative Recovery 
 
The percent relative recovery was calculated using the recovery-by-gain formula as 
follows: 
Relative recovery (%) = (Cdialysate /Csolution) × 100                                                                  
Where Cdialysate is the mean (n=5) concentration in the microdialysate; Csolution is the 
mean concentration (n=5) in the study solution.  
 
 Instrument and Analytical Method 
 
Vancomycin and tobramycin in plasma and microdialysate matrices were measured 
using validated LC-MS/MS methods. Drug-free compound sodium lactate IV solution 
and drug-free plasma solution were used to prepare calibration standards used in the 
assay. 
 
The LC-MS/MS used two Perkin Elmer LC-200 micro pumps and a CTC PAL 
autosampler equipped with an Applied Biosystems API2000 mass spectrometer 
detector. An electro-spray ionization (ESI) source interface operating in positive-ion 
mode was used for the multiple reaction monitoring (MRM) LC-MS/MS analysis. The 
interface settings consisted of the nebulizing gas flow of 40 L/min, turbo gas of 50 
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L/min, curtain gas 30 L/min, ion-spray voltage of 4500 V, a turbo-gas temperature of 
400°C, and the interface heater on. Two MRMs were monitored and summed for 
vancomycin, m/z of 725 to 144 and 725 to 99, whilst tobramycin was monitored at m/z 
of 468 to 163. 
 
Chromatographic separation of vancomycin, tobramycin, and the internal standard 
(teicoplanin) was achieved using a Waters Xterra C18 (5 µm) 2.1 × 150 mm analytical 
column using a gradient of mobile phases consisting of (a) 0.1% formic acid with 
10mM HFBA and (b) 80% methanol in 0.1% formic acid with 10 mM HFBA.  The mobile 
phase was operated using a concentration gradient for methanol, ranging from 5 to 
80%. The analytical method for tobramycin was similar to that used in other 
studies[237-239]. 
 
Vancomycin and tobramycin in plasma were assayed separately. For the extraction of 
vancomycin from plasma, 100 µL of plasma was treated with 400 µL of acetonitrile to 
precipitate proteins, with 600 µL of dichloromethane subsequently added to remove 
both the acetonitrile and lipids. For the extraction of tobramycin from plasma, 200 µL 
of plasma was treated with the addition of 50 µL of 30% trichloroacetic acid. Both 
vancomycin and tobramycin were assayed simultaneously in microdiaysate, with 10 
µL of sample being diluted with 40 µL of internal standard (teicoplanin, 100 µg/mL) for 
direct injection onto the instrumental analysis.  
 
Calibration standards were prepared using sequential dilution using a format of 0.1, 
0.2, 0.5, 1, 2, 5, 10, 20 and 50 µg/mL (abbreviated where necessary). The 
chromatographic calibration was linear for vancomycin from  0.1 to 50 µg/mL in 
plasma (LLOQ 0.0917 ± 0.011 (mean ± SD)) and 0.2 to 50 µg/mL in microdialysate 
(LLOQ 0.196 ± 0.010,) and for tobramycin from 0.2 to 50 µg/mL in plasma (LLOQ 
0.205 ± 0.012), and 0.1 to 20 µg/mL in microdialysate (LLOQ 0.111 ± 0.004). Quality 
control samples were prepared at three concentrations 0.6, 2 and 16 µg/mL with 
precision and accuracy within 15% for all analyses. All analyses passed the batch 
acceptance criteria. The assay was validated according to an international FDA 
guideline[240] in terms of stability, specificity, linearity, precision and accuracy. 
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 Statistical Analysis 
 
A linear regression model was used, with recovery as the dependent variable and flow 
rate and concentration as independent variables. This allowed us to examine if the 
recovery changed when the flow rate or concentration were altered. To estimate the 
variation in recovery we fitted the linear regression model using a Bayesian paradigm 
and modelled the result of a new test, using the 95% credible interval to estimate the 
likely range in percent recovery for a new test. As we assume a constant variance 
across dose, flow rate, and sample number, this credible interval will apply to any 
mean. We used 10,000 Markov chain Monte Carlo iterations with a burn-in of 10,000 
thinned by 3. All analyses were made using R version 3.0.2 (www.r-project.org) with 
the Bayesian analysis in WinBUGS version 3.1.4 [241]. 
 
 Results 
 
The temperature of all the study solutions was constant at room temperature 
(24.0 °C  0.5). The pH of all the study solutions was 7.40  0.04. The mean  SD 
concentrations of vancomycin and tobramycin are summarised in Table 4.1 A and B 
respectively.  
 
Table 4.2 A and B presents the mean  SD relative recoveries of vancomycin and 
tobramycin respectively.  
 
Table 4.1 A: Mean ( SD) vancomycin concentrations in microdialysate (µg/mL). 
 B: Mean ( SD) tobramycin concentrations in microdialysate 
A 
 Microdialysis Flow Rate (µL/min) 
Analyte Plasma 
Concentrations                         
(µg/mL) 
1 1.5 2 
Vancomycin 20 5.36 ( 0.50) 5.06 ( 0.32) 4.29 ( 0.50) 
5 1.63 ( 0.09) 1.37 ( 0.09) 1.03 ( 0.05) 
0.5 <LLOQ <LLOQ <LLOQ 
 
(LLOQ= lower limit of quantification) (LLOQ for vancomycin= 1 µg/mL) 
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B 
 Microdialysis Flow rate (µL/min) 
Analyte Plasma 
Concentrations 
(µg/mL) 
1 1.5 2 
Tobramycin 20 13.7(0.44) 13.7(0.57) 11.68(0.31) 
5 3.45(0.18) 3.47(0.09) 3.03(0.19) 
0.5 0.39(0.01) 0.32(0.01) 0.32(0.01) 
 
 
Table 4.2 A: Mean ( SD) vancomycin relative recovery (%). B: Mean ( SD) 
tobramycin relative recovery (%) 
A 
 
 Microdialysis Flow Rate (µL/min) 
Analyte Plasma 
Concentrations                         
(µg/mL) 
1 1.5 2 
Vancomycin 20 26.8 (0.50) 25.3 (0.32) 22.2 (050) 
5 32.6 (0.09) 27.5 (0.09) 20.7 (0.04) 
0.5 NC NC NC 
 
(NC= not calculated) 
 
B 
 
 Microdialysis Flow Rate (µL/min) 
Analyte Plasma 
Concentrations                         
(µg/mL) 
1 1.5 2 
Tobramycin 20 68.5 (2.23) 70.0 (2.89) 58.4 (1.55) 
5 69.0 (3.74) 69.5 (3.47) 60.7 (3.8) 
0.5 78.53 (3.13) 65.9 (2.70) 65.0 (1.70) 
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 Stability of relative recovery during in vitro microdialysis 
 
There was no significant inter-experiment variation in relative recovery. Relative 
recovery appeared stable for each microdialysis probe over the 100-minute sampling 
period. The variations were  11% for tobramycin and  14% for vancomycin (using 
the Bayesian 95% credible intervals).  
 
 Flow rate dependence on relative recovery 
 
As shown in  
 
Table 4.2 A, the relative recoveries for vancomycin were higher in the 1.0 µL/min and 
1.5 µL/min flow rates (mean 29.7% and 26.4%, respectively), compared with the 
2.0 µL/min flow rate group (mean 21.4%). The regression model in Table 4.3 shows 
that a flow rate of 2.0 µL/min had a significantly lower relative recovery than the 
reference flow rate of 1.0 µL/min. The relative recoveries remained stable for the 
duration of sampling, i.e. 100 minutes. 
 
In  
 
Table 4.2 B, relative recoveries for tobramycin were seen to be comparable in the 1.0 
µL/min and 1.5 µL/min flow rates (means 72.0% and 68.5%, respectively), but 
decreased at 2.0 µL/min (61.4%). There were no significant variations in the results 
over the duration of the study. Table 4.4 shows the regression model demonstrating 
the differences in the effect of flow rate on the relative recoveries, with a significantly 
lower relative recovery for flow rates of 1.5 and 2.0 µL/min compared with 1.0 µL/min.  
 
Table 4.3: Multiple regression analysis for relative recovery rates (mean % and 95% 
confidence interval) of vancomycin for different concentrations and perfusate flow 
rates. 
(Reference levels are 1.0 µL/min ﬂow rate and concentration 5.0 g/mL) 
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 Mean (%) 95% CI P value 
Intercept 29.2 23.7, 34.7 <0.001 
Concentration 20 
µg/mL 
1.0 –4.7, 6.7 0.712 
Flow rate 1.5 µL/min –6.1 –12.7, 0.5 0.070 
Flow rate 2.0 µL/min –11.6 –18.9, –4.3 0.003 
 
Table 4.4: Multiple regression analysis for relative recovery rates (mean % and 95% 
confidence interval) of tobramycin for different concentrations and perfusate flow 
rates. 
(Reference levels are ﬂow 1.0 µL/min and concentration 0.5 g/mL) 
 
 Mean (%) 95% CI P value 
Intercept 71.0 67.2, 74.8 <0.001 
Concentration 5.0 
µg/mL 
2.2 –1.9, 6.4 0.286 
Concentration 20 
µg/mL 
5.7 1.6, 9.9 0.008 
Flow rate 1.5 µL/min -5.7 –9.8, –1.5 0.009 
Flow rate 2.0 µL/min -12.0 –16.2, –7.9 <0.001 
 
 Concentration dependence relative recovery 
 
As shown in  
 
Table 4.2 A, the relative recoveries for vancomycin were higher for the 5.0 µg/mL 
concentration (range 21.4 to 35.8%) compared with the 20 µg/mL concentration (range 
19.4 to 30.5%). Importantly, the microdialysate in the 0.5 µg/mL group did not yield 
any results, as the concentrations were less than the lower limit of quantification of the 
assay (0.2 µg/mL). For tobramycin, the range of relative recoveries were as shown in  
 
Table 4.2 B and highest for concentration of 20 μg/mL (range 56 to 71.5%).  
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 Combined effect of drug concentration and flow rate 
 
For vancomycin (Table 4.3) there was no statistical difference between the 
concentrations, but there was a lower relative recovery for flow rate of 2.0 µL/min 
compared with flow rate of 1.0 µL/min (Mean difference −11.6%, 95% CI: −18.9 to 
−4.3%, P value= 0.003). The highest relative recovery was for a concentration of 5.0 
μg/mL and flow rate of 1.0 µL/min (Mean recovery 30.2%, 95% CI: 24.8% to 35.7%).  
For tobramycin (Table 4.4), there was a higher relative recovery for the concentration 
of 20 μg/mL compared with 0.5 μg/mL, with a mean increase of 5.7% (95% CI 1.7 to 
9.8%, P value = 0.008). Flow rates of 1.5 µL/min and 2.0 µL/min had lower relative 
recoveries than the flow rate of 1.0 µL/min, P value 0.008 and <0.001 respectively. 
The highest relative recovery was for a concentration of 20 μg/mL and flow rate 
1.0 µL/min (mean 76.8%, 95% CI: 73.0% to 80.6%). 
 
 Discussion 
 
Though in vitro microdialysis studies have been performed previously to examine 
probe recovery, to the best of our knowledge, this is the first study simulating in vivo 
conditions and examining the relative recoveries for a combination of antibiotics in 
plasma. Knowledge of potential drug effects on microdialysis recovery is essential as 
combination antibiotic therapy is commonly used clinically and if not accounted for in 
relative recovery, may risk under- or over-estimating drug concentrations in interstitial 
space fluid in in vivo studies. In vitro studies provide an ideal platform to study this 
effect and thus allow useful calibration for in vivo studies. Although there were inter-
experiment differences in the relative recovery, its practical relevance is negligible. In 
general, for a drug, inter-experiment relative recovery variations of 20% are 
acceptable under in vivo conditions [226]. 
 
Nosocomial infections due to methicillin-resistant Staphylococcus aureus (MRSA) and 
Pseudomonas spp are prevalent [242] and hence most therapies both, empirical and 
specific, would include vancomycin and tobramycin as part of the regimen [243]. 
Hence, for our study, we chose these two antibiotics. Interstitial space fluid 
concentrations of antibiotics could be affected by a number of factors during in vivo 
microdialysis. For Vancomycin, the reported values in the microdialysis samples  have 
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been variable with a wide range[244-246]. For tobramycin, there is dearth of data in 
the microdialysis samples but Bernardi et al[247] report a lung microdialysis study 
using tobramycin and Rodvold et al[9] report a range of lung penetration ratio for 
tobramycin. Hence, the 3 concentrations chosen for the study would encompass a 
wide range of possible values.  
 
In comparison to a previous study [230], our study showed that relative recoveries for 
vancomycin were lower (26% vs. 50%) across all flow rates and concentrations. 
Considering that MacVane et al [230] performed their study in a non-protein medium, 
our results could be explained by the protein binding of vancomycin. However, 
perfusate composition, membrane characteristics and other factors may also play a 
role in this phenomenon. 
 
For both drugs and all concentrations, we found improved relative recovery at lower 
flow rates. Hence, where possible, lower microdialysis flow rates should be preferred 
for optimal recovery. However, decreasing the flow rate could reduce the ability to 
sample frequently, due to the increased time required to collect the sample volume 
required for the assay. Less frequent sampling may adversely affect the temporal 
resolution of the data. Studies using drugs with narrow therapeutic index or in 
conditions with temporal fluctuations of drug concentration are likely to produce 
significant differences. Therefore, choosing a flow rate appropriate for the desired 
sampling frequency is an important consideration of all studies. In future and with 
improved analytic techniques, where measurement in a low volume is possible, this 
may not be an issue. 
 
Careful consideration of the expected interstitial space fluid concentration should be 
taken into account when performing studies. Here, the lower recovery rates caused 
the microdialysate concentration to fall below the lower limit of the assay, as we 
encountered in the group of low vancomycin concentrations. Therefore, in vitro 
calibration can help prevent loss of clinical samples from the same issue.  
 
 Limitations 
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The exact composition of the interstitial space fluid is likely different between individual 
tissues and could be different in illness[248]. Moreover, in critical illness the increased 
inflammation could lead to changes in the interstitial space fluid protein content[248]. 
We were unable to obtain interstitial fluid hence plasma was used for the study as the 
surrogate medium. Plasma offers a reasonable surrogate for this experiment as, while 
the protein concentrations are higher at around 60-80 g/L in a healthy adult, compared 
to interstitial fluid with protein content 24- 32 g/l (interstitial fluid to serum protein ratio 
~0.4)[249], this offers an insight into the conditions of a patient during critical illness 
where capillary leak syndrome may elevate the protein content in the interstitial fluid. 
Although we have attempted to mimic in vivo conditions, our study focussed on only 
two factors, drug concentration and perfusate flow rate, affecting relative recovery. 
There is currently no data on the effect of different concentrations of one antibiotic on 
the recovery rate of another antibiotic during combined antibiotic therapy. Our study 
did not investigate this effect but it remains a worthy subject for better characterisation 
of relative recoveries in this context. Processes such as pressure gradients, 
extracellular–microvascular exchange, metabolism, and tissue diffusion of the drug 
can affect the relative recovery of the drugs. In vivo recovery may be affected by 
experimental and/or disease conditions [229].  Besides these, microdialysis probe 
related factors such as membrane length, material and surface area, perfusate 
composition and temperature; tissue factors such as blood flow and temperature; the 
tissue- drug- probe material interactions could affect the drug concentrations resulting 
in even lower concentrations of the drug in the microdialysate [229]. With this study, 
we have attempted to establish a minimum set of conditions to be fulfilled for 
microdialysis based studies. When possible, future studies should include in vivo 
calibration for recovery calculations. 
 
 Conclusion 
 
In this simulated in vivo model, the in vitro relative recoveries for vancomycin and 
tobramycin varied with the perfusate flow rate and drug concentration. We recommend 
that a low perfusate flow rate  1 µL/min should be used to achieve optimal relative 
recovery. 
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Furthermore, we recommend performing in vitro recovery studies simulating in vivo 
conditions to accurately calibrate the microdialysis system prior to in vivo studies, to 
establish the most accurate combination of flow rate and drug concentration.  
Performing studies in plasma for moderate-to-highly protein bound drugs may better 
replicate in vivo conditions. Based on our study results, vancomycin and potentially 
other molecules of larger size and/or high protein binding need additional 
consideration for improving the relative recovery.  
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4.3 Conclusion of the chapter 4 “Effect of combination antibiotic therapy 
on microdialysis recovery rates” 
 
The study results help establish the optimal settings required to derive the maximal 
recovery using the microdialysis technique. We found that a perfusate flow rate of 1 
µL/min yielded the highest recovery for tobramycin and vancomycin. We were also 
able to successfully perform and validate the tobramycin and vancomycin assays on 
the small volumes (20 µL) and for a range of biologically relevant concentrations. 
These results will be used to perform the in vivo microdialysis studies that form part of 
this Thesis as described in Chapter 7.  
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Chapter 5 Effect of different tobramycin formulations on 
aerosol characteristics with mechanical ventilation. 
 
5.1 Synopsis 
 
The aim of this chapter is to describe the aerosol characteristics of two different 
tobramycin formulations used for aerosol therapy using a simulated mechanical 
ventilation set up. Key components of aerosol characterstics e.g. particle size 
distribution, inhaled mass, among others are described against different types of 
tracheal tubes and the sizes of these tracheal tubes.   
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5.2 Published manuscript entitled “Characterisation of 40 mg/mL and 
100 mg/mL tobramycin formulations for aerosol therapy with adult 
mechanical ventilation” 
 
The manuscript entitled, “Characterisation of 40 mg/mL and 100 mg/mL tobramycin 
formulations for aerosol therapy with adult mechanical ventilation” has been published 
in Pulmonary Pharmacology and Therapeutics (2018 Jun;50:93-99). 
 
The co-authors contributed to the manuscript as follows: All study design, experiments 
and data collection were performed by the PhD candidate, Jayesh Dhanani, under the 
supervision of Prof Jason Roberts, Prof Hak-Kim Chan and Dr. Patricia Tang. Dr. 
Steven Wallis and Dr. Suzanne Parker analysed the samples. 
Prof Adrian Barnett guided the PhD candidate, Jayesh Dhanani, in regards to the 
statistical analyses for the data. Ms Preeti Pandey assisted with measuring the 
physicochemical properties of the two tobramycin formulations. The final editing was 
done by the PhD candidate, Jayesh Dhanani, with supervision from Associate Prof 
Jeremy Cohen, Prof John Fraser and Prof Jason Roberts. The PhD candidate, Jayesh 
Dhanani, took the leading role in the manuscript preparation and writing.  
 
The manuscript is presented as published; except figures and tables have been 
inserted into the text at slightly different positions. Also, the numbering of the pages, 
figures and tables has been adjusted to fit the overall style of the Thesis. The 
references are found alongside the other references of the Thesis, in the section 
‘References’.  
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 Abstract 
 
Preservative-free tobramycin is commonly used as aerosolized therapy for ventilator 
associated pneumonia. The comparative delivery profile of the formulations of two 
different concentrations (100 mg/ml and 40 mg/ml) is unknown. This study aims to 
evaluate the aerosol characteristics of these tobramycin formulations (400 mg and 160 
mg respectively) in a simulated adult mechanical ventilation model. Simulated adult 
mechanical ventilation set up and optimal settings were used in the study. Inhaled 
mass study was performed using bacterial/viral filters at the tip of the tracheal tube 
and in the expiratory limb of circuit. Laser diffractometer was used for characterising 
particle size distribution. The physicochemical characteristics of the formulations were 
described and nebulization characteristics compared using two airways, an 
endotracheal tube (ET) and a tracheostomy tube (TT). For each type of tube, three 
internal tube diameters were studied, 7mm, 8mm and 9mm. The lung dose was 
significantly higher for 100 mg/ml solution (mean 121.3 mg vs 41.3 mg). Viscosity was 
different (2.11cp vs 1.58cp) for 100 mg/ml vs 40 mg/ml respectively but surface tension 
was similar. For tobramycin 100 mg/ml vs 40 mg/ml, the volume median diameter 
(2.02 vs 1.9 µm) was comparable. The fine particle fraction (98.5 vs 85.4%) was higher 
and geometric standard deviation (1.36 vs 1.62 µm) was significantly lower for 100 
mg/ml concentration. Nebulization duration was longer for 100 mg/ml solution (16.9 vs 
10.1 minutes). The inhaled dose percent was similar (30 %) but the exhaled dose was 
higher for 100 mg/ml solution (18.9 vs 10.4%). The differences in results were non-
significant for type of tube or size except for a small but statistically significant 
reduction in inhaled mass with TT compared to ET (0.06%). Aerosolized tobramycin 
100 mg/ml solution delivered higher lung dose compared to tobramycin 40 mg/ml 
solution. Tracheal tube type or size did not influence the aerosol characteristics and 
delivery parameters.  
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 Introduction 
 
Ventilator associated pneumonia (VAP) occurs commonly in hospitals and is 
associated with significant mortality and morbidity worldwide[3-6]. Due to the 
emergence of multidrug resistant organisms causing VAP and scarcity of newer 
antibiotics, aerosolized antibiotics are increasingly being used to treat VAP either as 
monotherapy or as an adjuvant agent[250]. Recent guidelines have suggested using 
both inhaled and intravenous antibiotics for VAP due to resistant organisms[251, 252]. 
However, there is little data to support its widespread use in patients with VAP[177, 
253]. Moreover, recent randomized controlled trials failed to demonstrate clinical 
outcome benefits of adjunctive aerosolized therapy compared to systemic therapy 
alone[17, 18]. For effective antibiotic therapy, optimal drug concentrations are 
essential at the site of action which for lung infections is considered the epithelial lining 
fluid[254]. Factors affecting the efficacy of aerosol delivery with mechanical ventilation 
(MV) include physicochemical properties of the antibiotic formulation (surface tension 
and viscosity), tracheal tube size and type [182],[13, 181]. As a result, antibiotic 
formulations for aerosol therapy should be tested for adequacy of delivery 
characteristics and hence effective therapy. According to the United States 
Pharmacopoeia 35 (USP 35), supplement NF 30[255], standard characterisation of 
nebulizer formulations involves two analyses:  
• Total drug substance delivered (inhaled mass) 
• Aerodynamic assessment of nebulized aerosols. 
 
Aerosolised tobramycin is effective against common VAP causing organisms[256, 
257] and injectable tobramycin formulations are commonly used for aerosol 
therapy[258]. Besides tobramycin for inhalation solution[256] (e.g. TOBI®, Novartis, 
Emeryville, CA), there are other preservative free tobramycin formulations used for 
aerosol therapy[16] and these are available in 40 mg/ml and 100 mg/ml 
concentrations. Despite being widely used, there is dearth of data regarding the effect 
of different tobramycin formulations on the aerosolised drug delivery efficacy with MV. 
Comparative data between the two formulations will enable clinicians to choose the 
formulation that is likely to result in maximal drug concentration at the effect site thus 
improving clinical outcomes.  
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The objective of this study was to describe the effect of tobramycin solution 
concentrations (100 mg/ml and 40 mg/ml) on the aerodynamic properties and aerosol 
output using an in vitro model of adult mechanical ventilation. These parameters were 
studied using different types of tracheal tubes (endotracheal and tracheostomy) and 
sizes (7, 8 and 9 mm internal diameter). The study hypothesis was that 100 mg/ml 
formulation has better aerosol characteristics for distal pulmonary drug delivery 
compared to the 40 mg/ml formulation.  
 
 Materials and Methods 
 
 Materials 
 
Commercially available agents were used for the study.  
Two commonly available tobramycin solutions were used:  
1. Tobramycin 500 mg/5 ml (Tobra-day®, Phebra, Australia) yielding a concentration 
of 100 mg/ml. 
2. Tobramycin 80 mg/2 ml (Tobramycin PF, Pfizer, Australia) yielding a concentration 
of 40 mg/ml. 
Two different types of tracheal tubes and three sizes for each type of the tracheal tube 
were used for the study. 
1. Endotracheal tubes (ET) size 7, 8 and 9 mm internal diameter [(I.D.); Portex, Smiths 
Medical International Ltd, UK] 
2. Tracheostomy tubes (TT) size 7, 8 and 9 mm I.D. (Portex, Smiths Medical 
International Ltd, UK).  
 
Recent guidelines support the use of a vibrating mesh nebulizer (VMN) for aerosolised 
antibiotic therapy with MV[19, 193]. Accordingly, disposable VMNs (Aeroneb pro, 
Aerogen Inc., Galway, Ireland) were employed for the study. For the collection of the 
aerosols, bacterial/viral filters (Filter Pads, Fisher and Paykel, Auckland, New 
Zealand) were used.  
 
 Physicochemical characteristics of tobramycin solutions 
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Viscosity of the solutions was examined using a DHR-3 rheometer (TA Instruments, 
USA) at 25°C. The data collection and calculations were performed using TRIOS 
software. Surface tension measurements of the solutions were conducted using a 
Texture Analyzer (Brookfield CT3 texture analyser, USA) at 25°C.  
 
 Study Set up 
 
The study set up consisted of a simulated mechanical ventilation set up and specific 
set up parameters for the inhaled mass and the particle size distribution study.   
 
5.2.3.3.1 Mechanical ventilation simulation set up  
 
For this study, we utilised a previously described methodology[259, 260] with an adult 
use ventilator (AVEA, VIASYS Respiratory Care Inc. 22745 Savi Ranch Parkway 
Yorba Linda, CA) and the following settings, volume control mode, synchronised 
intermittent mandatory ventilation (SIMV) with a tidal volume 500 ml. The inspiratory: 
expiratory ratio was set at 1:2, positive end-expiratory pressure (PEEP) at 5 cm H2O 
and the flow set at 40 litres per minute in a square wave pattern. As per the 
recommendations for aerosolised antibiotics with MV, the humidifier was turned off 
[250]. The inspiratory limb of the ventilator was connected to the VMN before the Y-
piece as per previous studies[259, 260], in keeping with local and international 
practice[259] and the manufacturer’s recommendations. The Y-piece was then 
connected to the elbow connection as per standard practice and the study tracheal 
tube attached at the end of the elbow connection.  
 
5.2.3.3.2 Inhaled mass study set up (Figure 5.1) 
 
Using a customised adaptor, the tip of the tracheal tube was inserted in the filter. The 
cuff was inflated to provide an air tight seal. Finally, the filter was connected to an adult 
test lung (Dräger Medical, Lubeck, Germany) to maintain closed circuit. Another filter 
was inserted in the expiratory limb of the circuit just after the Y-piece thus completing 
the circuit. 
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Figure 5.1: Schematic diagram illustrating the circuit set up for the inhaled mass study 
 
5.2.3.3.3 Particle size distribution study set up (Figure 5.2) 
 
The particle size distribution of the emitted aerosol was measured using a laser 
diffractometer (Spraytec; Malvern Instrument, Worcs, United Kingdom) with a real-
time sizer software. The tip of the tracheal tube (ET or TT) was connected to the inlet 
port of the inhalation cell of the laser diffractometer. A custom silicone adaptor was 
used as an interface between the tracheal tube and the inlet port. The cuff of the 
tracheal tube was inflated to enable a complete seal. An adult test lung (Dräger 
Medical, Lubeck, Germany) was connected to the outlet port with a filter interface. The 
set up thus enabled a closed circuit and facilitated continuous ventilator operation. 
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Figure 5.2: Schematic diagram illustrating the circuit set up for the particle size 
distribution study. 
 
 
 Inhaled mass study 
 
After completing the set-up, ventilation was commenced as per the settings described 
above. Using a 5-ml syringe, the nebulizer was filled with 4 ml of the tobramycin 
solution. The nebulizer was weighed before and after filling with the solution. After 
ensuring that closed circuit was maintained with no air leak, the nebulization was 
commenced. The experiment was continued till the mist of the aerosol was no longer 
visible at which time the ventilation was stopped, the filters disconnected and stored 
in a container. The duration of nebulization was noted. The study filters were stored at 
-80 °C for further analysis. The nebulizer was then removed and weighed. The 
disposable VMN was changed after each experiment and so were the circuit, filters, 
and the study tracheal tube. For each configuration, the study was performed in 
triplicate. 
 
 Particle size distribution measurement  
 
Mechanical ventilation was commenced as per the set up. Using a 5-ml syringe, the 
nebulizer was filled with 4 ml of the tobramycin solution, nebulization commenced and 
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the laser diffractometer was initiated. When there was no visible mist, ventilation was 
stopped. The nebulizer, circuit and the study tracheal tube were changed for each 
experiment which were performed in triplicate.  
 
 Sample analysis and data collection 
 
For the inhaled mass study, concentrations of tobramycin were measured by a HPLC-
MS/MS method on a Shimadzu Nexera UHPLC connected to a Shimadzu 8030+ triple 
quadrupole mass spectrometer. Tobramycin amount was calculated and expressed 
as milligrams (mg). 
 
The particle size distribution characteristics of the aerosol were measured using the 
continuous, real-time and in situ measurement using the laser diffractometer with the 
real-time sizer software.  
 
 Data analysis 
 
Gravimetric analysis[261] was used for calculations of the nominal dose, residual 
volume and nebulizer output using the following equations: 
 
Nominal dose (mg) = weight of nebulizer when filled – weight of empty nebulizer 
Residual volume (ml) = weight of filled nebulizer –weight of the nebulizer post 
nebulization. The residual volume and weight are related by the solution density which 
is practically 1. 
Thus, residual drug (mg) = residual volume x tobramycin concentration 
 
Total nebulizer output (mg) = weight of filled nebulizer – residual volume   
 
The aerosol characteristics of the two formulations were evaluated with two types of 
tracheal tubes and three sizes and expressed using the following parameters:  
1. Particle size distributions were expressed as dv10 (volume diameter under 
which 10 % of the sample resides), dv50 (volume median diameter; VMD), and 
dv95 (volume diameter under which 95 % of the sample resides). Additionally, 
the percentages of particles with size between 1 to 5 µm (fine particle fraction; 
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FPF) and geometric standard deviation (GSD) which describes the 
polydispersity of the aerosols were included.  
2. Nebulization time which was defined as the time from commencement of 
nebulization till no visible mist was produced. 
3. Inhaled mass % which was defined as the percent mass of nominal dose 
deposited on the filter at the tip of the study tracheal tube.  
4. Nebulizer output % which was defined as the percent nebulizer output of the 
nominal dose. 
5. Residual drug % which was defined as the percent residual drug of the nominal 
dose. 
6. Exhaled mass % which was defined as the percent mass of nominal dose 
deposited on the filter in the expiratory limb of the circuit.  
7. Lung dose was defined as the product of inhaled mass and the FPF. 
 
 Clinical significance of the parameters 
 
• The dv10, dv50 and dv95 are descriptions for volume weighted particle size 
distributions when measured by laser diffraction. A low dv50 or VMD could 
enable distal lung deposition. The dv10 and dv95 represent the sizes at the 
extremes of the distribution curve and indicate variability of particle sizes in an 
aerosol sample.    
• For pathologies in which distal lung deposition is required for clinical effect, a 
high FPF is desirable. This parameter is used in conjunction with inhaled mass 
%  
• As ventilator settings might need to be altered to optimise aerosol delivery, 
shorter nebulization time is preferable.  
• The inhaled mass % denotes the proportion of the drug in the nebulizer that 
gets to the end of the tracheal tube and is used in conjunction with FPF to derive 
the amount of drug that may reach distal lung regions. 
• The nebulizer output % and residual drug % are a measure of the nebulizer 
efficiency with high output % and low residual drug % being preferable.  
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• In a continuous nebulizer system, nebulization continues in the exhalation 
phase of respiration and therefore not available to the patient. High exhaled 
mass % therefore indicates high nebulized drug losses.  
• Lung dose is the actual amount of nebulized drug that is delivered to the distal 
lung. This is important for drugs from classes that are required to be deposited 
distally for clinical effect. E.g. antibiotics for the treatment of pneumonia. 
 
 Statistical analysis 
 
Multiple linear regression was carried out to estimate the effect of the explanatory 
variables on the outcomes. Results were presented as means with 95 % confidence 
intervals. All analyses were conducted using R version 3.4.2 
 
 Results 
 
All experimental results were obtained and analysed with no missing data. 
 
 Physicochemical characteristics 
 
The viscosity of the tobramycin 100 mg/ml was 2.11 versus 1.55 cP for the 40 mg/ml 
solution (Table 5.1). The surface tension was similar for the two solutions (71.18 and 
71.56 dyne/cm, respectively).  
 
Table 5.1: Comparative physicochemical and aerosol characteristics of tobramycin 
solutions- 100mg/ml and 40mg/ml (mean ± S.D.) using endotracheal tubes and 
tracheostomy tubes of sizes 7, 8 and 9 mm I.D. 
 Tobramycin Solutions 
 100mg/ml 40mg/ml 
Physicochemical characteristics (mean±S.D.) 
Surface tension 
(dyne/cm)  
71.20 ± 0.41 71.60±0.17 
Viscosity (cP) 2.12 1.58 
Aerosol Particle (mean±S.D.) 
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dv10 (µm) 1.32±0.05 0.98±0.05 
VMD (µm) 2.02±0.10 1.90±0.16 
dv95 (µm) 3.53±0.57 4.63±0.40 
FPF (%1-5µm) 98.51±0.19* 85.36±4.20 
GSD (µm) 1.36± 0.11* 1.62±0.23 
Duration, inhaled and exhaled mass (mean±S.D.) 
Nebulization duration 
(minutes) 16.93±2.29* 10.14±2.52 
Nebulizer output (%) 98.20±1.10 98.0±0.01 
Residual drug (%) 1.80±0.01 2.0±0.01 
Inhaled mass (%) 30.0±4.90 30.10±0.08 
Exhaled drug (%) 18.90±4.20* 10.40±0.03 
Lung dose (mg) 121.29±21.75* 41.31±10.04 
 
cP: centipoise; dv10: volume diameter under which 10% of the particles reside; VMD: 
volume median diameter; dv95: volume diameter under which 95% of the particles 
reside; FPF: fine particle fraction (1-5µm); GSD: geometric standard deviation; 
Nebulization duration: time from commencement of nebulization till no visible mist was 
produced; Inhaled mass %: percent mass of nominal dose deposited on the filter at 
the tip of the study tracheal tube; Nebulizer output %: percent nebulizer output of the 
nominal dose; Residual drug %: percent residual drug of the nominal dose; Exhaled 
mass %: percent mass of nominal dose deposited on the filter in the expiratory limb of 
the circuit; Lung dose: product of inhaled mass and the FPF. 
*p<0.05 
 
 Aerosol particle size and distribution 
 
Table 5.1 summarises the data comparing the aerosol characteristics for the two 
concentrations of tobramycin when used with the different tracheal tube types and 
sizes. The two formulations, 100 mg/ml and 40 mg/ml had a statistically significant 
(p<0.001) difference in mean GSD of 1.36 µm and 1.62 µm and the mean FPF 98.5 
% and 85.36 % respectively. Other parameters like dv10, dv95 were not statistically 
different. There were no significant differences for particle size and distribution 
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characteristics between tracheal tube type (ETT and TT) or size (7, 8 and 9 mm I.D.). 
Table 5.2 and Table 5.3 show the data for different concentrations in relation to 
tracheal tube types and sizes.  
 
Table 5.2: Aerosol characteristic for tobramycin 100mg/ml endotracheal tube (Top 
panel) and tracheostomy tube (Bottom panel) of 3 different sizes (mm- internal 
diameter) mean ± S.D. 
Variables Endotracheal tube size 
 7 mm 8 mm 9 mm 
Aerosol particle size distribution 
dv10 (µm) 1.27 ± 0.05  1.35 ± 0.04 1.42± 0.04 
VMD (µm) 1.98 ± 0.12 2.04±0.13 2.13± 0.1627 
dv95 (µm) 3.58±0.59 3.50±0.74 3.62±0.52 
FPF (% 1-5 µm) 97.95±0.20 99.13±0.24 99.44±0.30 
GSD (µm) 1.38± 0.12 1.35±0.18 1.34±0.16 
Duration, inhaled and exhaled mass 
Nebulization 
duration 
(minutes) 
19.11±0.10 18.79±1.09 18.56±2.36 
Nebulizer output 
(%) 
98.9±0.01 97.3±0.01 98.3±0.01 
Residual drug 
(%) 
1.1±1.2 2.7±1.5 1.9±1.3 
Inhaled mass* 
(%) 
26.5±0.01 28.1±0.04 34.5±0.05 
Exhaled drug 
(%) 
25.4±0.04 20.4±0.01 19.4±0.02 
Lung dose (mg) 106.53±12.29 113.40±15.43 145.86±12.64 
 
Variables Tracheostomy tube size 
 7 mm 8 mm 9 mm 
Aerosol particle size distribution 
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dv10 (µm) 1.20±0.04 1.30±0.05 1.36±0.08 
VMD (µm) 1.83±0.07 2.01±0.07 2.12±0.08 
dv95 (µm) 3.16±0.37 3.59±0.35 3.73±0.88 
FPF (% 1-5 µm) 97.21±0.15 98.43±0.14 98.9±0.12 
GSD (µm) 1.35±0.05 1.37±0.05 1.36±0.08 
Duration, inhaled and exhaled mass 
Nebulization 
duration 
(minutes) 
14.54±1.40 15.94±0.64 14.63±1.14 
Nebulizer output 
(%) 
97±0.02 98±0.01 98±0.006 
Residual drug 
(%) 
2.5±0.8 1±0.5 1.6±0.6 
Inhaled mass* 
(%) 
30.7±0.08 31.2±0.01 28.9±0.04 
Exhaled drug 
(%) 
15.1±0.01 16.6±0.01 16.6±0.02 
Lung dose (mg) 117.79±37.44 124.63±4.91 119.53±26.08 
 
cP: centipoise; dv10: volume diameter under which 10% of the particles resides;  
VMD:volume median diameter under which 50% of the particles resides; dv95:volume 
diameter under which 95% of the particles resides; FPF: fine particle fraction (1-5µm); 
GSD: geometric standard deviation; Nebulization duration: time from commencement 
of nebulization till no visible mist was produced; Inhaled mass %: percent mass of 
nominal dose deposited on the filter at the tip of the study tracheal tube; Nebulizer 
output %: percent nebulizer output of the nominal dose; Residual drug %: percent 
residual drug of the nominal dose; Exhaled mass %: percent mass of nominal dose 
deposited on the filter in the expiratory limb of the circuit; Lung dose: product of inhaled 
mass and the FPF. 
*P<0.05 
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Table 5.3: Aerosol characteristic for tobramycin 40mg/ml endotracheal tube (Top 
panel) and tracheostomy tube (Bottom panel) of 3 different sizes (mm- internal 
diameter) mean ± S.D. 
Variables Endotracheal tube size 
 7 mm 8 mm 9 mm 
Aerosol particle size distribution 
dv10 (µm) 0.92±0.05 0.96±0.05 1.01±0.05 
VMD (µm) 2.02±0.20 1.99±-.20 2.11±0.23 
dv95 (µm) 5.54±0.16 5.39±0.16 5.76±0.19 
FPF (% 1-5 µm) 81.41±4.74 82.1±5.04 82.3±6.00 
GSD (µm) 1.74±0.33 1.72±0.29 1.72±0.38 
Duration, inhaled and exhaled mass 
Nebulization 
duration 
(minutes) 
8.29±0.90 8.11±1.02 7.88±1.08 
Nebulizer output 
(%) 
97.5±0.01 99±0.01 98.4±0.01 
Residual drug 
(%) 
3±2.5 2±1.3 2±0.7 
Inhaled mass 
(%) 
39.4±0.07 
 
39.4±0.02 30.9±0.09 
Exhaled drug 
(%) 
9.4±0.02 16.3±0.04 8.8±0.01 
Lung dose (mg) 50.75±8.99 51.09±3.33 40.09±12.67 
 
Variables Tracheostomy tube size 
 7mm 8mm 9mm 
Aerosol particle size distribution 
dv10 (µm) 0.92±0.07 1.02±0.03 1.02±0.06 
VMD (µm) 1.76±0.14 1.80±0.10 1.75±0.10 
dv95 (µm) 3.96±0.76 3.67±0.46 3.48±0.67 
FPF (% 1-5µm) 85.48±4.01 90.27±1.69 90.65±3.74 
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GSD (µm) 1.59±0.12 1.51±0.06 1.47±0.15 
Duration, inhaled and exhaled mass 
Nebulization 
duration 
(minutes) 
13.22±2.79 11.36±0.96 12±1.40 
Nebulizer output 
(%) 
98.5±0.01 98.1±0.007 98.4±0.00 
Residual drug 
(%) 
1.5±0.6 1.9±0.7 1.6±1.3 
Inhaled mass 
(%) 
23.7±0.04 21.9±0.05 25.6±0.03 
Exhaled drug 
(%) 
9±0.03 9.7±0.02 8.8±0.01 
Lung dose (mg) 34.15±6.14 33.27±7.48 38.49±6.80 
 
cP: centipoise; dv10: volume diameter under which 10% of the sample resides;  
VMD:volume median diameter under which 50% of the particles resides; dv95:volume 
diameter under which 95% of the sample resides; FPF: fine particle fraction (1-5µm); 
GSD: geometric standard deviation; Nebulization duration: time from commencement 
of nebulization till no visible mist was produced; Inhaled mass %: percent mass of 
nominal dose deposited on the filter at the tip of the study tracheal tube; Nebulizer 
output %: percent nebulizer output of the nominal dose; Residual drug %: percent 
residual drug of the nominal dose; Exhaled mass %: percent mass of nominal dose 
deposited on the filter in the expiratory limb of the circuit; Lung dose: product of inhaled 
mass and the FPF. 
 
 Nebulization duration:  
 
The duration of nebulization for the 100 mg/ml tobramycin solution was significantly 
higher as compared to the 40 mg/ml solution (mean 16.9 vs 10.1 minutes; 95 % C.I.-
9.4,12.1; p<0.001). Tracheal tube type or size did not have significant effects on 
nebulization duration. 
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 Nebulizer output percent and Residual drug percent:  
 
The residual drug percent and hence the nebulizer output percent were similar for the 
two concentrations using both types of tracheal tube. The size of tracheal tubes did 
not affect the nebulizer output percent (Table 5.2 and Table 5.3). 
 
 Inhaled mass percent:  
 
The average inhaled mass percent was similar for the two concentrations, 30 % ± 0.04 
and 30.1 % ± 0.08 for 100 mg/ml and 40 mg/ml respectively. Regression analysis 
showed that the inhaled mass percentage was significantly less with TT compared to 
ET but having a small difference (mean difference 0.06%; 95% C.I.- 0.10, 0.01; p= 
0.01). The tracheal tube size did not have any significant effect on inhaled mass. 
 
 Exhaled drug percent:  
 
Compared to the 40 mg/ml formulation, the 100 mg/ml formulation showed statistically 
significantly greater loss of tobramycin in the expiratory filter (mean 18.9 % vs 10.4 %, 
p<0.001). There was insignificant effect of tracheal tube type or size on the exhaled 
drug percentage.  
 
 Lung dose: 
 
Lung dose was significantly higher in the 100 mg/ml solution (mean 121.29 mg vs 
41.31 mg, mean difference 79.98 mg, 95 % C.I.- 68.46, 91.5; p<0.001). There was no 
significant effect of tracheal tube type or size on the lung dose. 
 
 Discussion 
 
The main finding of the study was that the 100 mg/ml solution of preservative-free 
tobramycin delivered a higher dose to the lung compared to the 40 mg/ml solution. To 
our knowledge, this is the first study comparing two different concentrations of 
tobramycin for two different adult tracheal tube types and three internal diameters of 
tracheal tube. The mean GSD was smaller and mean FPF higher for the 100 mg/ml 
formulation which are favourable aerosol characteristics for distal lung deposition. The 
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viscosity of tobramycin 100 mg/ml (2.11 cP) was higher than the 40 mg/ml (1.58 cP) 
formulation, which has a measurable impact on the aerosol characteristics[182]. On 
the other hand, it took significantly longer to nebulize the 100 mg/ml solution. 
Compared to the 40 mg/ml solution, there was a significantly higher percent of 
expiratory filter loss of the 100 mg/ml solution. The tracheal tube type and size had no 
significant effects on all the study parameters except a small but statistically significant 
decrease in the inhaled mass percent with TT compared to ET.  
 
Adequate effect site antibiotic concentrations are essential for therapeutic effect[254] 
and hence, for the treatment of pneumonia, distal deposition is an important factor for 
antibiotic efficacy. Therefore, when considering the tobramycin formulation for aerosol 
therapy for VAP, lung dose (consists of inhaled mass and FPF) for the formulation is 
important.  
 
The amount of drug in an aerosol produced by an aerosol system that reaches the tip 
of the tracheal tube is the inhaled mass. The reported inhaled mass percent with 
mechanical ventilation for different antibiotics varies from 22 % to 66 %[80, 139, 140]. 
This has seen to increase to nearly 75 % if a device that synchronises with inspiration 
is used[262]. In this study, the inhaled mass percentage delivery for both 
concentrations were similar (mean 30.0 % for 100 mg/ml vs 30.1 % for 40 mg/ml). 
However, due to the higher drug concentration the inhaled mass quantity was higher 
with the 100 mg/ml solution. 
 
For distal respiratory tract deposition, aerosol particle size (aerodynamic diameter) is 
an important factor[130] with fine particle having sizes < 5 µm considered optimal by 
European Respiratory Society/International Society for Aerosols in Medicine 
(ERS/ISAM) Task Force Report on delivery of pharmaceutical aerosols[54]. Hence a 
high FPF is an optimal aerosol parameter for lower respiratory tract deposition[263]. 
The GSD of the aerosol is a measure of its polydispersity and describes the spread of 
the particles around the median particle size with a preferred combination of high FPF 
and low GSD for distal lung deposition[90].  Our study showed that nebulized 
tobramycin 100 mg/ml solution generated an aerosol with higher FPF and lower GSD 
compared with the 40 mg/ml solution. Consequently, the lung dose was higher for 100 
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mg/ml solution resulting in higher dose delivered to the patient potentially achieving 
higher lung concentrations for effective treatment of VAP. 
 
In one study, it was seen that increased viscosity improves nebulization up to a certain 
point after which it could lead to cessation of nebulization[182]. In the same study, for 
the Aeroneb pro the viscosity of >1.92 cP reduced the nebulization whereas surface 
tension had no effect. Lower viscosity also led to reduced FPF and increased VMD. 
However, in that study this effect was absent when Aeroneb pro nebulizer was used. 
Our study shows the same effect with the Aeroneb pro nebulizer as well. 
 
A shorter nebulization time is preferable to prevent adverse effects of the 
recommended ventilator settings that might be used to optimise aerosol delivery 
during nebulization[19]. Depending on the drug and delivery systems, there could be 
large variations in nebulization time from long (mean duration 47 minutes for 
teicoplanin[139]) to short (4.5 minutes for aztreonam[259]). In this study, it was faster 
to nebulize 40 mg/ml solution compared to the 100 mg/ml solution (mean difference 
10.7 minutes). This could be due to the lower viscosity of the 40 mg/ml solution, in line 
with findings from another study[182]. When choosing the tobramycin concentration 
for nebulization, the mean increase in the duration of 10 minutes will need to be 
considered by clinicians depending on the desired drug quantity to be delivered.  
 
For continuous nebulization systems, drug losses during nebulization occur due to 
higher residual volume and during expiratory phase of respiration. Previous data found 
that the residual volume for VMN ranged from 3 to 10 % while the exhaled drug percent 
varied from 7 to 22 % of the nominal dose[181]. In this study, the percent residual drug 
was similar (1.8 vs 2.0%) for both the concentrations but the exhaled drug percentage 
was higher for the 100 mg/ml solution (18.9 vs 10.4 %). The higher FPF may facilitate 
the expiratory filter losses for the 100 mg/ml solution whereas the loss for the 40 mg/ml 
solution likely occurred in the ventilator circuit due to large particle size. Our study did 
not measure the drug concentration in the parts of the ventilator circuit or the tracheal 
tube.  
Tracheal tube type and size could affect the aerosol delivery. Most studies have 
reported aerosol delivery data using one type of tracheal tube either ET[77, 78, 80, 
140] or TT[264]. Using MDI, Fuller et al found no difference in lung deposition of 
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aerosolised bronchodilators when compared between ET and TT[265]. Previous 
studies on effect of TT sizes on aerosol delivery have used jet nebulizer and showed 
a lung dose of 9 to 19 % of the nominal dose with higher dose for the larger size 
TT[123]. For ET, the size had no influence on the inhaled dose; however, the VMD 
reduced and FPF increased with the larger size ET[266].  In the present study, the 
nebulization duration and nebulizer output were comparable between the two types of 
tube. The data suggested a small (0.06 %) but statistically significant reduction in 
inhaled mass for when TT was used compared to ET. It is likely that the drug loss for 
TT is within the tracheal tube due to its curvature or the tube. A limitation of this study 
is it did not measure the drug in the tubes or parts of the circuit which would have been 
informative.  
 
The limitations of the present study include being an in vitro study using adult MV 
configuration, hence the results should be validated under clinical conditions before 
any recommendations could be made. Furthermore, the studies may need to be 
repeated in paediatric MV model. Moreover, the study used only two formulations of 
tobramycin and only three different sizes of TT and ET. The study did not include other 
formulations such as tobramycin for inhalation solution (TOBI) which is commonly 
used in cystic fibrosis population and in some VAP studies with good efficacy[256]. 
Finally, for our study objective only one drug and constant ventilator parameters were 
studied. However, differences in the ventilator settings could lead to variable aerosol 
drug delivery[13]. Future studies may address the effect of other drugs, different 
ventilator parameters and other type of tracheal tubes. Especially considering failure 
of recent clinical trials [17, 18], preclinical studies may help refine the various elements 
required to optimise nebulized antibiotic therapy with mechanical ventilation prior to 
future clinical trials. This work provides important information for clinical application for 
aerosolized tobramycin therapy with MV.  
 
 Conclusion 
 
Aerosolized tobramycin 100 mg/ml delivered higher lung dose than 40 mg/ml solution 
thus ideal for the treatment of VAP. Tracheal tube differences in type and sizes had 
minimal effect on the aerosol characteristics and delivery parameters. We recommend 
that although different parenteral antibiotic formulations and concentrations are 
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available and used for aerosol therapy, in vitro delivery efficacy should be studied to 
facilitate aerosolised antibiotic therapy with MV. 
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5.3 Conclusions of the chapter 5 “Effect of different tobramycin 
formulations on aerosol characteristics with mechanical ventilation.” 
 
This chapter has described in detail, the aerosol characteristics of the two formulations 
of tobramycin, 100 mg/mL and 40 mg/mL. We found that compared to the 40 mg/mL 
solution, aerosolizing tobramycin 100 mg/mL delivered a higher dose of drug that is 
likely to lead to higher lung ISF concentrations. We were also able to demonstrate that 
the types of tracheal tubes and their sizes did not have any effect on the delivered 
dose. This data will be used for the in vivo studies included in the Thesis.   
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Chapter 6 Pulmonary drug distribution of nebulized and 
intravenous tobramycin 
 
6.1 Synopsis 
 
The aim of this chapter is to compare the pulmonary distribution of intravenous and 
nebulized radiolabelled tobramycin using planar scintigraphic technique and 
quantitative distribution by measuring radioactivity in the lung, blood and 
extrapulmonary organs. Planar scintigraphy is a non-invasive technique used to 
investigate whole lung and regional lung distribution of radiolabelled antibiotics. This 
technique helps investigate the effect of airway branching and other anatomical 
consideration that may affect the aerosol deposition in the lungs.  
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6.2 Submitted manuscript entitled “Nebulized versus intravenous: a 
comparative lung distribution study in a mechanically ventilated 
ovine model using radiolabelled tobramycin.” 
 
The manuscript entitled, “Nebulized versus intravenous: a comparative lung 
distribution study in a mechanically ventilated ovine model using radiolabelled 
tobramycin” is submitted to the Journal of Antimicrobial Chemotherapy. 
 
The co-authors contributed to the manuscript as follows: All study design, experiments 
and data collection were performed by the PhD candidate, Jayesh Dhanani, under the 
supervision of Prof Jason Roberts, Dr Manoj Bhatt, Dr Benjamin Ahern, Sara Diab, 
and Dr Adeel Khan. Prof Adrian Barnett guided the PhD candidate, Jayesh Dhanani, 
in regards to the statistical analyses for the data. The scintigraphy analysis was 
performed under the supervision of Mr Steven Goodman and Dr Manoj Bhatt. The final 
editing was done by the PhD candidate, Jayesh Dhanani, with supervision from 
Associate Prof Jeremy Cohen, Prof John Fraser and Prof Jason Roberts. The PhD 
candidate, Jayesh Dhanani, took the leading role in the manuscript preparation and 
writing.  
 
The manuscript is presented as submitted; except figures and tables have been 
inserted into the text at slightly different positions. Also, the numbering of the pages, 
figures and tables has been adjusted to fit the overall style of the Thesis. The 
references are found alongside the other references of the Thesis, in the section 
‘References’.  
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 Abstract 
 
Ventilator associated pneumonia occurs commonly and nebulized antibiotics are 
being used for its treatment. Adequate pulmonary biodistribution is important for drug 
effect. There is a lack of pulmonary aerosol distribution data with mechanically 
ventilation. Pulmonary distribution of intravenous (i.v.) antibiotics is poorly understood. 
The aim of this study was to describe the comparative pulmonary regional distribution 
of i.v. and nebulized technetium 99m labelled tobramycin (99mTc-tobramycin) 400 mg 
in mechanically ventilated ovine model.  99mTc-tobramycin 400 mg was obtained 
following the radiolabelling process. Ten sheep were anesthetized and mechanically 
ventilated. Computed tomography (CT) was performed. Five sheep were given i.v. 
99mTc-tobramycin 400 mg and five were given nebulized 99mTc-tobramycin 400 mg. 
Planar images- dorsal, ventral and both lateral- were obtained using a gamma camera. 
Blood samples were obtained every 15 minutes. Lung, liver, both kidney, and urine 
samples were obtained post mortem. Whole lung deposition of nebulized 99mTc-
tobramycin 400 mg was significantly lower than i.v. 99mTc-tobramycin 400 mg. For both 
administration routes, upper lung zones had significantly lower percent deposition than 
the rest of the lungs. The middle zones had higher percent deposition for i.v. compared 
to nebulized. There was significantly higher dorsal distribution for nebulized 99mTc-
tobramycin 400 mg compared to i.v. and vice versa for ventral zone. The lung tissue 
concentrations of 99mTc-tobramycin were uniformly higher with i.v. compared to 
nebulized. There were significantly higher concentrations of 99mTc-tobramycin in 
blood, liver and urine with i.v. administration compared to nebulized. Qualitative and 
quantitatively, nebulization resulted in lower whole and regional lung deposition of 
99mTc-tobramycin with low blood and extra-pulmonary organ concentrations.  
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 Introduction 
 
The emergence of multiresistant organisms and paucity of newer drugs has led to  
nebulized antibiotics being increasingly considered a viable alternative to conventional 
therapy for the treatment of ventilator associated pneumonia (VAP)[167, 168] as an 
adjunct[1] or alone[267]. Gram negative organisms such as Pseudomonas aeruginosa 
are major causes of VAP and are associated with high morbidity and mortality 
rates[24]. The appeal of achieving high local concentrations with minimal systemic 
side effects makes it attractive to use nebulized antibiotics with narrow therapeutic 
index like aminoglycosides, e.g., tobramycin[258]. Indeed, nebulized tobramycin has 
been used for the treatment of VAP[256, 268-271].  
 
For nebulized antibiotics, pulmonary biodistribution is an important pharmacokinetic 
measure for drug efficacy[59]. Pulmonary regional aerosol distribution is affected by a 
number of factors especially with mechanical ventilation including among others, 
ventilator settings, circuit related factors, nebulizer specific parameters and patient 
related factors such as airway geometry, patency[13].  
 
Imaging studies using radioaerosols are commonly used for the non-invasive study of 
biodistribution of nebulized antibiotics[272]. Due to a suitable half-life, Technetium 
99m (99mTc) is the commonest radioactive element used for radiolabeling in 2D 
scintigraphy, sometimes with diethylene triamine penta-acetic acid[139]. Despite 
availability of other techniques[205], planar scintigraphy using a gamma camera is a 
validated technique for imaging of radioaerosols for the study of pulmonary 
biodistribution[273] and often considered ‘industry standard’ for this purpose[274].  
 
Animal models are commonly used for the study of various parameters affecting 
pulmonary drug delivery[185] and large animal models such as sheep are considered 
ideal for these studies[188]. Although a number of aerosol deposition studies are done 
in murine models, there are limitations for evaluating treatment response in disease 
conditions[275]. Sheep respiratory anatomy and physiology is well studied and is seen 
to better correlate to humans than that of rodents[276].  
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Although there is some data regarding biodistribution of nebulized tobramycin, there 
is little data in mechanical ventilation setting in a large animal model.  Whilst 
intravenous (i.v.) tobramycin as a therapy for VAP is commonly used, there is little 
data on its regional lung distribution. There is also paucity of data comparing the 
pulmonary biodistribution of radiolabeled tobramycin between i.v. and nebulized route 
of drug administration. Understanding the comparative distribution parameters of the 
two routes of administration for tobramycin will fill an important knowledge gap and 
lead to further research in the pharmacokinetics of nebulized antibiotics and clinical 
trials for treating VAP. 
 
The aim of this study was to describe the comparative pulmonary regional distribution 
of 400 mg 99mTc-labelled tobramycin (99mTc-tobramycin) between i.v. and nebulized 
route of administration in a mechanically ventilated healthy ovine model.   
 
 Methods 
 
 Ethics 
 
The University of Queensland Animal Ethics Committee approved the study (Approval 
no. SOM/268/16/RBWH). 
 
 Study design 
 
The study was performed as a comparative study in a mechanically ventilated sheep 
model. Five of the sheep were administered i.v. 99mTc-tobramycin and the other five, 
nebulized 99mTc-tobramycin.  
 
 Experimental method 
 
6.2.3.3.1 Radiolabelling method   
 
Tobramycin was radiolabelled adopting a validated method[277]. Stannous chloride 
(SnCl2) was prepared to 10 mg/mL in 0.5 M HCl in nitrogen filled vials to minimize 
oxidation. Radiolabelling was achieved by adding the pertechnetate (99mTcO4-) 
solution followed by; Tobra-dayTM solution 4 mL (100 mg/mL), stannous chloride 
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solution (10 mg/mL; 200 µL) and sodium bicarbonate buffer solution (0.2 M; 500 µL) 
to a shielded nitrogen vial. The solution was then gently shaken for a minute and then 
left to incubate for 20 minutes. A radiolabelling yield of >99% was observed and 
maintained for at least 18 hrs. The pH of the product solution was 6 and could be 
adjusted with addition of buffer solution. Labelling was performed with 400 mg of 
tobramycin yielding 99mTc-tobramycin 400mg. The volume was determined by the 
activity concentration of the pertechnetate but remained below 5 mL. Quality Control 
tests were performed on the product with the iTLC SG  using 85% methanol/water 
mobile phase. This showed 100% binding of technetium with the tobramycin tested 
and maintained for 18 hours.  
 
6.2.3.3.2 In vitro aerosol particle characterisation and inhaled mass measurement 
 
Aerosol particle size distribution was studied using a previously described in vitro 
method[259]. The studies were conducted using a mechanical ventilator (Puritan 
Bennett 720, Puritan Bennett, California, USA). The settings used were: synchronised 
intermittent mandatory ventilation mode, tidal volume 500 mLs, respiratory rate 14 per 
minute, positive end expiratory pressure 5 cm H2O, fraction of inspired oxygen 0.21. 
Vibrating mesh nebulizer (VMN) (Aeroneb pro, Aerogen, Galway, Ireland) was used 
for the study. The studies were repeated in triplicate. The aerosol particles were 
described as geometric diameter with standard deviation. Using the previously 
described in vitro method with the same ventilator settings as before and applying 
mass balance quantification technique 99mTc-tobramycin was used to quantify the 
percentage of nebulized drug dose delivered.  
 
6.2.3.3.3 Anaesthesia, ventilation and monitoring 
 
After anesthetizing, sheep were intubated orotracheally with an endotracheal tube. 
Tracheostomy was performed and mechanical ventilation commenced with settings 
titrated to arterial blood gases (ABG) to maintain the parameters within normal ranges. 
Monitoring was performed using electrocardiography, ABG, capnography, and pulse 
oximetry. The sheep were then maintained in ventral down position throughout the 
rest of the study with the head suspended in a sling.  
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6.2.3.3.4 Computed Tomography (CT) scan protocol 
 
The ventilated and anesthetized sheep then underwent CT scan of the lungs in the 
ventral down position. The images acquired were used to confirm normal lungs. The 
CT data was later used for delineating the regions of interest (ROI) on the planar 
scintigraphic images and for tissue attenuation calculations.  
 
6.2.3.3.5 Drug administration 
 
After the CT scan, 99mTc-tobramycin 400mg was administered according to the study 
groups as follows:  
 
I.V.  
99mTc-tobramycin 400 mg was injected through a lumen of central venous line and 
flushed with 10 mL normal saline. The radioactivity in syringe was measured before 
and after injection by a dose calibrator. The administered dose was calculated as 
follows- 
 
Administered dose (AD) = syringe radioactivity pre-injection - syringe residual 
radioactivity 
 
Nebulized 
A disposable VMN was inserted in the inspiratory arm of the circuit just before the Y 
piece. During nebulization the ventilation was changed to a square wave flow pattern 
and the humidifier was turned off for the duration of the nebulization as recommended. 
The VMN was filled with 99mTc-tobramycin 400 mg and nebulization commenced. 
Nebulization was considered complete when misting was no longer visible. 
Radioactivity in the nebulizer was measured before and after nebulization. The 
administered dose was then calculated as follows-   
 
Administered dose (AD) = Initial nebulizer radioactivity – post nebulization residual 
radioactivity. 
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6.2.3.3.6 Scintigraphy protocol 
 
A single head gamma camera (GE Starcam 600 XR/T Gamma Camera, GE 
Healthcare Global Diagnostic Imaging, Waukesha, WI, USA) was used for scanning 
purposes. Image acquisition started simultaneously with the start of administration of 
the radiopharmaceutical agent (i.v. or nebulized). Dynamic scan images were 
acquired over 20 minutes. Static image acquisition was commenced immediately after 
the dynamic phase (matrix 256x 256, 5 minutes per image- dorsal, ventral, left lateral 
and right lateral). A repeat dorsal image was taken at the end of the study to compare 
with the initial image to confirm lack of clearance. Blood samples were taken every 15 
minutes for one hour and measured for activity. 
 
6.2.3.3.7 Euthanasia 
 
Sheep were euthanized using sodium pentobarbitone (295 mg/mL, 0.5 mL/kg).  
 
6.2.3.3.8 Post mortem  
 
Prior to necropsy, the lungs were exsanguinated and flushed with two liters of saline 
using a pressure bag. At necropsy, direct tissue sampling from pre-defined regions of 
both lungs as upper, middle, and lower zones, liver, both kidneys and urine were taken 
and subjected to well counting using a scintillation well counter (model 2200 scaler 
ratemeter, Ludlum measurements Inc., Sweetwater, Texas).  
 
6.2.3.3.9 Data collection 
 
All the images were stored on a local computer for further analyses. Tissue and blood 
samples were analysed immediately using the scintillation well counter. The 
calibration factor to convert count rates to absolute activity was obtained using a 
described technique[278]. Correction for tissue attenuation was applied by taking the 
average attenuation correction factor over the lung region from the CT scans[279, 
280]. 
 
 Scintigraphic assessment of lung deposition  
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A planar scintigraphy assessment technique described by Newman et al using CT 
scan to calculate lung volumes for normalisation was used[273], [281]. The lung 
deposition of the 99mTc-tobramycin was expressed in counts and used for further 
calculations. 
 
Regional lung distribution was quantified using four schemes (Figure 6.1): peripheral-
central (P/C) ratios, dorsal-ventral ratios, right and left lung, and upper-middle-lower 
distribution. The P/C ratios were calculated from the dorsal scintigraphic images by 
dividing the total number of counts in the peripheral ROI by the total counts in the 
central ROI for the left and right lung (Figure 6.1-A). The upper-middle-lower 
distribution was found by measuring the counts in the zones and expressed as a 
percentage of total lung counts (Figure 6.1-B). The ventral-dorsal ratio was calculated 
by taking the sum of the counts in the dorsal ROI divided by the sum of the counts in 
the ventral ROI (Figure 6.1-C). The right and left lung distribution was calculated as a 
percentage of right or left lung counts to the total lung counts. All data were expressed 
as mean±S.D. The counts quantified in each ROI were corrected for decay, 
background and attenuation as described previously[273]. 
 
Figure 6.1:Schematic diagram explaining the scintigraphic assessment of lung 
deposition. 
A- describes the peripheral (P) and central (C) regions of interest (ROIs) in dorsal 
image. 
B- describes the upper (U), middle (M) and lower (L) zones of both lungs in dorsal 
image 
C- describes the dorsal (D) and ventral (V) zones of the lung in the lateral image 
 
 
 Quantitative tissue distribution analysis 
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Blood samples were measured for radioactivity for each time point and calculations 
were performed as follows: 
 
%AD/ g = Bloodcount/ totalcount x 100/ weight  
 
Where, AD meant administered dose for i.v. and nebulized 99mTc-tobramycin as 
defined before. The results of the data were expressed as %AD/mL of blood. 
 
Tissue samples from lung, liver, kidneys and urine were weighed. The 99mTc-
tobramycin concentration in each specimen of organ was calculated as follows:  
 
  %AD/ g = tissuecount/ totalcount x 100/ weight  
 
Where, AD meant administered dose for i.v. and nebulized 99mTc-tobramycin as 
defined before. The results of the data were expressed as %AD/g of tissue. 
 
 Statistical analysis 
 
Comparison between i.v. and nebulized 99mTc-tobramycin for the zonal distribution, 
dorsal to ventral distribution and right to left lung distribution was done using a simple 
unpaired t-test. When comparing the mean differences for lung tissue and extra 
pulmonary tissue levels, Bayesian regression model with a random intercept was used 
for each sheep and Bayesian p- values obtained. R version 3.4.3 for the plots and 
tables[282]  and WinBUGS version 1.4.3 for the Bayesian regression analysis were 
used[241]. 
 
 Results 
 
Ten healthy merino sheep (ewes, 35 to 45 kg) underwent anaesthesia and mechanical 
ventilation. The difference in the administered dose between the two groups was not 
significant, meanS.D. 637±105 MBq for the nebulized group versus meanS.D. 
649±137 MBq for the i.v. group. CT scans showed that all sheep had normal lung 
anatomy. 
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 Aerosol particle size and inhaled mass characterization 
 
A meanS.D. 98.9±0.12 % of the aerosol had fine particle fraction (1-5 µm) with a 
volume median diameter of meanS.D. 2.12±0.08 µm. A meanS.D. 39.3±2.36 % of 
the 99mTc-tobramycin was lost in the expiratory filter, meanS.D. 28.9±4.5 % was at 
the tip of the tracheostomy tube, meanS.D. 11.4±0.37 % was in the nebulizer and 
the nebulizer T-piece adaptor. The tracheostomy tube had a meanS.D. 9.29±1.09 % 
and the Y-piece had a meanS.D. 8.43±3.8 % of the nebulized dose deposited.  
 
 Qualitative regional distribution data 
 
The nebulization duration was mean 17 minutes ± 1 minute.  The attenuation 
correction factor was meanS.D. 1.90±0.05 in the i.v. group and meanS.D. 2.04±0.06 
for the nebulized group. The lung volume was meanS.D. 3.4±0.4 L in the i.v. group 
and meanS.D. 3.6 ± 0.5 L for the nebulized group. The camera calibration factor was 
0.012 MBq/counts/second and the well counter calibration factor was 2.4 Bq/count. 
The dynamic scans showed that the counts in the lung ROI increased in a linear 
fashion. This could indicate the absence of clearance during 99mTc-tobramycin 
deposition for both routes of administration.  
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Table 6.1 summarizes the regional lung distribution data from scintigraphic analysis.  
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Table 6.1: Quantitative lung distribution of tobramycin activity based on scintigraphic 
analysis. 
 Nebulized 
mean±SD 
I.V. mean±SD P- value 
Whole lung deposition (% of administered dose) 
 8.86±0.02 57.1±0.12 <0.001 
Apex to base distribution (% of deposited dose) 
Right lung (%)    
Upper  8.4±0.02 5.67±0.02 0.03 
Middle 22.3±0.02 24.7±0.08 0.03 
Lower 17.5±0.02 16.9±0.03 0.70 
Left lung (%)    
Upper  6.32±0.01 4.79±0.01 0.07 
Middle 24.1±0.03 27.2±0.08 0.02 
Lower 21.5±0.02 20.7±0.04 0.68 
Dorsal to ventral distribution (% of deposited dose) 
Dorsal (%) 68.9±0.04 58.9±0.02 0.003 
Ventral (%) 31.1±0.04 41.1±0.02 0.003 
Dorsal: Ventral ratio 2.27±0.48 1.44±0.14 0.016 
Right and left lung distribution (% of deposited dose) 
Right lung % 48.2±0.04 45.9±0.10 0.55 
Left lung % 51.9±0.04 54.1±0.10 0.55 
Right: Left lung ratio 0.94±0.17 0.91±0.38 0.83 
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Figure 6.2 shows the dorsal scintigraphic images for both administration routes. 
Figure 6.2: Static dorsal scintigraphic images of lung deposition of 99mTc-
tobramycin in ventilated sheep. Sheep were anesthetized, mechanically ventilated 
and administered 99mTc-tobramycin 400 mg with a vibrating mesh nebulizer. 
 
6.2.4.2.1 Whole lung deposition 
 
Whole lung deposition was significantly less with nebulized 99mTc-tobramycin 
compared to i.v. (mean 8.9% vs 57.1%, p<0.001). 
 
6.2.4.2.2 P/C ratio 
 
The P/C ratio data for the aerosol group is given in Table 6.2. The ratio was not 
significantly different between the two sides (p=0.21).  
 
Table 6.2: Lung P/C ratio (penetration index) in mechanically ventilated sheep with 
nebulized 99mTc- tobramycin. 
Sheep Right P/C Left P/C 
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1 0.76 0.82 
2 0.93 0.96 
3 0.89 1.04 
4 0.87 0.82 
5 1.01 1.06 
Mean, SD 0.89 ± 0.12 0.94 ± 0.14 (P=0.208) 
 
6.2.4.2.3 Dorsal to ventral ratio 
 
There was a significant difference in the dorsal to ventral ratio of 99mTc-tobramycin 
deposition between the i.v. to nebulized group (mean 2.27±0.48 versus 1.44±0.14, 
p=0.01). There was significantly increased dorsal distribution of the nebulized 99mTc-
tobramycin compared to i.v. (mean 68.9±0.04% versus 58.9±0.02%, p=0.003). For the 
i.v. group, the ventral distribution was dominant (mean 31.1±0.04% versus 
41.1±0.02%, p=0.003).  
 
6.2.4.2.4 Right and left lung  
 
The difference between right and left lung deposition were not significant for i.v. and 
for the nebulized route (p=0.75 for i.v. and p=0.85 for nebulized). The difference 
between the right to left lung deposition ratio between the two routes of administration 
was not significant (p=0.54).   
 
6.2.4.2.5 Upper, middle, lower zones 
 
For i.v. and nebulized route, the upper zones for both lungs had significantly less 
deposition of 99mTc-tobramycin compared to the middle and lower zones (p<0.001). 
The right upper zone had significantly higher deposition with nebulized compared to 
i.v. 99mTc-tobramycin (mean 8.4±0.02% versus 5.7±0.02%, p=0.02). On the other 
hand, the right and left middle zone had significantly higher deposition for i.v. 
compared to nebulized 99mTc-tobramycin (right mean 24.7±0.08% versus 22.3±0.02%, 
p=0.02; left mean 27.1±0.08 versus 24.1±0.02%, p=0.01). There were no significant 
differences between the two routes of administration in regards to the other regional 
deposition.   
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 Quantitative regional distribution data  
 
6.2.4.3.1 Tissues  
 
Table 6.3 shows the tissue distribution data. There was significantly higher 
concentration of 99mTc-tobramycin in liver with i.v. compared to nebulized delivery 
(mean 1.84±0.48 versus 0.08±0.001 %AD/g, p<0.001). There was also significantly 
higher urine concentration with i.v. compared to that of nebulized route of delivery 
(0.78±0.44 versus 0.3±0.21 %AD/g, p<0.001). For the kidneys, the differences were 
not statistically significant (p=0.84 for right kidney and p=0.79 for left kidney). There 
were significantly higher 99mTc-tobramycin concentrations in the lung tissues with i.v. 
compared to that of nebulized route for all lung areas in the right lung (upper p=0.01, 
middle p-<0.001, lower p=0.002) as well as in the left lung (upper p=0.001, middle 
p<0.001, lower p=0.001).   
 
Table 6.3: Quantitative tissue distribution of 99mTc-tobramycin activity. 
Lung Region Nebulized (%AD/g) I.V. (%AD/g) P-value 
Right Lung 
(median, IQR) 
   
Upper 0.30 (0.24-0.57) 1.27 (1.13–1.59) 0.017 
Middle 0.56 (0.461-0.611) 2.14 (1.77–7.59) <0.001 
Lower 0.67 (0.433-0.996) 3.62 (1.94- 5.94) 0.002 
Left Lung (median, 
IQR) 
   
Upper 0.24 (2.14- 3.33) 3.13 (1.28- 3.87) 0.001 
Middle 0.23 (1.01- 2.81) 3.68 (1.90-6.99) <0.001 
Lower 0.38 (2.29-8.19) 3.92 (3.43-5.14) 0.002 
Liver (mean±SD) 0.08±0.001 1.84±0.48 <0.001 
Right Kidney 
(mean±SD) 
0.09±0.04 0.21±0.12 0.84 
Left Kidney 
(mean±SD) 
0.07±0.03 0.21±0.1 0.79 
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Urine (mean±SD) 0.3±0.21 0.78±0.44 <0.001 
 
AD- administered dose; For i.v., AD = syringe radioactivity pre-injection - syringe 
residual radioactivity; For nebulized, AD= Initial nebulizer radioactivity – post 
nebulization residual radioactivity. 
 
6.2.4.3.2 Blood counts 
 
As shown in Table 6.4, the blood 99mTc-tobramycin concentrations were significantly 
less in the nebulized group compared to the i.v. group for all the time points (p=0.01).  
 
Table 6.4: Blood 99mTc-tobramycin activity levels for nebulized and i.v. 99mTc- 
tobramycin in mechanically ventilated sheep (mean, SD). 
Time points 
(minutes) 
Nebulized 
(%AD/mL)  
I.V. (%AD/mL) P-value 
15 0.01±0.001 0.06±0.03 0.01 
30 0.01.0±0.002 0.06±0.03 0.01 
45 0.01±0.007 0.06±0.03 0.01 
60 0.01±0.01 0.05±0.03 0.01 
 
 Discussion 
 
This is the first study to describe the comparative regional distribution of 99mTc-
tobramycin delivered by nebulized and i.v. route of administration with mechanical 
ventilation. The main finding of the study was that nebulized 99mTc-tobramycin 
achieved significantly lower whole lung deposition and regional lung tissue 
concentrations compared to i.v. 99mTc-tobramycin. The low concentrations in extra-
pulmonary organs and blood could potentially minimize systemic side effects with 
nebulized therapy compared to i.v.  
 
The whole lung deposition was significantly lower for nebulized 99mTc-tobramycin 
compared to i.v. (8.86 ± 0.02% versus 57.1±0.12%, p<0.001). The low lung deposition 
of nebulized 99mTc-tobramycin is similar to that in the previous studies with other 
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drugs[118, 280, 283]. Increased retention within the nebulizer, patient and other 
device related factors were some the reasons for the low levels in these studies[118, 
280, 283]. There could also be a significant proximal airway deposition which was not 
measured in this study. One reason for the reduced deposition in the present study 
could be due to the position of the VMN just before the Y-piece which could lead to 
significant aerosol loss in the expiratory filter as seen in previous studies[43]. Recent 
recommendations are to place the VMN 10- 15 cm from the Y-piece[19]. However, the 
effect of these nebulizer positions on the in vivo lung deposition using scintigraphic 
techniques is lacking. In the present study, the VMN position was chosen to mimic 
local and international practices[203] as well as the manufacturer’s recommendations. 
Hence, with the present configuration, if higher lung deposition is required for clinical 
effect, the dosage of nebulized tobramycin may need to be increased accordingly. 
Further in vivo studies should be done to assess the effect of the recommended VMN 
position[19]. The findings of low aerosol deposition compared to i.v. are significant 
especially since it has been known that epithelial lining fluid penetration of i.v. 
tobramycin is poor[284]. For lung infections, the site of antibiotic effect is interstitial 
space fluid and epithelial lining fluid[9]. Hence, whilst the scintigraphic study may 
indicate high deposition with i.v., it may not translate into drug penetration to the effect 
sites. Thus, deposition data derived from scintigraphy will need to be used in 
conjunction with lung tissue pharmacokinetic data for clinical interpretation. 
 
For optimal aerosol deposition in the distal lung, particle size 1- 5 µm is essential[90] 
and for aerosol therapy, the P/C ratio is considered as an index of lung penetration. In 
the present study, the P/C ratio of nebulized 99mTc-tobramycin was similar for both 
lungs (mean 0.89 for right and 0.94 for left; p=0.21). The in vitro particle sizing study 
showed that 99% particles were in the 1-5 µm size range. This could be one of the 
reasons for better penetration compared to that reported for DTPA and 99mTc labelled 
human serum albumin (0.32 to 0.75) [280, 285]. The correlation with actual drug 
concentrations will need to be investigated with further studies using other techniques. 
 
Our study also showed that there was higher nebulized 99mTc-tobramycin deposition 
in the left lung compared to i.v. (54.1±0.1% versus 51.9±0.04%, p-0.54) although this 
was not statistically significant. For the aerosol deposition, this right-left lung 
asymmetry is in keeping with the findings in experimental settings[286, 287] and is 
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likely due to airway geometry and the interaction between aerosol particles and airflow, 
called the Stokes number. Other studies have reported a right preponderance for lung 
deposition of DTPA with a wide variability in deposition between the lungs[285]. One 
reason for the variations in the distribution could be the effect of formulation and 
physicochemical properties of the aerosol on the deposition preference[182]. The 
effect and significance of different aerosol formulations on right-left lung deposition 
asymmetry needs further investigation. With i.v. 99mTc-tobramycin, similar blood flow 
for the two lungs could explain the similar deposition in both lungs[288]. 
 
For both the i.v. and nebulized routes, the upper lobe had lower deposition of 99mTc-
tobramycin (mean right 5.67 % and left 4.79%; mean right 8.4 % and left 6.32 %). The 
lung tissue concentration differences for 99mTc-tobramycin mimicked the scintigraphic 
differences (mean right 1.3 %AD/g and left 3.13 %AD/g; mean right 0.3 %AD/g and 
left 0.2 %AD/g). For nebulized drug deposition, this could be explained by less air flow 
due to the angle of the bronchi[286]. Moreover, there was increased deposition in the 
lower zones (mean right 17.5 % and left 21.5 %) and increased lung tissue 
concentrations of nebulized 99mTc-tobramycin (mean right 0.67 %AD/g and left 0.38 
%AD/g) similar to that seen in other studies[286]. This is likely due to higher proportion 
of ventilation of the lower lobes. On the other hand, Weers et al has previously 
attributed higher lower lobe lung distribution of inhaled gentamicin to gravity[289]. The 
apex of the lung is known to have reduced perfusion and could explain in part the 
reduced distribution in upper zones with i.v. administration[290]. Tissue samples are 
a composite of alveoli, interstitium, and blood, hence, although the tissue 
concentrations for 99mTc-tobramycin were higher for i.v., it is not possible to indicate 
the concentrations in the individual lung tissue compartments. Other methods such as 
microdialysis and bronchoalveolar lavage techniques should be used to further 
characterize the differential concentrations.  
 
The increased dorsal deposition in the nebulization group (mean dorsal 68.9 % versus 
ventral 31.1 %) in our study could be due to the effect of aerosol characteristics 
affecting the Stokes number such as density, viscosity and particle size diameter 
similar to the other asymmetrical distributions seen in experimental settings[286, 287]. 
Posture related asymmetry in aerosol deposition have also been attributed to change 
in functional residual capacity, airway size and geometry[291]. In one study on effect 
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of lateral decubitus position the decubitus-dependent lung had higher deposition[292].  
In supine position, due to shortening of antero-posterior distance the ventilation 
distribution is likely to be uniform[293]. In sheep, the ventilation distribution in the prone 
ventilation has not been described. Understanding effect of posture on aerosol 
deposition may aid targeted nebulized antibiotic therapy in localized diseases[294]. 
Further studies are necessary to tap into the benefits of postural effects on aerosol 
deposition.  Pulmonary blood flow in anesthetized mechanically ventilated sheep in 
prone position is well described[295]. Whilst the conventional approach would indicate 
that blood flow is gravity dependent, it has been shown not to be the case[296] and 
with minimal vertical perfusion gradient with mechanical ventilation and 
anesthesia[295]. This and possibly the differences in the local vascular density and 
architecture could explain the relatively higher dorsal distribution with i.v. albeit this 
was lesser than that seen with nebulization (mean dorsal 58.9 % versus ventral 41.1 
%).  
 
Finally, the significantly low blood and extra-pulmonary organ concentrations of 99mTc-
tobramycin potentially indicates minimal risk of systemic toxicity with nebulized 
therapy. This finding will need to be confirmed with quantification of plasma tobramycin 
levels.  
 
 Limitations 
 
The study has been performed in healthy sheep which may not reflect the 
pathophysiological changes in lung infection which could influence regional drug 
distribution[297]. Drug deposition studies using scintigraphic techniques do not 
provide data regarding drug concentrations in the interstitial space fluid. Moreover, the 
relationship between the antibiotic pharmacokinetics in lung and regional distribution 
of antibiotic in lungs by scintigraphy is not yet understood[204]. The nebulizer was 
placed just before the Y-piece which could affect the drug delivery. But as per a recent 
survey it is still one of the commonest nebulizer positions used[203]. The gamma 
camera provides only two-dimensional projection of distribution and is thus very limited 
in distinguishing the distribution among airway regions and relating deposition to three-
dimensional lung structure.  
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Further studies using this model should be done using the nebulizer positions yielding 
higher delivery in the in vitro studies. SPECT and or PET techniques could be used to 
improve resolution. Influence of postural changes on drug deposition merits further 
investigation especially in localized lung infections. Correlation studies to establish 
relationship between deposition and lung concentrations are required to guide clinical 
application.   
 
 Conclusion 
 
Nebulized 99mTc-tobramycin resulted in lower whole and regional lung deposition than 
i.v. both qualitatively and quantitatively. Compared to i.v., nebulized 99mTc-tobramycin 
also led to reduced concentrations in the extra-pulmonary organs and blood.   
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6.3 Conclusions of the chapter 6 “Pulmonary drug distribution of 
nebulized and intravenous tobramycin” 
 
We investigated and compared the pulmonary drug distribution of nebulized and 
intravenous 99mTc-tobramycin. We found that the whole lung and regional lung 
deposition was significantly lower with nebulized 99mTc-tobramycin than that with 
intravenous 99mTc-tobramycin. Although there was good distal penetration of the 
nebulized 99mTc-tobramycin, and the extrapulmonary concentrations were lower than 
that with intravenous therapy. We conclude that correlation studies of scintigraphic 
deposition to actual lung concentrations of antibiotics is necessary using techniques 
such as microdialysis.   
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Chapter 7 Lung concentrations of nebulized and 
intravenous tobramycin  
 
7.1 Synopsis 
 
The aim of this chapter is to compare the pharmacokinetics of intravenous and 
nebulized tobramycin in the three physiological compartments, the blood, interstitial 
space fluid of lung and epithelial lining fluid using a mechanically ventilated ovine 
model.  
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7.2 Submitted manuscript entitled “Lung pharmacokinetics of 
tobramycin by intravenous and nebulized dosing.” 
 
The manuscript entitled, “Lung pharmacokinetics of tobramycin by intravenous and 
nebulized dosing” has been submitted to Anaesthesiology. 
 
The co-authors contributed to the manuscript as follows: All study design, experiments 
and data collection were performed by the PhD candidate, Jayesh Dhanani, under the 
supervision of Prof Jason Roberts, Dr Jivesh Chaudhary, Sara Diab, Prof Michelle 
Chew and Prof John Fraser. Dr Steven Wallis and Dr Suzanne Parker helped with 
bioanalysis of the samples. Prof Adrian Barnett guided the PhD candidate, Jayesh 
Dhanani, in regards to the statistical analyses for the data. The final editing was done 
by the PhD candidate, Jayesh Dhanani, with supervision from Associate Prof Jeremy 
Cohen, Prof John Fraser and Prof Jason Roberts. The PhD candidate, Jayesh 
Dhanani, took the leading role in the manuscript preparation and writing.  
 
The manuscript is presented as submitted; except figures and tables have been 
inserted into the text at slightly different positions. Also, the numbering of the pages, 
figures and tables has been adjusted to fit the overall style of the Thesis. The 
references are found alongside the other references of the Thesis, in the section 
‘References’.  
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 Abstract 
 
Ventilator associated pneumonia occurs commonly in mechanically ventilated patients 
with poor outcomes despite intravenous antibiotics. Nebulized antibiotics may be used 
to treat this condition. However, there is limited pharmacokinetic data available to 
guide dosing. The aim of the study was to compare intravenous and nebulized 
tobramycin concentrations in the lung interstitial space fluid, epithelial lining fluid and 
plasma. Ten anesthetized and mechanically ventilated healthy ewes underwent 
surgical insertion of microdialysis catheters in upper and lower lobes of both lungs and 
the jugular vein. Five ewes were given intravenous tobramycin 400 mg and five were 
given nebulized tobramycin 400 mg. Microdialysis samples were collected every 20 
minutes for 8 hours. Bronchoalveolar lavage was performed at 1 and 6 hours. The 
peak lung interstitial space fluid concentrations were lower with intravenous 
tobramycin 20.2 mg/L versus the nebulized route 48.3 mg/L, p=0.002. Compared to 
other lobes, the left lower lobe had lower concentrations with intravenous route. Both 
lower lobes had higher concentrations with nebulized route. Median lung penetration 
was higher with nebulized compared to intravenous tobramycin (155% versus 79%, 
p=0.002). Mean epithelial lining fluid concentrations were lower with intravenous 
tobramycin compared to nebulized tobramycin at 1-hour (0.53 mg/L versus 1270 mg/L, 
p<0.001) and 6- hours (0.42 mg/L versus 54.1 mg/L, p<0.001). The mean/median 
peak plasma tobramycin concentrations were 24.1 mg/L for intravenous and 17.0 
mg/L, p=0.08 for nebulized route. Compared with intravenous tobramycin, nebulized 
tobramycin achieved higher lung interstitial fluid and epithelial lining fluid 
concentrations without increasing systemic concentrations.   
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 Introduction 
 
Ventilator associated pneumonia (VAP) due to Pseudomonas aeruginosa and other 
gram-negative organisms occurs frequently[298], and is associated with significant 
morbidity and mortality[299]. Drugs from the aminoglycoside class, such as 
tobramycin, are recommended for the treatment of VAP[300] which are effective 
against numerous gram negative organisms including P. aeruginosa, Klebsiella 
pneumoniae, and Acinetobacter baumanii[301]. Despite systemic antibiotic therapy, 
therapeutic failure is common[302]. One reason for this lack of effect could be poor 
lung penetration due to low lung epithelial lining fluid (ELF) concentrations of 
tobramycin[284]. Increasing the systemic doses could lead to toxicities such as 
nephrotoxicity.  
 
For treatment of VAP, nebulized tobramycin is used frequently, either as monotherapy 
or as an adjuvant[257],[250].  However, aerosol delivery and lung deposition (and 
hence antibiotic concentrations in the lung) can be affected by mechanical ventilation 
parameters[13].    
 
Despite its widespread use, there is very little data on the pharmacokinetics (PK) of 
nebulized antibiotics[303]. Rat and rabbit model-based studies provide some data on 
the PK of nebulized and intravenous (i.v.) tobramycin[304, 305]. However, 
interspecies differences in pulmonary anatomy limit the application of these data to 
humans. Similarly, PK data from studies in spontaneously breathing cystic fibrosis 
patients [22, 306] makes it difficult to apply the same for VAP therapy. Experimental 
pneumonia studies have been useful in the understanding of the PK of nebulized 
antibiotics with epithelial lining fluid (ELF) or tissue homogenization technique having 
inherent limitations[138, 307]. Sheep are a commonly used for large animal model 
respiratory research and for inhalation therapy studies[185]. Compared to the human 
lung, sheep also have similar anatomical and physiological features[308].   
 
For most bacterial pneumonia, the lung interstitium is considered as the site of 
infection and adequate antibiotic concentrations are important for drug effect[309]. 
Currently available PK methods used for nebulized antibiotics have significant 
limitations that affect their ability to sample the interstitial space fluid (ISF)[23]. Lung 
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microdialysis is a validated technique for the sampling of ISF and measurement of free 
antibiotic concentration[23].  
 
The aim of this study was to compare the regional pulmonary and systemic 
concentrations of tobramycin after nebulization and i.v. administration in a 
mechanically ventilated healthy ovine model. 
 
 Methods 
 
Ethics approval was obtained from the Queensland University of Technology animal 
ethics committee (Approval no. 1100000052). 
 
 Study design 
 
The study was performed using ten merino sheep (10 ewes, 40 to 50 kg) which were 
anesthetized and mechanically ventilated. Five sheep were administered i.v. 
tobramycin and the other five given nebulized tobramycin. Figure 7.1 shows the study 
set up.  
 
Figure 7.1: Study set up showing the operating theatre set up, the sheep position, and 
instrumentation. 
 
Intercostal catheter
Mechanical Ventilator
Microdialysis pump
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 Experimental method 
 
7.2.3.2.1 Anaesthesia, ventilation and monitoring 
 
The sheep were anesthetized and orotracheally intubated using an endotracheal tube. 
Tracheostomy was performed and mechanical ventilation was commenced with initial 
settings as per lung protective ventilation guidelines and subsequently adjusted 
according to the arterial blood gases to maintain normal parameters. 
Monitoring was performed using ECG, ABG, capnography, pulse oximetry and CVP 
monitoring.  
 
7.2.3.2.2 Microdialysis probe insertion 
 
Bilateral thoracotomies were performed in the 5th intercostal space. Under direct 
vision, microdialysis probes (CMA 63; CMA Microdialysis AB, Stockholm, Sweden) 
were inserted, one probe each in the upper and lower lobes of both lungs. An 
intercostal catheter was placed on each side and the thoracotomy incisions was 
closed. An intravascular microdialysis catheter (CMA 64; CMA Microdialysis AB, 
Stockholm, Sweden) was inserted in the left jugular vein through a percutaneously 
inserted 18G cannula (B.Braun Australia Pty Ltd, Bella Vista, Australia). CMA 107 
pumps (CMA Microdialysis AB, Stockholm, Sweden) were used to perfuse the 
microdialysis catheters.  
 
Gentamicin (4 mg/L) as a perfusate was used for in vivo microdialysis calibration was 
done as per the internal indicator method[310, 311]. The perfusate flow was 
maintained at 1 µl/min for one hour to achieve steady state equilibrium. Thereafter, 
samples were collected at every 20 minutes in a microvial (CMA, Microdialysis AB) for 
eight hours, with time 0 h being the commencement of drug administration. Samples 
were stored at -80°C for further analysis. 
 
7.2.3.2.3 Drug Administration 
 
Intravenous 
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Tobramycin 400mg (Tobra-day, Phebra 500mg/5ml) was injected through the central 
venous line as a thirty-minute infusion. 
 
Nebulization 
Tobramycin 400 mg (4ml) (Tobra-day, Phebra 500 mg/5 ml) was nebulized using a 
disposable vibrating mesh nebulizer (Aeroneb Pro, Aerogen, Galway, Ireland) which 
was inserted in the inspiratory limb of the circuit just before the Y-piece. The 
nebulization was complete when there was no visible mist.  
 
7.2.3.2.4 Bronchoalveolar lavage (BAL) 
 
BAL fluid was collected from both lower lobes using a fibreoptic bronchoscope 
(Olympus, Center Valley, PA, USA) prior to drug administration and repeated at 1 hour 
and 6-hours after the completion of drug administration. Samples were stored at -80°C 
for further analysis. 
 
 Sample analysis 
 
BAL fluid and plasma urea concentration values were obtained for further calculations 
of tobramycin in the ELF (CELF) with a commercially available assay (UniCel DxC 800, 
Beckman Coulter, CA, USA).  
 
The gentamicin and tobramycin concentrations in the microdialysis samples and the 
tobramycin concentrations in the BAL samples reported were measured by an LC-
MS/MS method using a simple dilution preparation and HILIC chromatography on a 
Shimadzu Nexera2 system coupled to a Shimadzu 8030+ triple quadrupole mass 
spectrometer (Kyoto, Japan). Recovery data was used to calculate the corrected 
tobramycin concentrations in the microdialysate.  
 
 Data analysis 
 
7.2.3.4.1 Tobramycin concentration in ELF. 
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The volume of ELF in each sample was calculated as previously described[310, 312, 
313]-  
VELF= ([Urea (mg/l)]BAL / [Urea (mg/l)]PLASMA X VBAL.  
Therefore, the concentration of tobramycin in the ELF from the BAL fluid is-  
 
[Tobramycin or TOB]ELF= [TOB]BALX (VBAL/ VELF) 
 
7.2.3.4.2 Microdialysis recovery 
 
The relative recovery (RR) was calculated by loss of gentamicin for each 
microdialysate using the internal reference method[310, 311], as per the equation: 
RRGent= (Cin - Cout)/Cin 
where RR = relative recovery, Cin= gentamicin concentration in the perfusate and Cout= 
gentamicin concentration in the dialysate.  
 
7.2.3.4.3 Tobramycin concentration in ISF 
 
The corrected tobramycin concentration in the microdialysate was calculated as: 
CISF= Cdialysate / RR 
where CISF= tobramycin concentration in the interstitial space fluid and Cdialysate= 
tobramycin concentration in microdialysate  
 
 Pharmacokinetic analysis 
 
The pharmacokinetic analyses of tobramycin were performed for microdialysis and 
plasma samples using non-compartmental methods. Lung penetration was used to 
describe the percentage drug penetration into the ISF and defined as fAUCISF / 
AUCplasma x 100 and calculated from the AUC0-last where AUCISF and AUCplasma are area 
under the concentration-time curve from 0 to 8 hours (AUClast) for ISF and plasma 
respectively and expressed as a percentage and fAUC is the AUC of the unbound 
concentration. 
 
 Statistical analysis  
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Plasma PK parameters between i.v. and nebulized route were compared using simple 
unpaired t- test. When comparing i.v. and nebulized route, the mean differences 
between the lung ISF and BAL concentrations of tobramycin, Bayesian regression 
model with a random intercept was used for each sheep and Bayesian p- values 
obtained. R statistical language version 3.4.3[282] and WinBUGS version 1.4.3[241] 
for the Bayesian regression analysis were used. 
 
 Results 
 
Ten healthy merino sheep (ewes, 40 to 50 kg) underwent anaesthesia and mechanical 
ventilation.  
 
 Lung ISF PK 
 
The in vivo recovery values determined were 43% for lung ISF. The combined median 
ISF PK parameters with ranges comparing the two routes of administration are given 
in Table 7.1. The median peak concentrations (Cmax) was significantly lower for i.v. 
tobramycin 20.2 mg/L (range 12-26.2) vs 48.3 mg/L (range 8.7-512, p=0.002) for 
nebulized. The lung penetration was significantly higher for nebulized compared to i.v. 
tobramycin; 155% (65-475) vs 79% (62-132, p=0.002) respectively.  
 
Table 7.1: Comparative lung pharmacokinetic parameters between intravenous and 
nebulized tobramycin (median, IQR). 
Pharmacokinetic 
Parameter 
Intravenous 
Tobramycin 
Nebulized 
Tobramycin 
p-value 
Cmax (mg/liter) 20.2 (12-26.2) 48.3 (8.7- 513) 0.002 
Tmax (h) 0.83 (0.66-1.33) 0.66 (0.33- 1.33) 0.28 
Cmin (mg/liter) 1.27 (0.44-2.25) 1.92 (0.67- 4.91) 0.13 
AUMC0-last (mg-
h/liter) 
168 (55.3-251) 224 (97.6- 664) 0.11 
AUMC0-∞(mg-h/liter) 233 (90.3-318) 566 (256- 2674) 0.01 
AUC0-last(mg-h/liter) 59.6 (26-81.4) 108 (32.6- 441) 0.01 
AUC0-∞(mg-h/liter) 69.0 (26.9- 94.6) 252 (103-791) 0.001 
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MRT (h) 3.8 (3.2-4.1) 1.6 (1.1-3.1) 0.02 
kel (h) 0.26 (0.24-0.33) 0.25 (0.11-0.42) 0.60 
Lung penetrationa 
(%) 
79 (62-132) 155 (65-475) 0.002 
 
Cmax: maximum concentration; Tmax: time that Cmax was observed; Cmin: minimum 
concentration; AUMC0-last: area under the moment curve from 0 h to the last 
measurement at the completion of the study; AUMC0-∞: area under the moment curve 
from 0 h to infinity; AUC0-last: area under the concentration-time curve from 0 h to the 
last measurement at the completion of the study; AUC0-∞: area under the 
concentration- time curve from 0 h to infinity; MRT: mean residence time; Kel: 
elimination rate constant; fAUCISF tissue: unbound AUC in interstitial space fluid of lung; 
AUCplasma: AUC in plasma using unbound concentrations. 
a fAUCISF / AUCplasma x 100 and calculated from the AUC0-last 
The regional lung ISF PK parameters for i.v. tobramycin were not statistically 
significant and are given in Table 7.2.  
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Table 7.2: Pharmacokinetic parameters of tobramycin in the right and left, upper and lower lobes as well as plasma (Intravenous 
group). 
 Right lung Left Lung  
Pharmacokinetic Parameter Upper lobe Lower lobe Upper Lobe Lower Lobe Plasma 
Median value (IQR) Median value (IQR) Median value (IQR) 
Cmax (mg/liter) 23.6 (14.9-24) 21.8 (13.9-26.7) 23.8 (15.7-26.6) 12.4 (5.81-18.5) 24.1 (22.8-27.6)* 
Tmax (h) 0.66 (0.66-1) 1.66 (0.66-2) 0.66 (0.66-1) 1 (0.66-2) 0.66 (0.66-0.66) 
Cmin (mg/liter) 1.22 (1.05-1.46) 1.33 (1.16-2.85) 2.08 (0.42-2.25) 0.89 (0.43-2.13) 1.78 (1.34-1.79) 
AUMC0-last (mg-h/liter) 196 (128-258) 168 (167-251) 152 (56.5-199) 64.3 (49.6-181) 154 (128-192) 
AUMC0-∞(mg-h/liter) 225 (186-418) 291 (238-318) 228 (99-296) 128 (63.1-284) 210 (169-263) 
AUC0-last(mg-h/liter) 80.7 (44.7-81.4) 58.5 (55.1-91) 60.6(29.7-72) 26.2 (21-62.1) 64.8 (53.6-68.5) 
AUC0-∞(mg-h/liter) 83.5 (49.6-95.5) 70.7 (61-94.6) 67.4 (30.6-80.2) 27.2 (26-70.7) 70 (57.4-75.2) 
MRT (h) 3.96 (3.76-4.15) 3.9 (3.08-3.9) 3.39 (3.25-3.69) 4.01 (3.41-4.93) 2.94 (2.69-3)* 
kel (h) 0.26 (0.24-0.27) 0.25 (0.25-0.32) 0.31 (0.27-0.5) 0.25 (0.21-0.33) 0.36 (0.35-0.38)* 
Lung penetrationa (%) 88 (69-137) 90 (80-139) 78 (71-93) 63 (32-67)  
 
Cmax: maximum concentration; Tmax: time that Cmax was observed; Cmin: minimum concentration; AUMC0-last: area under the moment 
curve from 0 h to the last measurement at the completion of the study; AUMC0-∞: area under the moment curve from 0 h to infinity; 
AUC0-last: area under the concentration-time curve from 0 h to the last measurement at the completion of the study; AUC0-∞: area 
under the concentration- time curve from 0 h to infinity; MRT: mean residence time; Kel: elimination rate constant; fAUCISF tissue: 
unbound AUC in interstitial space fluid of lung; AUCplasma: AUC in plasma using unbound concentrations. 
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a fAUCISF / AUCplasma x 100 and calculated from the AUC0-last 
*p<0.05 
 
The regional lung ISF PK parameters for nebulized tobramycin were not statistically significant and are given in Table 7.3.  
Table 7.3: Pharmacokinetic parameters of tobramycin in the right and left, upper and lower lobes as well as plasma (Nebulized 
group). 
 Right lung Left Lung  
Pharmacokinetic Parameter Upper lobe Lower lobe Upper Lobe Lower Lobe Plasma 
Median value (IQR) Median value (IQR) Median value (IQR) 
Cmax (mg/liter) 70.4 (18.8-128) 444 (8.3-630)  11.8 (6.76-26.3) 474 (8.83-5748) 17.8 (14.4-18.2)* 
Tmax (h) 1 (0.58-1.17) 0.66 (0.33-0.66) 1.33 (0.33-2.33) 1 (0.33-1.33) 1 (1-1.33) 
Cmin (mg/liter) 1.66 (0.81-5.31) 4.95 (1.67-11.57) 1.74 (0.43-2.1) 2.44 (0.74-4.31) 1.53 (0.7-1.88) 
AUMC0-last (mg-h/liter) 142 (101-409) 305 (101-1027) 176 (81.7-468) 273 (141-2452) 181 (174-217) 
AUMC0-∞(mg-h/liter) 608 (127-1947) 844 (544-1453) 501 (273-521) 2514 (340-3153) 382 (252-490) 
AUC0-last(mg-h/liter) 69.2 (44.9-153) 284 (32.7-549) 48.6 (24.2-147) 230 (38.4-5092) 61.3 (56.9-69.4) 
AUC0-∞(mg-h/liter) 179 (103-506) 325 (109-1065) 195 (92.6-472) 279 (224-2459) 71.7 (68-89) 
MRT (h) 3.19 (1.33-3.55) 1.67 (1.36-1.88) 2.67 (1.72-2.94) 1.22 (1.02-1.62) 5.32 (5.04-5.5)* 
kel (h) 0.28 (0.2-0.31) 0.25 (0.21-0.31) 0.11 (0.1-0.23) 0.38 (0.25-0.66) 0.18 (0.17-0.21)* 
Lung penetrationa (%) 193 (74-225) 434 (47-500) 85 (68-116) 332 (67-4300)  
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Cmax: maximum concentration; Tmax: time that Cmax was observed; Cmin: minimum concentration; AUMC0-last: area under the moment 
curve from 0 h to the last measurement at the completion of the study; AUMC0-∞: area under the moment curve from 0 h to infinity; 
AUC0-last: area under the concentration-time curve from 0 h to the last measurement at the completion of the study; AUC0-∞: area 
under the concentration- time curve from 0 h to infinity; MRT: mean residence time; Kel: elimination rate constant; fAUCISF tissue: 
unbound AUC in interstitial space fluid of lung; AUCplasma: AUC in plasma using unbound concentrations. 
a fAUCISF / AUCplasma x 100 and calculated from the AUC0-last 
* p<0.05 
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The regional lung ISF PK parameters were not statistically significant between the i.v. 
and nebulized tobramycin. However, the study was not powered to detect a difference. 
Figure 7.2 shows the regional concentration-time profile in a graphical form.  
 
Figure 7.2: Log scaled plot showing regional concentration-time profile for lung ISF 
and plasma with nebulized and i.v. tobramycin. 
 
 
 Plasma PK  
 
The median plasma and ISF PK parameters with ranges (min to max) for the upper 
and lower lung areas of both lungs are given in Table 7.2 and Table 7.3 for i.v. and 
nebulized tobramycin respectively. Comparison of results between the i.v. and 
nebulized administration groups shows significant differences for some PK parameter 
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estimates including higher values in the i.v. group for plasma Cmax (i.v. 24.1 mg/L, 
range 22.7-27.5; versus nebulized 17.0 mg/L, range 14.4- 18.2) p=0.08.  
 
 ELF concentrations and CELF/Cp between i.v. and nebulized tobramycin 
(Table 7.4) 
 
The mean ELF concentration for tobramycin was significantly lower for i.v. compared 
to nebulized tobramycin group at 1-hour (0.53 mg/L vs 1270 mg/L, p< 0.001) and at 6 
hours (0.42 mg/L vs 54.1 mg/L, p<0.001 respectively). Similarly, at 1 hour, the mean 
CELF/Cp was significantly lower for i.v. compared to nebulized (0.02 vs 81.08, p<0.001) 
and at 6 hours (0.18 vs 11.7, p<0.001) 
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Table 7.4: Comparative tobramycin concentration levels in ELF and ratio of ELF to plasma concentration for intravenous and 
nebulized tobramycin. 
Data is for two-time points; 1 hour and 6-hour post administration of the drug. The p-values compare the intravenous tobramycin to 
nebulized tobramycin. 
 
 1 hour 6 hours 
 Intravenous tobramycin Nebulized 
tobramycin  
p-value Intravenous 
tobramycin  
Nebulized 
tobramycin  
p-value 
ELF concentration 
(mg/L; mean±SD) 
0.53 ± 0.78 1270 ± 715 <0.001 0.42 ± 0.15 54.1 ± 41.4 <0.001 
Celf/Cp (mean±SD) 0.02±0.03  81.08± 49.9 <0.001 0.18±0.18 11.7 ± 10.10 <0.001 
 
ELF- epithelial lining fluid 
Celf- Tobramycin concentration in epithelial lining fluid 
Cp- Tobramycin concentration in plasma 
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 Discussion 
 
This is the first study to quantitatively characterise and compare the concentration and 
disposition of tobramycin in regional lung ISF, ELF and plasma following i.v. and 
nebulized administration using microdialysis technique. The main finding of this study 
is that nebulized tobramycin achieves significantly higher peak concentrations with 
more extensive lung penetration in the lung ISF and ELF with low plasma 
concentrations thus potentially minimising systemic side effects as compared to i.v.  
 
Following nebulization, the peak plasma concentration was significantly lower 
compared to i.v. (median 17.8, range 14.4-18.2 mg/L for nebulized; median 24.1, 
range 22.8-27.6 mg/L for i.v., p= 0.08). Previous studies have described low plasma 
trough concentrations <0.5 mg/L after administration of 300 mg of i.v. tobramycin[314]. 
The authors have even suggested that drug level monitoring may not be necessary 
with nebulized tobramycin. Although our study did not complete the 24-hour dosing 
interval period for tobramycin therapy, the low end-study concentrations would 
indicate reduced trough concentrations with nebulized tobramycin. Thus, systemic 
toxicity is likely less with nebulized antibiotics, though further validation is required with 
this and other nebulized antibiotics.  
 
For tobramycin, which displays a concentration-dependent bactericidal activity, the 
ISF Cmax is the central PK parameter defining effectiveness. In the lung ISF, the peak 
tobramycin concentrations were significantly higher when tobramycin was nebulized 
compared to when given i.v. (median 48.3 mg/L vs 20.2 mg/L, p=0.002). Lung 
penetration was significantly higher with nebulized tobramycin compared to i.v. 
tobramycin (1.55 vs 0.79, p=0.002). For tobramycin, the Cmax/MIC ratio 7-10 is the 
pharmacodynamic index associated with increased clinical cure[315] and >10 for 
resistance suppression[316]. With the EUCAST MIC for Pseudomonas of 4 mg/L, the 
desired Cmax is > 40 mg/L. The data from our study indicates that it is possible to 
achieve these targets with nebulized tobramycin. Taken together, the low plasma 
concentrations and higher ISF concentrations seen after nebulized tobramycin confers 
an advantage for this route by potentially minimising systemic side effects as 
compared to i.v. 
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For i.v. tobramycin, the Cmax and the other PK parameters in the left lower lobe 
appeared lower as compared to the other lung lobes. The differences did not achieve 
statistical significance, possibly due to small sample size. The reduced Cmax in the left 
lower lobe could represent differences in blood flow or could also be due to 
atelectasis[317] by cardiac and other mediastinal structures which could not be 
excluded. 
 
There was a higher Cmax and other PK parameters of drug exposure in both lower 
lobes compared to upper lobes with nebulized tobramycin. In left upper lobe, the ISF 
Cmax were lower with nebulized compared to i.v. tobramycin. In the right upper lobe, 
the ISF Cmax was higher with nebulized tobramycin compared to i.v. Although these 
differences were not statistically significant, small sample size may have limited these 
differences from achieving statistical significance. In supine position in healthy 
spontaneously breathing humans, alveolar deposition of aerosols is seen to be directly 
proportional to ventilation with increased deposition in lower lobes[318]. Our study 
shows similar deposition patterns in mechanically ventilated sheep.  
 
The low ELF concentration and the low ELF/serum tobramycin concentration ratio with 
i.v. tobramycin compared to nebulized tobramycin is expected as evidenced in 
critically ill setting[284] and in pneumonia[319]. The high water solubility feature of 
aminoglycosides impede their ability to cross cell membranes leading poor ELF 
penetration with i.v. administration[320]. The concentrations with i.v. tobramycin were 
lower in our study (ELF 0.53 mg/ml and ELF/serum ratio 2%) than that reported in the 
studies where the reported ELF concentrations range from 1.6 mg/ml to 4 mg/L and 
the ratios of 12 to 30%[284, 319]. Some of the studies did not measure free tobramycin 
and were not in mechanically ventilated setting which may affect the results. Nebulized 
tobramycin resulted in higher ELF concentration in all studies. In our study, the 
concentrations were higher (1270 mg/L) than most reported studies. This could be due 
to higher nebulized dose (400 mg in our study versus 300 mg in most other studies). 
Inter-species variation could account for the differences as well. At 6 hours the ELF 
concentrations decreased to 54 mg/L for nebulized and 0.42 mg/L for i.v. tobramycin. 
Thus, compared to the values at 2 hours, the ELF concentrations for nebulized 
tobramycin seems to decrease more than that of i.v. This could be as a result of high 
lung deposition of nebulized tobramycin due to effective aerosol delivery and 
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concentration gradient based transport into the ISF and blood and less with the 
mucociliary clearance mechanism. This is further likely due to the high water solubility, 
low protein binding, small molecular mass and negative charge on the tobramycin 
molecule. With i.v. administration however, due to high plasma concentrations, the 
clearance could be predominantly due to the mucociliary escalator mechanism.      
 
 Limitations  
 
The study was conducted in a large animal model and extrapolation of this data to 
humans may not yield the same results. The animals were not randomized to the two 
routes of administration and the study was not blinded. However, we attempted to 
mitigate possible bias due to this by assessor-blinding i.e. drug concentrations were 
measured by a person unaware of the allocation. The effect of different ventilator 
settings on aerosol delivery is well known but its effect on the antibiotic PK is relatively 
unknown. The study was not powered to measure the regional lung tobramycin PK 
differences. The study was performed in healthy conditions and pneumonia and other 
lung conditions could influence the PK parameters in unpredictable fashion. Although 
there was no visible trauma to the lung, there is a possibility of undetected lung trauma 
which may impact the microdialysis results. No radiographic investigations were 
performed to exclude atelectasis and other lung abnormalities that may influence lung 
antibiotic PK. As the insertion of the microdialysis probe is a blind procedure, issues 
such as malposition or effect of respiratory movement of the lungs on the microdialysis 
membranes could impact the microdialysis results as well, although we believe this 
was unlikely in our study as our RR values were similar to results reported in previously 
published studies.  
 
Further studies are required to study the effect of other parameters such as 
synchronised nebulization, different formulations and ventilator settings. Patient 
related factors such as effect of posture, airways disease and mucus need 
consideration in these studies. Lung microdialysis could be used in evaluating the PK 
of other nebulized antibiotics. Pharmacodynamic (PD) studies and clinical studies are 
required to determine clinical effectiveness.  
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 Conclusion 
 
In a mechanically ventilated large animal model, nebulized tobramycin results in 
higher lung ISF concentrations and achieves high lung penetration without increasing 
systemic concentrations. PK/PD studies in lung infections are required for dosing 
guidelines in nebulized therapy.  
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7.3 Conclusions of the chapter 7 “Lung concentrations of nebulized and 
intravenous tobramycin” 
 
In this chapter, we have evaluated and compared the lung concentrations of 
tobramycin when delivered by intravenous and nebulized route in a mechanically 
ventilated ovine model. We found that the lung ISF and epithelial lining fluid 
concentrations were significantly higher with nebulized tobramycin compared to 
intravenous tobramycin. In addition, the plasma concentrations of tobramycin were 
significantly lower with nebulized tobramycin compared to intravenous tobramycin. 
These findings indicate that nebulized tobramycin could be used to achieve higher 
concentrations at the site of infection for the treatment of VAP without causing 
systemic side effects.  
 
 162 
Chapter 8 General discussion, conclusions and future 
directions 
 
For optimal antibiotic effect, adequate concentrations are essential at the site of 
infection. Inadequate tissue antibiotic concentrations could lead to therapeutic failure 
of antibiotic therapy. Nebulized antibiotic therapy has potential for achieving high lung 
tissue antibiotic concentrations whilst minimising systemic toxicity. Although it is an 
exciting new frontier, it is fraught with challenges. Nebulized antibiotic therapy, 
especially with mechanical ventilation, is affected by a number of factors. Optimisation 
of the formulation and delivery system is necessary for effective aerosol delivery. 
Pharmacokinetic data of nebulized antibiotics with mechanical ventilation could guide 
accurate dosing to achieve adequate tissue antibiotic concentrations thus improving 
outcomes in the critically ill patients.  
 
8.1 Summary of findings       
 
Nebulized antibiotics are increasingly being used for the treatment of ventilator 
associated pneumonia due to high failure rates with systemic therapy, emergence of 
multiresistant organisms and the appeal of achieving high local antibiotic 
concentrations without causing systemic toxicity. However, mechanical ventilation 
associated factors such as ventilator settings and circuit related factors could influence 
antibiotic delivery and disposition in the lungs. In this Thesis, we have conclusively 
demonstrated that nebulized tobramycin with mechanical ventilation results in high 
lung interstitial fluid concentrations. 
 
A thorough review of literature was conducted to explore the principles of aerosol 
therapy in critically ill patients. In particular, it was important to identify the key 
knowledge gaps regarding the emerging role of nebulized therapy in critical care. 
Some key findings were that dosing of the nebulized antibiotics is based on data on a 
combination of cystic fibrosis patient trials and experimental animal data using whole 
tissue or bronchoalveolar lavage fluids. Very little human study data was available and 
comprised of treatment guidelines derived from sputum or bronchoalveolar lavage-
based pharmacokinetic data. There were a number of factors identified which could 
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affect nebulized antibiotic therapy with mechanical ventilation. Thus, it was determined 
that further studies are necessary to optimise nebulized antibiotic delivery and lung 
pharmacokinetics of nebulized antibiotics need to be to further investigated to 
accurately guide dosing schedules.  
 
As lung microdialysis was determined as the investigation technique of choice to 
describe the lung pharmacokinetics of nebulized antibiotics, it was necessary to 
calibrate the microdialysis system in an in vitro setting to optimise its use in the in vivo 
settings later. The in vitro microdialysis studies were conducted using three different 
perfusate flow rates (1, 1.5 and 2 µL/min) and concentrations (0.5, 5 and 20 ug/mL). 
Fresh frozen plasma provided the protein content to simulate in vivo conditions. 
Vancomycin and tobramycin were chosen as they are commonly used combinations 
for empirical antibiotic therapy in mechanically ventilated patients. For tobramycin, the 
1 µL/min flow and 20 µg/mL concentration resulted in the highest recovery. It was 
determined that for in vivo studies, the perfusate flow rate will be 1 µL/min.  
 
To investigate the aerosol characteristics of the two-available preservative-free 
tobramycin formulations (40 mg/mL and 100 mg/mL) with mechanical ventilation, two 
techniques were used in concert. Particle size distribution studies were performed 
using a laser diffractometer and a bacterial/viral filter was used to capture nebulized 
tobramycin. The studies were performed using a vibrating mesh nebulizer with a 
mechanical ventilator with fixed settings. Two different types of tracheal tubes 
(endotracheal and tracheostomy) of three sizes (7, 8 and 9 mm I.D.) were used. The 
lung dose i.e. the amount of drug in the particle size range suitable for distal lung 
deposition was seen to be highest with the 100 mg/mL with no effect of type or size of 
tracheal tubes. For in vivo studies, it was determined that the 100 mg/mL formulation 
would be used.  
 
Pulmonary drug distribution is an important determinant of drug effect. Using 
technetium-99m, tobramycin 400 mg was radiolabelled with a known technique. In an 
anesthetized, mechanically ventilated sheep model, technetium-99m tobramycin was 
given i.v. or nebulized in five sheep per route of administration. Planar scintigraphy 
images were obtained and analysed. Blood samples and post mortem lung and extra-
pulmonary tissues (liver, both kidneys and urine) were sampled and measured for 
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radioactivity. It was found that the whole lung and regional lung deposition was lower 
with nebulized compared to i.v. route. This was attributed to significant drug loss during 
exhalation likely due to the position of the nebulizer in the circuit. Not surprisingly, the 
extra-pulmonary and blood concentrations were higher with i.v. administration.  It was 
concluded that it may be possible to attain more extensive lung deposition if the 
delivery system could be optimised further to minimise drug loss. 
 
Using a similar anesthetized, mechanically ventilated sheep model, tobramycin 400 
mg was either given i.v. or nebulized. Microdialysis catheters were inserted in the 
lungs (bilateral upper and lower lobes) and jugular vein. Samples were collected every 
20 minutes for 8 hours. BAL was performed at 1- hour and 6-hours. It was observed 
that the lung interstitial space fluid and epithelial lining fluid concentrations for 
tobramycin was significantly higher with nebulized therapy; for nebulized vs i.v. route 
the peak ISF values were a median 48.3 mg/L vs 20.2 mg/L, p=0.002 respectively and 
1-hour ELF values were mean 0.53 mg/L vs 1270 mg/L, p<0.001 respectively. 
Simultaneously the blood concentrations were lower. Thus, indicating that with 
nebulization, it is possible to achieve high target site tobramycin concentrations 
without manifesting potentially toxic concentrations systemically.  
 
8.2 Suggested future research  
 
Recent clinical trials of nebulized antibiotic therapy in patients with ventilator 
associated pneumonia have failed to demonstrate superiority over conventional 
therapy[17, 18]. Based on the findings of this Thesis, nebulized antibiotic therapy with 
mechanical ventilation is influenced by different factors which should be optimized to 
achieve therapeutic concentrations at site of action. Stronger preliminary data is 
required to derive optimal settings required for effective nebulized antibiotic delivery. 
Further studies are suggested to address the following issues: 
 
• Using the well validated methods used in the studies included in this Thesis, it 
is important to investigate the pharmacokinetics of nebulized antibiotics in 
diseased state such as pneumonia and ARDS.  
• A number of antibiotic formulations for nebulized therapy are already in use and 
more are being investigated. It is necessary to investigate the physicochemical 
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properties such as, viscosity, surface tension, osmolality and pH, of each 
different antibiotic formulation and their specific aerosol characteristics during 
aerosolized therapy. This could help identify the need for further modifications 
to improve the physicochemical properties of the formulation to maximise the 
aerosol delivery.  
• Whilst the use of nebulized antibiotics is becoming more prevalent, there are a 
lack of adequate data to guide dosing. A pharmacokinetic database including 
optimal ventilator settings, device specific parameters and encompassing a 
variety of nebulized antibiotics should be established to guide optimised 
nebulized antibiotic dosing.  
• Whilst the need for data is recognised in the scientific community, studies in 
this area are undertaken using different methods. This in turn reduces the 
generalizability as the data output from different methods such as different 
sampling (sputum, BAL, tissue homogenate), delivery devices and ventilator 
settings; may not be comparable, leading to inadequate data. Standardisation 
of study pathways is necessary. Newer delivery devices and formulations can 
be developed should be studied using the research pathway described in this 
Thesis.  
• There are obvious theoretical benefits of nebulized antibiotic therapy for 
achieving high lung concentrations without causing systemic toxicity. 
Randomised controlled clinical trials in ventilated patients with pneumonia due 
to multiple drug resistant organisms comparing co-therapy using nebulized and 
systemic therapy to systemic therapy alone is necessary to demonstrate 
efficacy in bacterial eradication, faster resolution of pneumonia hence reducing 
ventilator dependent days and limiting organ failure rates is necessary using 
effective delivery systems. It is also necessary to standardise therapy and study 
definitions relating to entry criteria and outcomes so that studies can be 
compared and/or meta-analysed where possible. 
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Metabolism, Clearance, and Absorption. In: Advances in Delivery Science and 
Technology. Edited by Hickey HDCSaAJ: Springer; 2011: 21-50. 
85. Zhang LN, Sun JP, Xue XY, Wang JX: Exogenous pulmonary surfactant for 
acute respiratory distress syndrome in adults: A systematic review and meta-
analysis. Exp Ther Med 2013, 5(1):237-242. 
86. Kesecioglu J, Beale R, Stewart TE, Findlay GP, Rouby JJ, Holzapfel L, Bruins P, 
Steenken EJ, Jeppesen OK, Lachmann B: Exogenous natural surfactant for 
treatment of acute lung injury and the acute respiratory distress syndrome. 
American journal of respiratory and critical care medicine 2009, 180(10):989-994. 
87. Anzueto A, Jubran A, Ohar JA, Piquette CA, Rennard SI, Colice G, Pattishall EN, 
Barrett J, Engle M, Perret KA et al: Effects of aerosolized surfactant in patients 
with stable chronic bronchitis: a prospective randomized controlled trial. 
JAMA 1997, 278(17):1426-1431. 
88. Rubin BK, Fink JB: Aerosol therapy for children. Respiratory care clinics of North 
America 2001, 7(2):175-213, v. 
89. Rubin BK: Air and soul: the science and application of aerosol therapy. 
Respiratory care 2010, 55(7):911-921. 
174 
 
 
174 
90. Heyder J: Deposition of inhaled particles in the human respiratory tract and 
consequences for regional targeting in respiratory drug delivery. Proc Am 
Thorac Soc 2004, 1(4):315-320. 
91. Patton JS, Fishburn CS, Weers JG: The lungs as a portal of entry for systemic 
drug delivery. Proceedings of the American Thoracic Society 2004, 1(4):338-344. 
92. Smith C, Goldman RD: Nebulizers versus pressurized metered-dose inhalers 
in preschool children with wheezing. Canadian family physician Medecin de 
famille canadien 2012, 58(5):528-530. 
93. Khoo SM, Tan LK, Said N, Lim TK: Metered-dose inhaler with spacer instead of 
nebulizer during the outbreak of severe acute respiratory syndrome in 
Singapore. Respiratory care 2009, 54(7):855-860. 
94. Mitchell J: Combining Treatment With Pressurized Metered Dose Inhaler-
Valved Holding Chamber (pMDI+VHC) With Dosimetric Therapy Via A Breath 
Actuated Nebulizer (BAN) In Patient Titration For Obstructive Lung Diseases 
(thoracic). In: American Thoracic Society International Conference: 2013; 2013. 
95. Thomas M, Williams AE: Are outcomes the same with all dry powder inhalers? 
International journal of clinical practice Supplement 2005(149):33-35. 
96. Selroos O, Borgstrom L, Ingelf J: Use of dry powder inhalers in acute 
exacerbations of asthma and COPD. Therapeutic advances in respiratory 
disease 2009, 3(2):81-91. 
97. Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM: Medication nebulizer 
performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. 
Chest 1996, 110(2):498-505. 
98. Haynes JM: Randomized controlled trial of a breath-activated nebulizer in 
patients with exacerbation of COPD. Respiratory care 2012, 57(9):1385-1390. 
99. Ari A, Fink JB: Guidelines for aerosol devices in infants, children and adults: 
which to choose, why and how to achieve effective aerosol therapy. Expert 
Rev Respir Med 2011, 5(4):561-572. 
100. Watts AB, McConville JT, Williams RO, 3rd: Current therapies and technological 
advances in aqueous aerosol drug delivery. Drug Dev Ind Pharm 2008, 
34(9):913-922. 
101. Laube BL, Benedict GW, Dobs AS: Time to peak insulin level, relative 
bioavailability, and effect of site of deposition of nebulized insulin in patients 
with noninsulin-dependent diabetes mellitus. Journal of aerosol medicine : the 
175 
 
 
175 
official journal of the International Society for Aerosols in Medicine 1998, 11(3):153-
173. 
102. Byron PR, Patton JS: Drug delivery via the respiratory tract. Journal of aerosol 
medicine : the official journal of the International Society for Aerosols in Medicine 
1994, 7(1):49-75. 
103. Corkery K: Inhalable drugs for systemic therapy. Respiratory care 2000, 
45(7):831-835. 
104. Anderson M, Svartengren M, Bylin G, Philipson K, Camner P: Deposition in 
asthmatics of particles inhaled in air or in helium-oxygen. The American review 
of respiratory disease 1993, 147(3):524-528. 
105. Goode ML, Fink JB, Dhand R, Tobin MJ: Improvement in aerosol delivery with 
helium-oxygen mixtures during mechanical ventilation. American journal of 
respiratory and critical care medicine 2001, 163(1):109-114. 
106. Hess DR, Acosta FL, Ritz RH, Kacmarek RM, Camargo CA, Jr.: The effect of 
heliox on nebulizer function using a beta-agonist bronchodilator. Chest 1999, 
115(1):184-189. 
107. Tonnellier M, Ferrari F, Goldstein I, Sartorius A, Marquette CH, Rouby JJ: 
Intravenous versus nebulized ceftazidime in ventilated piglets with and 
without experimental bronchopneumonia: comparative effects of helium and 
nitrogen. Anesthesiology 2005, 102(5):995-1000. 
108. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL: 
Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis 
sputum. Am Rev Respir Dis 1985, 132(4):761-765. 
109. VanDyke RD, McPhail GL, Huang B, Fenchel MC, Amin RS, Carle AC, Chini BA, 
Seid M: Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. 
An instrumental variables analysis. Ann Am Thorac Soc 2013, 10(3):205-212. 
110. Vazquez-Espinosa E, Giron RM, Gomez-Punter RM, Garcia-Castillo E, Valenzuela 
C, Cisneros C, Zamora E, Garcia-Perez FJ, Ancochea J: Long-term safety and 
efficacy of tobramycin in the management of cystic fibrosis. Ther Clin Risk 
Manag 2015, 11:407-415. 
111. Craven DE, Lichtenberg DA, Goularte TA, Make BJ, McCabe WR: Contaminated 
medication nebulizers in mechanical ventilator circuits. Source of bacterial 
aerosols. The American journal of medicine 1984, 77(5):834-838. 
176 
 
 
176 
112. Ely EW, Baker AM, Evans GW, Haponik EF: The distribution of costs of care in 
mechanically ventilated patients with chronic obstructive pulmonary disease. 
Critical care medicine 2000, 28(2):408-413. 
113. Guerin C, Fassier T, Bayle F, Lemasson S, Richard JC: Inhaled bronchodilator 
administration during mechanical ventilation: how to optimize it, and for 
which clinical benefit? Journal of aerosol medicine and pulmonary drug delivery 
2008, 21(1):85-96. 
114. Kondili E, Alexopoulou C, Prinianakis G, Xirouchaki N, Vaporidi K, Georgopoulos 
D: Effect of albuterol on expiratory resistance in mechanically ventilated 
patients. Respiratory care 2011, 56(5):626-632. 
115. Duarte AG: Inhaled bronchodilator administration during mechanical 
ventilation. Respiratory care 2004, 49(6):623-634. 
116. Dhand R: Inhalation therapy with metered-dose inhalers and dry powder 
inhalers in mechanically ventilated patients. Respiratory care 2005, 
50(10):1331-1334; discussion 1344-1335. 
117. Boukhettala N, Poree T, Diot P, Vecellio L: In vitro performance of spacers for 
aerosol delivery during adult mechanical ventilation. Journal of aerosol 
medicine and pulmonary drug delivery 2015, 28(2):130-136. 
118. Harvey CJ, O'Doherty MJ, Page CJ, Thomas SH, Nunan TO, Treacher DF: Effect 
of a spacer on pulmonary aerosol deposition from a jet nebuliser during 
mechanical ventilation. Thorax 1995, 50(1):50-53. 
119. Ari A, Areabi H, Fink JB: Evaluation of aerosol generator devices at 3 locations 
in humidified and non-humidified circuits during adult mechanical ventilation. 
Respiratory care 2010, 55(7):837-844. 
120. Michotte JB, Jossen E, Roeseler J, Liistro G, Reychler G: In vitro comparison of 
five nebulizers during noninvasive ventilation: analysis of inhaled and lost 
doses. Journal of aerosol medicine and pulmonary drug delivery 2014, 27(6):430-
440. 
121. Ari A, Harwood RJ, Sheard MM, Fink JB: An in vitro evaluation of aerosol 
delivery through tracheostomy and endotracheal tubes using different 
interfaces. Respiratory care 2012, 57(7):1066-1070. 
122. Piccuito CM, Hess DR: Albuterol delivery via tracheostomy tube. Respiratory 
care 2005, 50(8):1071-1076. 
177 
 
 
177 
123. Pitance L, Vecellio L, Delval G, Reychler G, Reychler H, Liistro G: Aerosol delivery 
through tracheostomy tubes: an in vitro study. J Aerosol Med Pulm Drug Deliv 
2013, 26(2):76-83. 
124. Mazela J, Polin RA: Aerosol delivery to ventilated newborn infants: historical 
challenges and new directions. European journal of pediatrics 2011, 170(4):433-
444. 
125. Svartengren M, Philipson K, Linnman L, Camner P: Airway resistance and 
deposition of particles in the lung. Experimental lung research 1984, 7(3-4):257-
269. 
126. American Association for Respiratory C, Restrepo RD, Walsh BK: Humidification 
during invasive and noninvasive mechanical ventilation: 2012. Respiratory 
care 2012, 57(5):782-788. 
127. Ferron GA, Upadhyay S, Zimmermann R, Karg E: Model of the deposition of 
aerosol particles in the respiratory tract of the rat. II. Hygroscopic particle 
deposition. Journal of aerosol medicine and pulmonary drug delivery 2013, 
26(2):101-119. 
128. Golshahi L, Tian G, Azimi M, Son YJ, Walenga R, Longest PW, Hindle M: The use 
of condensational growth methods for efficient drug delivery to the lungs 
during noninvasive ventilation high flow therapy. Pharmaceutical research 
2013, 30(11):2917-2930. 
129. Tian G, Longest PW, Li X, Hindle M: Targeting aerosol deposition to and within 
the lung airways using excipient enhanced growth. Journal of aerosol medicine 
and pulmonary drug delivery 2013, 26(5):248-265. 
130. Dolovich MA: Influence of inspiratory flow rate, particle size, and airway caliber 
on aerosolized drug delivery to the lung. Respir Care 2000, 45(6):597-608. 
131. Fink JB, Dhand R, Duarte AG, Jenne JW, Tobin MJ: Aerosol delivery from a 
metered-dose inhaler during mechanical ventilation. An in vitro model. 
American journal of respiratory and critical care medicine 1996, 154(2 Pt 1):382-
387. 
132. Hess DR: The mask for noninvasive ventilation: principles of design and 
effects on aerosol delivery. Journal of aerosol medicine : the official journal of the 
International Society for Aerosols in Medicine 2007, 20 Suppl 1:S85-98; discussion 
S98-89. 
178 
 
 
178 
133. Brandao DC, Lima VM, Filho VG, Silva TS, Campos TF, Dean E, de Andrade AD: 
Reversal of bronchial obstruction with bi-level positive airway pressure and 
nebulization in patients with acute asthma. The Journal of asthma : official 
journal of the Association for the Care of Asthma 2009, 46(4):356-361. 
134. Dhand R: The role of aerosolized antimicrobials in the treatment of ventilator-
associated pneumonia. Respiratory care 2007, 52(7):866-884. 
135. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, 
Schoenfeld D, Thompson BT, National Heart L, Blood Institute ACTN: Higher 
versus lower positive end-expiratory pressures in patients with the acute 
respiratory distress syndrome. N Engl J Med 2004, 351(4):327-336. 
136. Bayat S, Porra L, Albu G, Suhonen H, Strengell S, Suortti P, Sovijarvi A, Petak F, 
Habre W: Effect of positive end-expiratory pressure on regional ventilation 
distribution during mechanical ventilation after surfactant depletion. 
Anesthesiology 2013, 119(1):89-100. 
137. Barrowcliffe MP, Zanelli GD, Jones JG: Pulmonary clearance of radiotracers 
after positive end-expiratory pressure or acute lung injury. Journal of applied 
physiology 1989, 66(1):288-294. 
138. Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, Wallet F, 
Becquemin MH, Le Naour G, Marquette CH et al: Nebulized and intravenous 
colistin in experimental pneumonia caused by Pseudomonas aeruginosa. 
Intensive Care Med 2010, 36(7):1147-1155. 
139. Guillon A, Mercier E, Lanotte P, Haguenoer E, Darrouzain F, Barc C, Sarradin P, 
Si-Tahar M, Heuze-Vourc'h N, Diot P et al: Aerosol Route to Administer 
Teicoplanin in Mechanical Ventilation: In Vitro Study, Lung Deposition and 
Pharmacokinetic Analyses in Pigs. J Aerosol Med Pulm Drug Deliv 2015, 
28(4):290-298. 
140. Ferrari F, Liu ZH, Lu Q, Becquemin MH, Louchahi K, Aymard G, Marquette CH, 
Rouby JJ: Comparison of lung tissue concentrations of nebulized ceftazidime 
in ventilated piglets: ultrasonic versus vibrating plate nebulizers. Intensive 
Care Med 2008, 34(9):1718-1723. 
141. Dubus JC, Vecellio L, De Monte M, Fink JB, Grimbert D, Montharu J, Valat C, Behan 
N, Diot P: Aerosol deposition in neonatal ventilation. Pediatr Res 2005, 
58(1):10-14. 
179 
 
 
179 
142. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, Prat G, Boulain T, 
Morawiec E, Cottereau A et al: High-flow oxygen through nasal cannula in acute 
hypoxemic respiratory failure. N Engl J Med 2015, 372(23):2185-2196. 
143. Reminiac F, Vecellio L, Heuze-Vourc'h N, Petitcollin A, Respaud R, Cabrera M, Le 
Pennec D, Diot P, Ehrmann S: Aerosol Therapy in Adults Receiving High Flow 
Nasal Cannula Oxygen Therapy. Journal of aerosol medicine and pulmonary drug 
delivery 2015. 
144. Ong HX, Traini D, Ballerin G, Morgan L, Buddle L, Scalia S, Young PM: Combined 
Inhaled Salbutamol and Mannitol Therapy for Mucus Hyper-secretion in 
Pulmonary Diseases. The AAPS journal 2014, 16(2):269-280. 
145. Moss RB: Administration of aerosolized antibiotics in cystic fibrosis patients. 
Chest 2001, 120(3 Suppl):107S-113S. 
146. Retsch-Bogart GZ: Update on new pulmonary therapies. Current opinion in 
pulmonary medicine 2009, 15(6):604-610. 
147. Weller S, Jones LS, Lou Y, Piscitelli S, Peppercorn A, Ng-Cashin J: Safety, 
tolerability and pharmacokinetics of orally inhaled zanamivir: a randomized 
study comparing Rotacap/Rotahaler and Rotadisk/Diskhaler in healthy 
adults. Antiviral therapy 2013, 18(6):827-830. 
148. Fauvel M, Farrugia C, Tsapis N, Gueutin C, Cabaret O, Bories C, Bretagne S, 
Barratt G: Aerosolized liposomal amphotericin B: prediction of lung 
deposition, in vitro uptake and cytotoxicity. International journal of 
pharmaceutics 2012, 436(1-2):106-110. 
149. Escobar L, Gai MN, Regueira T, Andresen M: [Pharmacokinetic considerations 
in critically ill patients]. Revista medica de Chile 2012, 140(6):780-788. 
150. Task Force for D, Treatment of Pulmonary Hypertension of European Society of C, 
European Respiratory S, International Society of H, Lung T, Galie N, Hoeper MM, 
Humbert M, Torbicki A, Vachiery JL et al: Guidelines for the diagnosis and 
treatment of pulmonary hypertension. The European respiratory journal 2009, 
34(6):1219-1263. 
151. Mehra MR, Park MH, Landzberg MJ, Lala A, Waxman AB, International Right Heart 
Failure Foundation Scientific Working G: Right heart failure: Toward a common 
language. The Journal of heart and lung transplantation : the official publication of 
the International Society for Heart Transplantation 2014, 33(2):123-126. 
180 
 
 
180 
152. Waxman AB, Zamanian RT: Pulmonary arterial hypertension: new insights into 
the optimal role of current and emerging prostacyclin therapies. The American 
journal of cardiology 2013, 111(5 Suppl):1A-16A; quiz 17A-19A. 
153. Pacheo J, Arnold H, Skrupky L, Watts P, Micek ST, Kollef MH: Predictors of 
Outcome in 216 Patients with Ards Treated with Inhaled Epoprostenol. 
Respiratory care 2013. 
154. Upward JW, Strong HA, George CF, Ogilive BC, Challenor V, Conway N: 
Hypotension in response to iloprost, a prostacyclin analogue. British journal of 
clinical pharmacology 1986, 21(2):241-243. 
155. Jelic S, Cunningham JA, Factor P: Clinical review: airway hygiene in the 
intensive care unit. Critical care 2008, 12(2):209. 
156. Robinson BR, Athota KP, Branson RD: Inhalational therapies for the ICU. Current 
opinion in critical care 2009, 15(1):1-9. 
157. Dorsch W, Auch E, Powerlowicz P: Adverse effects of acetylcysteine on human 
and guinea pig bronchial asthma in vivo and on human fibroblasts and 
leukocytes in vitro. International archives of allergy and applied immunology 1987, 
82(1):33-39. 
158. Hak-Kim Chan DR, Patricia Tang, John D. Brannan, Paul Phipps: Safety Of 
Administering Dry Powder Mannitol To Stimulate Sputum Clearance In 
Intubated Intensive Care Patients With Sputum Retention: A Pilot Study 
(thoracic). In: 2012; 2012. 
159. de Prost N, Ricard JD, Saumon G, Dreyfuss D: Ventilator-induced lung injury: 
historical perspectives and clinical implications. Annals of intensive care 2011, 
1(1):28. 
160. de Prost N, Costa EL, Wellman T, Musch G, Winkler T, Tucci MR, Harris RS, 
Venegas JG, Vidal Melo MF: Effects of surfactant depletion on regional 
pulmonary metabolic activity during mechanical ventilation. Journal of applied 
physiology 2011, 111(5):1249-1258. 
161. Gadek JE: Consensus on surfactant and inhaled nitric oxide for ARDS. Journal 
of aerosol medicine : the official journal of the International Society for Aerosols in 
Medicine 1996, 9(1):155-162. 
162. Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, Jacobs BR, 
Jefferson LS, Conaway MR, Egan EA et al: Effect of exogenous surfactant 
181 
 
 
181 
(calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 
2005, 293(4):470-476. 
163. Kermeen FD, McNeil KD, Fraser JF, McCarthy J, Ziegenfuss MD, Mullany D, 
Dunning J, Hopkins PM: Resolution of severe ischemia-reperfusion injury post-
lung transplantation after administration of endobronchial surfactant. The 
Journal of heart and lung transplantation : the official publication of the International 
Society for Heart Transplantation 2007, 26(8):850-856. 
164. Sole-Lleonart C, Roberts JA, Chastre J, Poulakou G, Palmer LB, Blot S, Felton T, 
Bassetti M, Luyt CE, Pereira JM et al: Global survey on nebulization of 
antimicrobial agents in mechanically ventilated patients: a call for 
international guidelines. Clin Microbiol Infect 2016, 22(4):359-364. 
165. Ehrmann S, Roche-Campo F, Sferrazza Papa GF, Isabey D, Brochard L, Apiou-
Sbirlea G, network Rr: Aerosol therapy during mechanical ventilation: an 
international survey. Intensive Care Med 2013, 39(6):1048-1056. 
166. Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G: Penetration 
of gentamicin into the alveolar lining fluid of critically ill patients with 
ventilator-associated pneumonia. Chest 2005, 128(2):545-552. 
167. Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A, Golmard JL, Rouby JJ, Nebulized 
Antibiotics Study G: Efficacy of high-dose nebulized colistin in ventilator-
associated pneumonia caused by multidrug-resistant Pseudomonas 
aeruginosa and Acinetobacter baumannii. Anesthesiology 2012, 117(6):1335-
1347. 
168. Abdellatif S, Trifi A, Daly F, Mahjoub K, Nasri R, Ben Lakhal S: Efficacy and 
toxicity of aerosolised colistin in ventilator-associated pneumonia: a 
prospective, randomised trial. Ann Intensive Care 2016, 6(1):26. 
169. Katzman M, Meade W, Iglar K, Rachlis A, Berger P, Chan CK: High incidence of 
bronchospasm with regular administration of aerosolized pentamidine. Chest 
1992, 101(1):79-81. 
170. van Heerden PV, Caterina P, Filion P, Spagnolo DV, Gibbs NM: Pulmonary 
toxicity of inhaled aerosolized prostacyclin therapy--an observational study. 
Anaesth Intensive Care 2000, 28(2):161-166. 
171. Lu Q, Yang J, Liu Z, Gutierrez C, Aymard G, Rouby JJ, Nebulized Antibiotics Study 
G: Nebulized ceftazidime and amikacin in ventilator-associated pneumonia 
182 
 
 
182 
caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011, 
184(1):106-115. 
172. Dr.Marcel Jost DRA, Dr.Lucien Beaudouin, Dr.Udo Eickmann, Dr.Michel Falcy: 
Occupational Risk Prevention in Aerosol Therapy. In: ISSA Prevention Series 
No 2035 (E). Edited by Services IISotPoORiH. Hamburg, Germany. 
173. Zitter JN, Maldjian P, Brimacombe M, Fennelly KP: Inhaled Dornase alfa 
(Pulmozyme) as a noninvasive treatment of atelectasis in mechanically 
ventilated patients. Journal of critical care 2013, 28(2):218 e211-217. 
174. National Heart L, Blood Institute Acute Respiratory Distress Syndrome Clinical 
Trials N, Matthay MA, Brower RG, Carson S, Douglas IS, Eisner M, Hite D, Holets 
S, Kallet RH et al: Randomized, placebo-controlled clinical trial of an 
aerosolized beta(2)-agonist for treatment of acute lung injury. American journal 
of respiratory and critical care medicine 2011, 184(5):561-568. 
175. Kalanuria AA, Ziai W, Mirski M: Ventilator-associated pneumonia in the ICU. Crit 
Care 2014, 18(2):208. 
176. Povoa FCC, Cardinal-Fernandez P, Maia IS, Reboredo MM, Pinheiro BV: Effect of 
antibiotics administered via the respiratory tract in the prevention of 
ventilator-associated pneumonia: A systematic review and meta-analysis. J 
Crit Care 2017, 43:240-245. 
177. Zampieri FG, Nassar AP, Jr., Gusmao-Flores D, Taniguchi LU, Torres A, Ranzani 
OT: Nebulized antibiotics for ventilator-associated pneumonia: a systematic 
review and meta-analysis. Crit Care 2015, 19:150. 
178. Rello J, Sole-Lleonart C, Rouby JJ, Chastre J, Blot S, Poulakou G, Luyt CE, Riera 
J, Palmer LB, Pereira JM et al: Use of nebulized antimicrobials for the treatment 
of respiratory infections in invasively mechanically ventilated adults: a 
position paper from the European Society of Clinical Microbiology and 
Infectious Diseases. Clin Microbiol Infect 2017, 23(9):629-639. 
179. Patton JS, Byron PR: Inhaling medicines: delivering drugs to the body through 
the lungs. Nat Rev Drug Discov 2007, 6(1):67-74. 
180. Tayab ZR, Hochhaus G: Pharmacokinetic/pharmacodynamic evaluation of 
inhalation drugs: application to targeted pulmonary delivery systems. Expert 
Opin Drug Deliv 2005, 2(3):519-532. 
183 
 
 
183 
181. Dugernier J, Ehrmann S, Sottiaux T, Roeseler J, Wittebole X, Dugernier T, Jamar 
F, Laterre PF, Reychler G: Aerosol delivery during invasive mechanical 
ventilation: a systematic review. Crit Care 2017, 21(1):264. 
182. Ghazanfari T, Elhissi AM, Ding Z, Taylor KM: The influence of fluid 
physicochemical properties on vibrating-mesh nebulization. Int J Pharm 2007, 
339(1-2):103-111. 
183. Fernandes CA, Vanbever R: Preclinical models for pulmonary drug delivery. 
Expert Opin Drug Deliv 2009, 6(11):1231-1245. 
184. Jaafar-Maalej C, Andrieu V, Elaissari A, Fessi H: Assessment methods of inhaled 
aerosols: technical aspects and applications. Expert Opin Drug Deliv 2009, 
6(9):941-959. 
185. Phalen RF, Oldham MJ, Wolff RK: The relevance of animal models for aerosol 
studies. J Aerosol Med Pulm Drug Deliv 2008, 21(1):113-124. 
186. Mercier E, Darrouzain F, Montharu J, Guillon A, Diot P, Paintaud G, Vecellio L: 
Lung and serum teicoplanin concentration after aerosol and intravenous 
administration in a rat model. J Aerosol Med Pulm Drug Deliv 2014, 27(4):306-
312. 
187. MacLoughlin RJ, Higgins BD, Laffey JG, O'Brien T: Optimized aerosol delivery to 
a mechanically ventilated rodent. J Aerosol Med Pulm Drug Deliv 2009, 
22(4):323-332. 
188. Cryan SA, Sivadas N, Garcia-Contreras L: In vivo animal models for drug 
delivery across the lung mucosal barrier. Adv Drug Deliv Rev 2007, 
59(11):1133-1151. 
189. Sakagami M: In vivo, in vitro and ex vivo models to assess pulmonary 
absorption and disposition of inhaled therapeutics for systemic delivery. Adv 
Drug Deliv Rev 2006, 58(9-10):1030-1060. 
190. Lange M, Hamahata A, Enkhbaatar P, Esechie A, Connelly R, Nakano Y, Jonkam 
C, Cox RA, Traber LD, Herndon DN et al: Assessment of vascular permeability 
in an ovine model of acute lung injury and pneumonia-induced Pseudomonas 
aeruginosa sepsis. Crit Care Med 2008, 36(4):1284-1289. 
191. Enkhbaatar P, Joncam C, Traber L, Nakano Y, Wang J, Lange M, Connelly R, Kulp 
G, Saunders F, Huda R et al: Novel ovine model of methicillin-resistant 
Staphylococcus aureus-induced pneumonia and sepsis. Shock 2008, 
29(5):642-649. 
184 
 
 
184 
192. Rello J, Sole-Lleonart C, Rouby JJ, Chastre J, Blot S, Poulakou G, Luyt CE, Riera 
J, Palmer LB, Pereira JM et al: Use of Nebulized Antimicrobials for the 
Treatment of Respiratory Infections in Invasively Mechanically Ventilated 
Adults: A Position Paper from the European Society of Clinical Microbiology 
and Infectious Diseases. Clin Microbiol Infect 2017. 
193. Poulakou G, Siakallis G, Tsiodras S, Arfaras-Melainis A, Dimopoulos G: Nebulized 
antibiotics in mechanically ventilated patients: roadmap and challenges. 
Expert Rev Anti Infect Ther 2017, 15(3):211-229. 
194. Rello J, Rouby JJ, Sole-Lleonart C, Chastre J, Blot S, Luyt CE, Riera J, Vos MC, 
Monsel A, Dhanani J et al: Key conceptional considerations on nebulization of 
antimicrobial agents to mechanically ventilated patients. Clin Microbiol Infect 
2017. 
195. Acute Respiratory Distress Syndrome N, Brower RG, Matthay MA, Morris A, 
Schoenfeld D, Thompson BT, Wheeler A: Ventilation with lower tidal volumes 
as compared with traditional tidal volumes for acute lung injury and the acute 
respiratory distress syndrome. N Engl J Med 2000, 342(18):1301-1308. 
196. Mukhopadhyay S, Staddon GE, Eastman C, Palmer M, Davies ER, Carswell F: The 
quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. 
Respir Med 1994, 88(3):203-211. 
197. de Lange ECM: Recovery and Calibration Techniques: Toward Quantitative 
Microdialysis. In: Microdialysis in Drug Development. Edited by Müller M. New 
York, NY: Springer New York; 2013: 13-33. 
198. Baldwin DR, Wise R, Andrews JM, Honeybourne D: Microlavage: a technique for 
determining the volume of epithelial lining fluid. Thorax 1991, 46(9):658-662. 
199. Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, Allaouchiche B: 
Steady-state plasma and intrapulmonary concentrations of cefepime 
administered in continuous infusion in critically ill patients with severe 
nosocomial pneumonia. Crit Care Med 2003, 31(8):2102-2106. 
200. FDA: Guidance for Industry: Bioanalytical Method Validation. Draft Guidance. 
In. Edited by US Department of Health and Human Services FDA, Revision 1; 2013. 
201. Pritchard JN: The influence of lung deposition on clinical response. J Aerosol 
Med 2001, 14 Suppl 1:S19-26. 
202. Vecellio None L, Grimbert D, Becquemin MH, Boissinot E, Le Pape A, Lemarie E, 
Diot P: Validation of laser diffraction method as a substitute for cascade 
185 
 
 
185 
impaction in the European Project for a Nebulizer Standard. J Aerosol Med 
2001, 14(1):107-114. 
203. Ehrmann S, Roche-Campo F, Bodet-Contentin L, Razazi K, Dugernier J, Trenado-
Alvarez J, Donzeau A, Vermeulen F, Thevoz D, Papanikolaou M et al: Aerosol 
therapy in intensive and intermediate care units: prospective observation of 
2808 critically ill patients. Intensive Care Med 2016, 42(2):192-201. 
204. Scheuch G, Bennett W, Borgstrom L, Clark A, Dalby R, Dolovich M, Fleming J, Gehr 
P, Gonda I, O'Callaghan C et al: Deposition, imaging, and clearance: what 
remains to be done? J Aerosol Med Pulm Drug Deliv 2010, 23 Suppl 2:S39-57. 
205. Newman S, Fleming J: Challenges in assessing regional distribution of inhaled 
drug in the human lungs. Expert Opin Drug Deliv 2011, 8(7):841-855. 
206. Biddiscombe MF, Meah SN, Underwood SR, Usmani OS: Comparing lung 
regions of interest in gamma scintigraphy for assessing inhaled therapeutic 
aerosol deposition. J Aerosol Med Pulm Drug Deliv 2011, 24(3):165-173. 
207. Boisson M, Jacobs M, Gregoire N, Gobin P, Marchand S, Couet W, Mimoz O: 
Comparison of intrapulmonary and systemic pharmacokinetics of colistin 
methanesulfonate (CMS) and colistin after aerosol delivery and intravenous 
administration of CMS in critically ill patients. Antimicrob Agents Chemother 
2014, 58(12):7331-7339. 
208. Petitcollin A, Dequin PF, Darrouzain F, Vecellio L, Boulain T, Garot D, Paintaud G, 
Ternant D, Ehrmann S: Pharmacokinetics of high-dose nebulized amikacin in 
ventilated critically ill patients. J Antimicrob Chemother 2016, 71(12):3482-3486. 
209. Herkner H, Muller MR, Kreischitz N, Mayer BX, Frossard M, Joukhadar C, Klein N, 
Lackner E, Muller M: Closed-chest microdialysis to measure antibiotic 
penetration into human lung tissue. Am J Respir Crit Care Med 2002, 
165(2):273-276. 
210. Stahle L, Arner P, Ungerstedt U: Drug distribution studies with microdialysis. 
III: Extracellular concentration of caffeine in adipose tissue in man. Life Sci 
1991, 49(24):1853-1858. 
211. Elmquist WF, Sawchuk RJ: Application of microdialysis in pharmacokinetic 
studies. Pharm Res 1997, 14(3):267-288. 
212. Chaurasia CS: In vivo microdialysis sampling: theory and applications. 
Biomed Chromatogr 1999, 13(5):317-332. 
186 
 
 
186 
213. Lonnroth P, Jansson PA, Smith U: A microdialysis method allowing 
characterization of intercellular water space in humans. Am J Physiol 1987, 
253(2 Pt 1):E228-231. 
214. Nahar K, Gupta N, Gauvin R, Absar S, Patel B, Gupta V, Khademhosseini A, Ahsan 
F: In vitro, in vivo and ex vivo models for studying particle deposition and 
drug absorption of inhaled pharmaceuticals. Eur J Pharm Sci 2013, 49(5):805-
818. 
215. Kampmeier T, Arnemann P, Hessler M, Rehberg S, Morelli A, Westphal M, Lange 
M, Van Aken H, Ertmer C: Provision of physiological data and reference values 
in awake and anaesthetized female sheep aged 6-12 months. Vet Anaesth 
Analg 2017. 
216. Caballero J, Rello J: Combination antibiotic therapy for community-acquired 
pneumonia. Ann Intensive Care 2011, 1:48. 
217. Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, Laporta D, Lapinsky 
S, Ellis P, Mirzanejad Y et al: Early combination antibiotic therapy yields 
improved survival compared with monotherapy in septic shock: a propensity-
matched analysis. Crit Care Med 2010, 38(9):1773-1785. 
218. Klibanov OM, Raasch RH, Rublein JC: Single versus combined antibiotic 
therapy for gram-negative infections. Ann Pharmacother 2004, 38(2):332-337. 
219. Lamer C, de Beco V, Soler P, Calvat S, Fagon JY, Dombret MC, Farinotti R, Chastre 
J, Gibert C: Analysis of vancomycin entry into pulmonary lining fluid by 
bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 
1993, 37(2):281-286. 
220. Engineer MS, Ho DH, Bodey GP, Sr.: Comparison of vancomycin disposition in 
rats with normal and abnormal renal functions. Antimicrob Agents Chemother 
1981, 20(6):718-722. 
221. Farin D, Piva GA, Gozlan I, Kitzes-Cohen R: A modified HPLC method for the 
determination of vancomycin in plasma and tissues and comparison to FPIA 
(TDX). J Pharm Biomed Anal 1998, 18(3):367-372. 
222. Matzke GR, Zhanel GG, Guay DR: Clinical pharmacokinetics of vancomycin. 
Clin Pharmacokinet 1986, 11(4):257-282. 
223. Kitzes-Cohen R, Farin D, Piva G, Ivry S, Sharony R, Amar R, Uretzky G: 
Pharmacokinetics of vancomycin administered as prophylaxis before cardiac 
surgery. Ther Drug Monit 2000, 22(6):6 1-667. 
187 
 
 
187 
224. Muller M, Stass H, Brunner M, Moller JG, Lackner E, Eichler HG: Penetration of 
moxifloxacin into peripheral compartments in humans. Antimicrob Agents 
Chemother 1999, 43(10):2345-2349. 
225. Joukhadar C, Derendorf H, Muller M: Microdialysis. A novel tool for clinical 
studies of anti-infective agents. Eur J Clin Pharmacol 2001, 57(3):211-219. 
226. Muller M: Science, medicine, and the future: Microdialysis. BMJ 2002, 
324(7337):588-591. 
227. de la Pena A, Liu P, Derendorf H: Microdialysis in peripheral tissues. Adv Drug 
Deliv Rev 2000, 45(2-3):189-216. 
228. Joukhadar C, Muller M: Microdialysis: current applications in clinical 
pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet 
2005, 44(9):895-913. 
229. Lange ECM: Recovery and Calibration Techniques: Toward Quantitative 
Microdialysis. In: Microdialysis in Drug Development. Edited by Müller M. New 
York, NY: Springer New York; 2013: 13-33. 
230. MacVane SH, Housman ST, Nicolau DP: In vitro microdialysis membrane 
efficiency of broad-spectrum antibiotics in combination and alone. Clin 
Pharmacol 2014, 6:97-101. 
231. Kehr J: A survey on quantitative microdialysis: theoretical models and 
practical implications. J Neurosci Methods 1993, 48(3):251-261. 
232. Abrahamsson P, Winso O: An assessment of calibration and performance of 
the microdialysis system. J Pharm Biomed Anal 2005, 39(3-4):730-734. 
233. Shippenberg TS, Thompson AC: Overview of microdialysis. Curr Protoc Neurosci 
2001, Chapter 7:Unit7 1. 
234. Sun H, Maderazo EG, Krusell AR: Serum protein-binding characteristics of 
vancomycin. Antimicrob Agents Chemother 1993, 37(5):1132-1136. 
235. Gordon RC, Regamey C, Kirby WM: Serum protein binding of the 
aminoglycoside antibiotics. Antimicrob Agents Chemother 1972, 2(3):214-216. 
236. Ba BB, Bernard A, Iliadis A, Quentin C, Ducint D, Etienne R, Fourtillan M, Maachi-
Guillot I, Saux MC: New approach for accurate simulation of human 
pharmacokinetics in an in vitro pharmacodynamic model: application to 
ciprofloxacin. J Antimicrob Chemother 2001, 47(2):223-227. 
188 
 
 
188 
237. Guo MX, Wrisley L, Maygoo E: Measurement of tobramycin by reversed-phase 
high-performance liquid chromatography with mass spectrometry detection. 
Anal Chim Acta 2006, 571(1):12-16. 
238. Arsand JB, Jank L, Martins MT, Hoff RB, Barreto F, Pizzolato TM, Sirtori C: 
Determination of aminoglycoside residues in milk and muscle based on a 
simple and fast extraction procedure followed by liquid chromatography 
coupled to tandem mass spectrometry and time of flight mass spectrometry. 
Talanta 2016, 154:38-45. 
239. Chen L, Chen H, Shen M: Hydrophilic interaction chromatography combined 
with tandem mass spectrometry method for the quantification of tobramycin 
in human plasma and its application in a pharmacokinetic study. J Chromatogr 
B Analyt Technol Biomed Life Sci 2014, 973C:39-44. 
240. Federal Drug Administration CfDEaR: Guidance for Industry: Bioanalytical 
Method Validation, 2001. 2001. 
241. Lunn DJ, Thomas A, Best N, Spiegelhalter D: WinBUGS &ndash; A Bayesian 
modelling framework: Concepts, structure, and extensibility. Statistics and 
Computing 2000, 10(4):325-337. 
242. Sydnor ER, Perl TM: Hospital epidemiology and infection control in acute-care 
settings. Clin Microbiol Rev 2011, 24(1):141-173. 
243. Tamma PD, Cosgrove SE, Maragakis LL: Combination therapy for treatment of 
infections with gram-negative bacteria. Clin Microbiol Rev 2012, 25(3):450-470. 
244. Bue M, Birke-Sorensen H, Thillemann TM, Hardlei TF, Soballe K, Tottrup M: 
Single-dose pharmacokinetics of vancomycin in porcine cancellous and 
cortical bone determined by microdialysis. Int J Antimicrob Agents 2015, 
46(4):434-438. 
245. Housman ST, Bhalodi AA, Shepard A, Nugent J, Nicolau DP: Vancomycin Tissue 
Pharmacokinetics in Patients with Lower-Limb Infections via In Vivo 
Microdialysis. J Am Podiatr Med Assoc 2015, 105(5):381-388. 
246. Skhirtladze K, Hutschala D, Fleck T, Thalhammer F, Ehrlich M, Vukovich T, Muller 
M, Tschernko EM: Impaired target site penetration of vancomycin in diabetic 
patients following cardiac surgery. Antimicrob Agents Chemother 2006, 
50(4):1372-1375. 
189 
 
 
189 
247. Bernardi PM, Barreto F, Dalla Costa T: Application of a LC-MS/MS method for 
evaluating lung penetration of tobramycin in rats by microdialysis. J Pharm 
Biomed Anal 2017, 134:340-345. 
248. Wiig H, Swartz MA: Interstitial fluid and lymph formation and transport: 
physiological regulation and roles in inflammation and cancer. Physiol Rev 
2012, 92(3):1005-1060. 
249. Rutili G, Arfors KE: Protein concentration in interstitial and lymphatic fluids 
from the subcutaneous tissue. Acta Physiol Scand 1977, 99(1):1-8. 
250. Sole-Lleonart C, Rouby JJ, Blot S, Poulakou G, Chastre J, Palmer LB, Bassetti M, 
Luyt CE, Pereira JM, Riera J et al: Nebulization of Antiinfective Agents in 
Invasively Mechanically Ventilated Adults: A Systematic Review and Meta-
analysis. Anesthesiology 2017, 126(5):890-908. 
251. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, 
Napolitano LM, O'Grady NP, Bartlett JG, Carratala J et al: Executive Summary: 
Management of Adults With Hospital-acquired and Ventilator-associated 
Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases 
Society of America and the American Thoracic Society. Clin Infect Dis 2016, 
63(5):575-582. 
252. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, 
Napolitano LM, O'Grady NP, Bartlett JG, Carratala J et al: Management of Adults 
With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical 
Practice Guidelines by the Infectious Diseases Society of America and the 
American Thoracic Society. Clin Infect Dis 2016, 63(5):e61-e111. 
253. Russell CJ, Shiroishi MS, Siantz E, Wu BW, Patino CM: The use of inhaled 
antibiotic therapy in the treatment of ventilator-associated pneumonia and 
tracheobronchitis: a systematic review. BMC Pulm Med 2016, 16:40. 
254. Onufrak NJ, Forrest A, Gonzalez D: Pharmacokinetic and Pharmacodynamic 
Principles of Anti-infective Dosing. Clin Ther 2016, 38(9):1930-1947. 
255. Pharmacopoeia US: USP35-NF30 In., vol. 36. United States: Phamacopeial Forum 
(PF); 2011: 534. 
256. Hallal A, Cohn SM, Namias N, Habib F, Baracco G, Manning RJ, Crookes B, 
Schulman CI: Aerosolized tobramycin in the treatment of ventilator-associated 
pneumonia: a pilot study. Surg Infect (Larchmt) 2007, 8(1):73-82. 
190 
 
 
190 
257. Migiyama Y, Hirosako S, Tokunaga K, Migiyama E, Tashiro T, Sagishima K, 
Kamohara H, Kinoshita Y, Kohrogi H: Aerosolized tobramycin for Pseudomonas 
aeruginosa ventilator-associated pneumonia in patients with acute 
respiratory distress syndrome. Pulm Pharmacol Ther 2017, 45:142-147. 
258. Le J, Ashley ED, Neuhauser MM, Brown J, Gentry C, Klepser ME, Marr AM, Schiller 
D, Schwiesow JN, Tice S et al: Consensus summary of aerosolized 
antimicrobial agents: application of guideline criteria. Insights from the 
Society of Infectious Diseases Pharmacists. Pharmacotherapy 2010, 30(6):562-
584. 
259. Rodriguez A, Cabrera M, Reyes LF, Bodi M, Trefler S, Canadell L, Barahona D, 
Ehrmann S, Martin-Loeches I, Restrepo MI et al: In vitro evaluation of aerosol 
delivery of aztreonam lysine (AZLI): an adult mechanical ventilation model. 
Expert Opin Drug Deliv 2017, 14(12):1447-1453. 
260. Yang SH, Yang TM, Lin HL, Tsai YH, Fang TP, Wan GH: Size distribution of 
salbutamol/ipratropium aerosols produced by different nebulizers in the 
absence and presence of heat and humidification. Pulm Pharmacol Ther 2017. 
261. Tandon R, McPeck M, Smaldone GC: Measuring nebulizer output. Aerosol 
production vs gravimetric analysis. Chest 1997, 111(5):1361-1365. 
262. Kadrichu N, Boc S, Corkery K, Challoner P: In vitro efficiency of Amikacin Inhale, 
a novel drug-device delivery system. Critical Care 2013, 17(Suppl 2):P81-P81. 
263. Carvalho TC, Peters JI, Williams RO, 3rd: Influence of particle size on regional 
lung deposition--what evidence is there? Int J Pharm 2011, 406(1-2):1-10. 
264. Palmer LB, Smaldone GC, Simon SR, O'Riordan TG, Cuccia A: Aerosolized 
antibiotics in mechanically ventilated patients: delivery and response. Crit 
Care Med 1998, 26(1):31-39. 
265. Fuller HD, M.; Turpie, F.; Posmituck, G.; Wong Pack, W.; Newhouse, M.: Aerosol 
deposition to the lungs by MDI in ventilated patients: endotracheal tubes vs 
tracheostomy. Chest 1990, 98(2):27S. 
266. Penconek A, Odziomek M, Niedzielska A, Arkadiusz M: Delivery of Nebulised 
Drugs using Endotracheal Tube. In: Chemical and Process Engineering. vol. 33; 
2012: 689. 
267. Ehrmann S, Chastre J, Diot P, Lu Q: Nebulized antibiotics in mechanically 
ventilated patients: a challenge for translational research from technology to 
clinical care. Ann Intensive Care 20 7, 7(1):78. 
191 
 
 
191 
268. Arnold HM, Sawyer AM, Kollef MH: Use of adjunctive aerosolized antimicrobial 
therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter 
baumannii ventilator-associated pneumonia. Respir Care 2012, 57(8):1226-
1233. 
269. Czosnowski QA, Wood GC, Magnotti LJ, Croce MA, Swanson JM, Boucher BA, 
Fabian TC: Adjunctive aerosolized antibiotics for treatment of ventilator-
associated pneumonia. Pharmacotherapy 2009, 29(9):1054-1060. 
270. Badia JR, Soy D, Adrover M, Ferrer M, Sarasa M, Alarcon A, Codina C, Torres A: 
Disposition of instilled versus nebulized tobramycin and imipenem in 
ventilated intensive care unit (ICU) patients. J Antimicrob Chemother 2004, 
54(2):508-514. 
271. Ghannam DE, Rodriguez GH, Raad, II, Safdar A: Inhaled aminoglycosides in 
cancer patients with ventilator-associated Gram-negative bacterial 
pneumonia: safety and feasibility in the era of escalating drug resistance. Eur 
J Clin Microbiol Infect Dis 2009, 28(3):253-259. 
272. Pitcairn GR, Joyson AD, Hirst PH, Newman SP: Radionuclide Imaging for 
Assessing Pulmonary Drug Delivery. International Journal of Pharmaceutical 
Medicine 2003, 17(1):11-15. 
273. Newman S, Bennett WD, Biddiscombe M, Devadason SG, Dolovich MB, Fleming 
J, Haeussermann S, Kietzig C, Kuehl PJ, Laube BL et al: Standardization of 
techniques for using planar (2D) imaging for aerosol deposition assessment 
of orally inhaled products. J Aerosol Med Pulm Drug Deliv 2012, 25 Suppl 1:S10-
28. 
274. Smaldone GC: Radionuclide scanning, respiratory physiology, and 
pharmacokinetics. J Aerosol Med 2001, 14(2):135-137. 
275. Kirschvink N, Reinhold P: Use of alternative animals as asthma models. Curr 
Drug Targets 2008, 9(6):470-484. 
276. Clau MDLHGLB: The Sheep as a Large Animal Experimental Model in 
Respiratory Diseases Research. Archivos de Bronconeumología 2010, 
46(10):499- 501. 
277. Al-Kouraishi S: Labelling and quality control of gentamycin with99mTc and 
biodistribution. Journal of Radioanalytical and Nuclear Chemistry 1988, 
125(1):203-211. 
192 
 
 
192 
278. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, Robertson JS, 
Howell RW, Wessels BW, Fisher DR et al: MIRD pamphlet no. 16: Techniques 
for quantitative radiopharmaceutical biodistribution data acquisition and 
analysis for use in human radiation dose estimates. J Nucl Med 1999, 
40(2):37S-61S. 
279. Patton JA, Turkington TG: SPECT/CT physical principles and attenuation 
correction. J Nucl Med Technol 2008, 36(1):1-10. 
280. Thomas SH, O'Doherty MJ, Fidler HM, Page CJ, Treacher DF, Nunan TO: 
Pulmonary deposition of a nebulised aerosol during mechanical ventilation. 
Thorax 1993, 48(2):154-159. 
281. Schulz H, Eder G, Heyder J: Lung volume is a determinant of aerosol bolus 
dispersion. J Aerosol Med 2003, 16(3):255-262. 
282. R Development Core Team: R: A language and environment for statistical 
computing. In. Vienna, Austria: R Foundation for Statistical Computing; 2017. 
283. Harvey CJ, O'Doherty MJ, Page CJ, Thomas SH, Nunan TO, Treacher DF: 
Comparison of jet and ultrasonic nebulizer pulmonary aerosol deposition 
during mechanical ventilation. Eur Respir J 1997, 10(4):905-909. 
284. Boselli E, Breilh D, Djabarouti S, Guillaume C, Rimmele T, Gordien JB, Xuereb F, 
Saux MC, Allaouchiche B: Reliability of mini-bronchoalveolar lavage for the 
measurement of epithelial lining fluid concentrations of tobramycin in 
critically ill patients. Intensive Care Med 2007, 33(9):1519-1523. 
285. Dugernier J, Reychler G, Wittebole X, Roeseler J, Depoortere V, Sottiaux T, 
Michotte JB, Vanbever R, Dugernier T, Goffette P et al: Aerosol delivery with two 
ventilation modes during mechanical ventilation: a randomized study. Ann 
Intensive Care 2016, 6(1):73. 
286. Lambert AR, O'Shaughnessy P, Tawhai MH, Hoffman EA, Lin CL: Regional 
deposition of particles in an image-based airway model: large-eddy 
simulation and left-right lung ventilation asymmetry. Aerosol Sci Technol 2011, 
45(1):11-25. 
287. Moller W, Meyer G, Scheuch G, Kreyling WG, Bennett WD: Left-to-right 
asymmetry of aerosol deposition after shallow bolus inhalation depends on 
lung ventilation. J Aerosol Med Pulm Drug Deliv 2009, 22(4):333-339. 
288. Melsom MN, Flatebo T, Kramer-Johansen J, Aulie A, Sjaastad OV, Iversen PO, 
Nicolaysen G: Both gravity and non-gravity dependent factors determine 
193 
 
 
193 
regional blood flow within the goat lung. Acta Physiol Scand 1995, 153(4):343-
353. 
289. Smith DJ, Gambone LM, Tarara T, Meays DR, Dellamary LA, Woods CM, Weers 
J: Liquid dose pulmonary instillation of gentamicin PulmoSpheres 
formulations: tissue distribution and pharmacokinetics in rabbits. Pharm Res 
2001, 18(11):1556-1561. 
290. West JB: Regional differences in the lung. Chest 1978, 74(4):426-437. 
291. Sa RC, Zeman KL, Bennett WD, Prisk GK, Darquenne C: Effect of Posture on 
Regional Deposition of Coarse Particles in the Healthy Human Lung. J Aerosol 
Med Pulm Drug Deliv 2015, 28(6):423-431. 
292. Alcoforado L, Pessoa Filho LC, Brandao DC, Galvao AM, Reinaux CM, Andrade 
AD: Influence of change in lateral decubitus on pulmonary aerosol deposition. 
Rev Bras Fisioter 2011, 15(4):278-283. 
293. Kaneko K, Milic-Emili J, Dolovich MB, Dawson A, Bates DV: Regional distribution 
of ventilation and perfusion as a function of body position. J Appl Physiol 1966, 
21(3):767-777. 
294. Bennett WD, Brown JS, Zeman KL, Hu SC, Scheuch G, Sommerer K: Targeting 
delivery of aerosols to different lung regions. J Aerosol Med 2002, 15(2):179-
188. 
295. Walther SM, Domino KB, Glenny RW, Hlastala MP: Pulmonary blood flow 
distribution in sheep: effects of anesthesia, mechanical ventilation, and 
change in posture. Anesthesiology 1997, 87(2):335-342. 
296. Walther SM, Domino KB, Glenny RW, Polissar NL, Hlastala MP: Pulmonary blood 
flow distribution has a hilar-to-peripheral gradient in awake, prone sheep. J 
Appl Physiol (1985) 1997, 82(2):678-685. 
297. Brown JS, Zeman KL, Bennett WD: Regional deposition of coarse particles and 
ventilation distribution in healthy subjects and patients with cystic fibrosis. J 
Aerosol Med 2001, 14(4):443-454. 
298. Kollef MH, Chastre J, Fagon JY, Francois B, Niederman MS, Rello J, Torres A, 
Vincent JL, Wunderink RG, Go KW et al: Global prospective epidemiologic and 
surveillance study of ventilator-associated pneumonia due to Pseudomonas 
aeruginosa. Crit Care Med 2014, 42(10):2178-2187. 
299. Melsen WG, Rovers MM, Bonten MJ: Attributable mortality of ventilator-
associated pneumonia - Authors' reply. Lancet Infect Dis 2013, 13(12):1015. 
194 
 
 
194 
300. Borgatta B, Rello J: How to approach and treat VAP in ICU patients. BMC Infect 
Dis 2014, 14:211. 
301. Hermann T: Aminoglycoside antibiotics: old drugs and new therapeutic 
approaches. Cell Mol Life Sci 2007, 64(14):1841-1852. 
302. Tumbarello M, De Pascale G, Trecarichi EM, Spanu T, Antonicelli F, Maviglia R, 
Pennisi MA, Bello G, Antonelli M: Clinical outcomes of Pseudomonas 
aeruginosa pneumonia in intensive care unit patients. Intensive Care Med 
2013, 39(4):682-692. 
303. Stockmann C, Roberts JK, Yellepeddi VK, Sherwin CM: Clinical 
pharmacokinetics of inhaled antimicrobials. Clin Pharmacokinet 2015, 
54(5):473-492. 
304. Marchand S, Gobin P, Brillault J, Baptista S, Adier C, Olivier JC, Mimoz O, Couet 
W: Aerosol therapy with colistin methanesulfonate: a biopharmaceutical 
issue illustrated in rats. Antimicrob Agents Chemother 2010, 54(9):3702-3707. 
305. Sullivan BP, El-Gendy N, Kuehl C, Berkland C: Pulmonary Delivery of 
Vancomycin Dry Powder Aerosol to Intubated Rabbits. Mol Pharm 2015, 
12(8):2665-2674. 
306. Yapa SWS, Li J, Patel K, Wilson JW, Dooley MJ, George J, Clark D, Poole S, 
Williams E, Porter CJ et al: Pulmonary and systemic pharmacokinetics of 
inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: 
targeting advantage of inhalational administration. Antimicrob Agents 
Chemother 2014, 58(5):2570-2579. 
307. Landersdorfer CB, Nguyen TH, Lieu LT, Nguyen G, Bischof RJ, Meeusen EN, Li J, 
Nation RL, McIntosh MP: Substantial Targeting Advantage Achieved by 
Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal 
Model. Antimicrob Agents Chemother 2017, 61(1). 
308. Guillamon Mde L, Clau LB: [The sheep as a large animal experimental model in 
respiratory diseases research]. Arch Bronconeumol 2010, 46(10):499-501. 
309. Zeitlinger M, Muller M, Joukhadar C: Lung microdialysis--a powerful tool for the 
determination of exogenous and endogenous compounds in the lower 
respiratory tract (mini-review). AAPS J 2005, 7(3):E600-608. 
310. Larsson CI: The use of an "internal standard" for control of the recovery in 
microdialysis. Life Sci 1991, 49(13):PL73-78. 
195 
 
 
195 
311. Scheller D, Kolb J: The internal reference technique in microdialysis: a 
practical approach to monitoring dialysis efficiency and to calculating tissue 
concentration from dialysate samples. J Neurosci Methods 1991, 40(1):31-38. 
312. Yamazaki K, Ogura S, Ishizaka A, Oh-hara T, Nishimura M: Bronchoscopic 
microsampling method for measuring drug concentration in epithelial lining 
fluid. Am J Respir Crit Care Med 2003, 168(11):1304-1307. 
313. Rennard SI, Basset G, Lecossier D, Odonnell KM, Pinkston P, Martin PG, Crystal 
RG: Estimation of Volume of Epithelial Lining Fluid Recovered by Lavage 
Using Urea as Marker of Dilution. J Appl Physiol 1986, 60(2):532-538. 
314. Burdette SD, Limkemann AJ, Slaughter JB, Beam WB, Markert RJ: Serum 
concentrations of aerosolized tobramycin in medical, surgical, and trauma 
patients. Antimicrob Agents Chemother 2009, 53(10):4568. 
315. Moore RD, Lietman PS, Smith CR: Clinical response to aminoglycoside 
therapy: importance of the ratio of peak concentration to minimal inhibitory 
concentration. J Infect Dis 1987, 155(1):93-99. 
316. Tam VH, Ledesma KR, Vo G, Kabbara S, Lim TP, Nikolaou M: Pharmacodynamic 
modeling of aminoglycosides against Pseudomonas aeruginosa and 
Acinetobacter baumannii: identifying dosing regimens to suppress 
resistance development. Antimicrob Agents Chemother 2008, 52(11):3987-3993. 
317. Benumof JL: Mechanism of decreased blood flow to atelectatic lung. J Appl 
Physiol Respir Environ Exerc Physiol 1979, 46(6):1047-1048. 
318. Sa RC, Zeman KL, Bennett WD, Prisk GK, Darquenne C: Regional Ventilation Is 
the Main Determinant of Alveolar Deposition of Coarse Particles in the Supine 
Healthy Human Lung During Tidal Breathing. J Aerosol Med Pulm Drug Deliv 
2017, 30(5):322-331. 
319. Carcas AJ, Garcia-Satue JL, Zapater P, Frias-Iniesta J: Tobramycin penetration 
into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther 
1999, 65(3):245-250. 
320. Mombelli G, Coppens L, Thys JP, Klastersky J: Anti-Pseudomonas activity in 
bronchial secretions of patients receiving amikacin or tobramycin as a 
continuous infusion. Antimicrob Agents Chemother 1981, 19(1):72-75. 
 
  
196 
 
 
196 
Appendices: 
Appendix 1- Ethics approval certificates 
 
 
 
197 
 
 
197 
 
 
 
 
 
198 
 
 
198 
 
 
 
 
 
199 
 
 
199 
 
 
 
 
 
200 
 
 
200 
 
 
 
 
 
201 
 
 
201 
 
 
 
